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Abstract 
 
The epithelial restricted αvβ6 integrin is known to have minimal expression in healthy 
tissue and to be upregulated in cancer and healing wounds. This thesis explores the 
role of αvβ6 in cancer and tests the hypothesis that αvβ6 has a prognostic and 
therapeutic utility in cancer.  
 
Using immunohistochemistry, increased αvβ6 expression was found in non-
melanoma skin cancers (NMSC), particularly in morphoeic type basal cell carcinoma. 
In cell culture experiments, αvβ6 was found to activate TGF-β and promote 
myofibroblast differentiation, producing a tumour stroma rich in smooth muscle actin 
(SMA). These findings prompted a study of αvβ6 and SMA as prognostic indicators 
in oral squamous cell carcinoma (OSCC).  A study of 282 cases of OSCC found that 
although αvβ6 was not a prognostic marker, patients with high SMA levels had a 
highly significant increased risk of disease specific mortality (HR 3.06 [CI 1.65-5.66], 
p<0.001).  
 
Next, the utility of αvβ6 as a target was explored through the development of a single 
chain antibody fragment (scFv) specific for αvβ6. The scFv was tested for the 
delivery of targeted magnetic fluid hyperthermia (MFH), an experimental cancer 
treatment based on the generation of heat by magnetic nanoparticles when placed 
within an alternating magnetic field. The αvβ6-specific scFv (B6.3) was manufactured 
and high ligand specificity confirmed on ELISA and FACS analysis. B6.3 was 
successfully conjugated to two alternative iron nanoparticles. In-vitro studies 
demonstrated increased cellular uptake of scFv-nanoparticle complexes and greater 
cellular toxicity on exposure to MFH compared to nanoparticles alone.  
 
In conclusion, αvβ6 is a potential target for therapy in NMSC and OSCC.  SMA is 
found to be an independent prognostic marker in OSCC and αvβ6 identified as a pro-
invasive factor in morphoeic BCC.  Finally, the production αvβ6 specific scFvs and 
use for in-vitro MFH potentiates the development of αvβ6 targeted MFH cancer 
therapy.  
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1.1 The αvβ6 Integrin 
 
1.1.1  Background 
 
Integrins are heterodimeric molecules that span the membrane of cells provide a 
direct connection between the extracellular matrix and the intracellular cytoskeleton 
potentiating bidirectional communication between the internal cell environment and 
the surrounding extracellular components (Akiyama et al 1995). As well as mediating 
cell adhesion, integrins are involved in development, immune responses, leukocyte 
signalling, haemostasis, cancer and integrins are receptors for many bacteria and 
viruses.  
 
The basic structure of an integrin consists of alpha and beta subunits that are non-
covalently associated with an extracellular globular domain and a long cytoplasmic 
tail (figure 1.1). The intracellular component of integrins contains the carboxy termini 
of the alpha and beta domains, is less than 60 amino acids in length and interacts with 
the cellular cytoskeleton through a series of protein kinase mediated reactions. All 
integrins except one (α6β4) bind to and regulate the intracellular actin monofilament 
system which in turn regulates cell motility.  The extracellular domain of the integrin 
is globular in shape and contains the ligand binding site which coordinates the 
interaction of the cell with the external environment (Hynes 2002).  
 
 
 
Figure 1.1 - Generalised integrin structure showing α and β subunits spanning the cell membrane 
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So far there are known to be 24 possible combinations of the 18 alpha and 8 beta 
subunits that make up the integrin family all of which, on binding to ligand activate a 
series of intracellular signaling pathways (figure 1.2).  Integrins have previously been 
identified to play an important part in cellular survival (Meredith et al 1993), 
proliferation, regulation of gene expression (Werb et al 1989) and tumour progression 
(Guo and Giancotti 2004).   
 
Altered integrin expression has been reported in many tumours and has long been 
known to play a role in the progression of squamous cell carcinoma (SCC) of the skin 
and head and neck (Jones et al 1993 and 1997, Lyons and Jones 2007). SCC develops 
due to abnormal changes in the epithelium as keratinocyte cells undergo 
differentiation to become the protective cells on the outer layer of our skin or mucosa.  
Prior to undergoing differentiation, the basal layer of stratified squamous epithelium 
is anchored by integrins which interact specifically with proteins making up the 
extracellular matrix of the basement membrane. Abnormalities in integrin function 
alter the way cells interact with their local environment and these molecules have 
been implicated in the development and progression of SCC (Watt 2002). 
 
Interactions between integrins and the intracellular actin based cytoskeleton are 
complex however an overview is given in figure 1.2 and table 1.1 below. 
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Figure 1.2 - Pathways involved following integrin binding to ligand showing adaptor proteins (pale blue) linking integrins to actin filaments, enzymes (red) and other integrin 
associated proteins in dark blue.
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Integrin associated protein Proposed Function 
FAK 
Focal Adhesion Kinase 
An intracellular tyrosine kinase protein - mediates 
signal transduction pathways initiated either at the 
sites of cell attachment or at growth factor 
receptors. 
Vin 
Vinculin 
A key regulator of Focal Adhesions and interacts 
with talin and -actinin 
Talin Actin-binding protein essential role in inside-out 
integrin activation and early coupling of 
extracellular ligand-bound integrins to the 
cytoskeleton through recruitment of other proteins 
such as paxillin, vinculin, α-actinin, tensin, and 
zyxin 
PAK 
P21 activated Kinase 
Regulation of the Erk pathway, acting primarily at 
the level of Raf-1 and involved with Rac-
mediated actin reorganization of the membrane of 
migrating cells 
Pax 
Paxillin 
Localizes to focal adhesions possibly through a 
direct association with ß-integrin tails or an 
intermediate protein ‘X’ such as vinculin and 
actopaxin that bind actin directly to regulators of 
actin cytoskeletal dynamics such as the ARF 
GAP, PKL, the exchange factor PIX and the p21-
activated kinase, PAK.  
Zyx 
Zyxin 
Focal adhesion protein which shuttles between the 
focal adhesion and the nucleus, influences actin 
assembly and organization as well as cell motility 
SHIP2  
Src homology 2 (SH2) domain-containing inositol 
5-phosphatase 2. 
Catalyses the dephosphorylation of 
phosphatidylinositol 3,4,5-trisphosphate 
[PtdIns(3,4,5)P3] to phosphatidylinositol 3,4-
bisphosphate. Interacts with cell cytoskeleton 
proteins including venexin. 
CSK Negative regulatory kinase for SFK. Leads to 
enhanced phosphorylation of FAK and paxilllin, 
enhanced cell scattering, rearrangement of actin 
cytoskeleton and increased cell 
adhesion/migration and invasiveness. 
Tensin Negatively regulates actin assembly by capping 
the barbed end of filaments and controls the 
transmission of force between actin cytoskeleton 
and focal adhesions. 
 
Nex 
Nexilin 
Actin filament binding protein localised at cell 
matrix adherens junction. 
Pall 
Palladin 
Binds directly to F-actin, crosslinking actin 
filaments into bundles, 
PIX 
PAK-interacting exchange factor 
PIX strongly stimulates PAK activity and is 
important for PAK recruitment and localization to 
focal complexes and focal adhesions. 
PI3K 
phosphatidyl inositol 3-kinase  
Activated form, PtdIns(3,4,5)P3, targets various 
kinases to influence mitogenic signalling, cell 
survival and cytoskeletal remodelling. 
PKL 
paxillin kinase linker  
 
On cell adhesion to fibronectin and rac activation, 
PKL is phosphorylated by Src and/or FAK 
allowing localization to focal adhesions and for 
paxillin binding 
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ERM 
ezrin–radixin–moesin proteins  
Interact via their FERM domains with signaling 
molecules including phosphatidylinositol 3-kinase 
or a Rho-specific guanine nucleotide dissociation 
inhibitor (GDI). 
Fim  
Fimbrin 
Actin crosslinker contributing to cell mechanics 
in a myosin-II-dependent manner allowing for 
cell contractility and  modulating change in cell-
shape. 
VASP 
vasodilator-stimulated phosphoprotein 
Enhances actin polymerization, localises at the 
tips of actin fibers. 
Fil 
filamin  
Actin crosslinker protein. Cells lacking filamin 
expression exhibit unstable surfaces, are incapable 
of locomotion, and have impaired mechanical 
resistance 
PINCH 
Cysteine-histidine rich protein 
Forms complex IPP with integrin-linked kinases 
and Parvins which act as regulators of gene 
transcription or cell–cell adhesion. 
 
 
Table 1.1 - Descriptions of the role of integrin associated proteins shown in figure 2.2 
 
 
In normal human epidermis, the most abundant integrins are α2β1 (a collagen 
receptor), α3β1 (primarily a laminin receptor) and α6β4 (a laminin receptor) (Watt 
2002).  The αvβ5 integrin (a vitronectin receptor) is expressed at lower levels, the 
α5β1 integrin (fibronectin receptor) and αvβ6 integrins (receptor for tenascin and 
fibronectin) are either expressed at low levels or undetectable in normal epidermis, 
but are upregulated during wound healing in vivo.   
 
In general, as keratinocytes move through the layers of the epidermis, integrin 
expression is downregulated from a maximal expression at the basement membrane to 
minimal or negative expression at the superficial stratum corneum (Figure 1.3). 
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Figure 1.3 - Layers of epidermis showing morphological change in epidermal cells and the decreased 
expression of integrins moving from the basement membrane to the skin surface. 
 
 
Examining SCC sections using immunohistochemistry staining for integrin 
expression reveals variations between sections within the same tumour and between 
different tumour samples. Occasionally, complete loss of a particular integrin occurs 
throughout a tumour, whereas expression of other integrins in the same tumour seems 
normal (Jones 1993).  
 
Integrin overexpression, when integrins are expressed throughout the tumour mass, is 
frequently seen and has been shown to correlate with poor prognosis as in the case of 
α6β4 (Rabinovitz and Mercurio 1996, van Waes et al 1995) and αvβ6 (Thomas et al 
2006).  The αvβ6 integrin is of particular interest as it is not constitutively expressed 
in normal healthy epithelium but is upregulated in healing wounds and in 
carcinogenesis (Breuss et al 1995).  Furthermore, as αvβ6 is expressed solely on 
epithelial cells, the integrin has generated much interest as a novel target for epithelial 
cancer therapies.   
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1.1.2 αvβ6 and wound healing 
 
In vitro studies have shown that αvβ6 is important for coordinating keratinocyte 
interaction with fibronectin, tenascin and vitronectin, which are important constituents 
of the early wound matrix (Busk et al 1992, Koivisto et al 1999). Maximal expression 
of αvβ6 was seen relatively late during mucosal and dermal wound healing, after the 
two migrating edges of the wound epithelium have joined (Haapasalmi et al 1996). 
Workers have also shown that in the re-epithelialisation of normal human wounds 
there is a switch in integrin expression from αvβ5 to αvβ6 (Clark et al 1996).  Further 
studies have shown that αvβ6-dependent upregulation of the type IV collagenase 
MMP-9 facilitates cell movement by allowing keratinocytes to detach from the 
basement membrane (Thomas et al 2001).  
 
Although exact mechanisms for regulation of αvβ6 turnover in wound healing are not 
yet fully understood, the integrin may be important in the late stabilisation of wounds 
through a TGFβ mediated pathway.  TGFβ is important in wound healing for the 
regulation of re-epithelialisation, suppression of inflammation, deposition of 
extracellular matrix and formation of scar tissue (Verrecchia et al 2002).  It is possible 
that expression of αvβ6 in wound healing may alter the rate of repair or morphology 
of the wound. In vivo work using a transgenic mouse which constitutively expresses 
αvβ6 found that these mice healed without significant scarring and rates of wound 
healing and TGFβ levels were similar to controls (Hakkinen 2004).  Interestingly, the 
same group noted that mice overexpressing αvβ6 spontaneously developed chronic 
skin ulcers containing activated fibroblasts and macrophages, and these ulcers 
expressed higher levels of TGFβ compared to normal skin in the same mice. These 
data suggest that in situations of chronic inflammation, the fibrosis and ulceration that 
occurs may be αvβ6-mediated. 
 
 
 
 
 
 
 
 30 
1.1.3 αvβ6 activates TGFβ 
 
The transforming growth factor β family consists of three isoforms (TGFβ 1,2,3) that 
are involved in modulation of inflammation, inhibition of growth, regulation of ECM 
turnover and cancer metastasis (Yang 2010). The TGFβs are secreted in inactive form 
with the larger TGFβ molecule non covalently associated with the latency associated 
peptide (LAP) and in most cases, this complex is joined by a third protein, the latent 
TGFβ binding protein 1 (LTBP1).  The exact mechanisms for activation of TGFβ are 
incompletely understood however it is known that LAPβ1 contains the tripeptide 
sequence RGD and that LAPβ1 is a ligand for αvβ6 (Wipff and Hines 2008). Binding 
of the LAP peptide to αvβ6 integrin has further been shown to activate TGFβ1 
(Munger et al 1999) and TGFβ3 (Annes et al 2002).  The αvβ6 dependent LAP 
mediated activation of TGFβ depends on a conformational change in the latent TGFβ 
and not on the cleavage of LAP from TGFβ. Studies using cells expressing mutant β6 
could only activate TGFβ when the β6 was able to interact with actin in the cell 
cytoskeleton via phosphorylation of adaptor proteins including FAK and paxillin 
(Munger et al 1999). Thus the activation of TGFβ1 through binding of LAPβ1 to 
αvβ6 is further dependent on the ability of the αvβ6 to interact with the actin 
cytoskeleton. 
 
Upregulation of TGFβ has previously been shown to be both a promoter and inhibitor 
of carcinogenesis (Elliott and Blobe 2005, Akhurst and Derynck 2001) so evidence 
that αvβ6 upregulates TGFβ further suggests the cytokine has a complex role in the 
development of cancer.  It is possible that in the early stages of tumour growth, TGFβ 
is inhibitory and that as the cancer grows, TGFβ becomes a tumour promoter which 
may explain the differences described as to it’s effects (Elliott and Blobe 2005). 
 
 
1.1.4 αvβ6 and the promotion of carcinogenesis 
 
In common with other αv integrins, when binding to ligand, αvβ6 recognises the 
arginine-glycine-aspartate (RGD) tripeptide motif.  It is through this motif that αvβ6 
interacts with the extracellular matrix and one mechanism by which the integrin 
modulates cellular motility, migration and invasion.  Carcinogenesis involves 
 31 
disruption of normal interactions with the cell’s milleu which is characterised by 
disrupted cytoskeletal organisation and altered adhesion dependent responses.  One 
suggested mechanism for the promotion of carcinogenesis is the phenotypic change in 
cell type from epithelial to the more invasive mesenchymal type.  Bates et al (2005) 
showed that αvβ6 overexpression was associated with a change in colon carcinoma 
cells from epithelial to mesenchymal type.  Others have shown that αvβ6 is 
overexpressed at the leading edge of oral SCC tumours suggesting that the integrin is 
upregulated as tumours become more invasive (Regezi et al 2002).   Recently, 
blockade of the αvβ6 integrin has been shown to inhibit tumour progression in vivo 
using human pharyngeal cancer xenographs in mice (van Aarsen et al 2008). Table 
1.2 lists tumour types shown to express αvβ6. 
 
 
 
Tissue No of Tumours % Expressing αvβ6 Reference 
Oral SCC 40 
11 
40 
38 
30 
5 
100 
100 
100 
94.7 
90 
80 
Regezzi et al 2002 
Impola et al 2004 
Jones et al 1997 
Hsiao et al 2010 
Breuss et al 1995 
Hamidi et al 2000 
Oesophagus 56 68 Van Aarsen et al 2008 
Pancreas 34 100 Siphos et al 2004 
Breast 45 100 Arihiro et al 2000 
Skin 49 84 Van Aarsen et al 2008 
Cervix 85 
46 
59 
92 
Hazelbag et al 2007 
Van Aarsen et al 2008 
Endometrial carcinoma 126 42 Hecht et al 2008 
Lung 51 
271 
50 
56 
Smyth et al 1995 
Elayadi 2007 
Gastric 38 
300 
47 
36.7% 
Kawashima et al 2003 
Zhang et al 2008 
Colon 488 38 Bates et al 2005 
 
Table 1.2 - Published data on αvβ6 expression levels in various epithelial malignancies 
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Ramos et al (2007) showed that transfecting β6 into poorly invasive Oral Squamous 
Cell Carcinoma (OSCC) cells enhanced tumour growth rate five fold compared to non 
transfected cells when injected into nude mice.  The same group showed the β6-
transfected cells invaded deep into muscle whereas the non transfected cells did not 
cross the muscle fascia suggesting β6 promotes invasion in OSCC cells.  More 
recently Ramos et al (2009) have suggested that αvβ6 expression in OSCC cells may 
trigger epithelial to mesenchymal transition (EMT) which causes cells to become 
more invasive.  This finding is in agreement with Bates et al (2005) who described the 
role of αvβ6 in EMT in colon carcinoma. 
 
 
It has been suggested that one other possible mechanism by which αvβ6 promotes 
invasion is through the upregulation of proteases or collagenases including matrix 
metallo- proteases (MMP) 3 and 9.  MMPs are a family of zinc dependent 
endopeptidases that act to degrade the components of the extracellular matrix (Munshi 
and Stack 2006).  Thomas et al (2001) used OSCC cells retrovirally transfected with 
β6 cDNA and found this cell line to be significantly more invasive through Matrigel® 
in Transwell® invasion assays compared to controls with low levels of αvβ6.  The 
mechanism for the increased invasion was described to be through αvβ6-dependent 
upregulation of the type IV collagenase MMP-9 (and to a lesser extent MMP-2). In a 
similar study using colon carcinoma cells, αvβ6 has been shown to regulate MMP-9 
by a process modulated through the extracellular- regulated kinase (ERK) binding to 
the β6 cytoplasmic tail (Niu et al 2002).   More recently, Fouchier et al (2007) 
described the involvement of αvβ6 in the adhesion of HT29-D4 adenocarcinoma cells 
to fibrinogen that had been processed by MMP9 in the presence of high concentration 
of Mn2+. This process was shown to occur via the activation of the Extracellular 
Signal Regulated Kinase (ERK)/ Mitogen Activated Protein Kinase (MAPK) pathway 
and MMP9. 
 
The HS1 associated protein HAX-1 has also been implicated as a partner for αvβ6 in 
the promotion of carcinogenesis.  Ramsay et al (2007) found that the interaction 
between HAX-1 and αvβ6 was important for the clathrin-mediated endocytosis of the 
receptor and influenced the invasive behaviour of OSCC cells.  Evidence is emerging 
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that the rate of clathrin mediated receptor recycling is important in determining the 
invasive capacity for the cell and the ultimately the rate of cancer progression 
(Lanzetti and DiFiore 2008).  So it is by several mechanisms that αvβ6 has been 
shown to be important in cancer progression. 
 
 
1.1.5 αvβ6 as a prognostic indicator 
 
Interestingly, αvβ6 has been shown to be expressed in leukoplakia, a premalignant 
lesion of the oral mucosa as well as in salivary gland neoplasias (Westernoff et al 
2005).  This observation suggests that the integrin may play a role in the progression 
from normal mucosa to malignancy (Hamidi et al 2000).  Furthermore, upregulation 
of αvβ6 is associated with increased cellular invasion and more aggressive 
carcinomas so it is conceivable that patients with tumours expressing higher levels of 
αvβ6 may have a worse prognosis than those with low levels of the integrin.   
 
Bates et al (2005) showed that αvβ6 enhanced the tumorigenic properties of colon 
carcinoma and in an analysis of 488 colorectal carcinomas that the β6 subunit was 
associated with significantly poorer prognosis.  The same group also showed that 
distant metastases were also strongly positive for β6 suggesting the integrin is 
associated with disease progression and a poorer prognosis. Expression of αvβ6 has 
also been described in the lymph nodes of patients with gastric carcinoma 
(Kawashima et al 2003).  Other workers have shown αvβ6 to be expressed in gastric 
carcinomas and interestingly, overexpression was found to correlate with reduced 
survival in gastric carcinoma patients (Zhang et al 2008). 
 
Overexpression of αvβ6 has also been shown to be an unfavourable prognostic marker 
in cervical carcinoma.  Hazelbag et al (2007) looked at paraffin fixed specimens of 
cervical SCC from 86 women who had undergone radical hysterectomy and found 
that high levels of αvβ6 expression was significantly associated with more advanced 
disease at time of resection. Furthermore, patients with tumour cells that stained 
strongly for αvβ6 on immunohistochemistry had a shorter overall five year survival 
rate.   
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1.2 Oral Squamous Cell Carcinoma  
 
Squamous Cell Carcinoma (SCC) is a malignant tumour of epithelial cells which is 
locally invasive and prone to distant metastases if left untreated.  The epithelium is in 
effect our barrier to the external environment and it is the epithelial cells which 
constitute the external and internal linings of the body.  Common sites for SCCs to 
arise are on the epidermal layer of the skin, the lining of the cervix, the oesophagus 
and the mucosal surfaces of the head and neck aero digestive tracts.  The prognosis of 
SCC very much depends on the site, for example epidermal SCC if detected early 
enough is treated by surgical excision which is frequently curative. In contrast, when 
SCC arises in the head and neck region, 5 year survival rates are less than 50% and 
there have been little improvement in the mortality figures over the past 30 years.  
 
Overall, greater than ninety percent of oral cancers are SCC’s with the remaining ten 
percent made up from lymphomas, adenocarcinomas, salivary gland tumours, 
sarcomas and other rarer tumour types. Worldwide there are an estimated 405,000 
new cases of oral squamous cell carcinomas (OSCC) every year.  Every year there are 
approximately 320,000 deaths from OSCC, resulting in an average incidence rate of 
8.8 and 5.1 per 100,000 males and females. These figures place OSCC as the eighth 
leading cause of death from cancer worldwide (Shibuya et al 2002).  There are large 
regional variations in the level of OSCC, the highest incidence being in Somme, 
France with an average rate of 43.1 new cases per 100,000 in men and 4.7 cases per 
100,000 in women. In women, the highest incidence of OSCC is found in Bangalore, 
India, with an average rate of 11.2 cases per 100,000.  The lowest incidence for males 
was reported in Quito, Ecuador, with an average of 2.4 new cases per 100,000 and the 
lowest worldwide incidence for females was reported in Kangwha County, Korea, 
with an average rate of 0.5 per 100,000 (Parkin et al 2002). In the United States of 
America, The National Cancer Institute's Surveillance, Epidemiology and End Results 
Program (SEER) reported that between 1997 and 2002, the median age of oral and 
oropharyngeal cancer diagnosis was 63 years, and the median age at death was 68 
years (Ries et al 2005). 
 
As with many cancers, tobacco use is a major risk factor and in 1957, Wynder and 
Bross first identified cigarette smoking to be an independent risk factor for oral and 
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oropharyngeal cancer. Later, tobacco and alcohol were confirmed to be the two major 
risk factors for the development of oral cancers and were even seen to be synergistic 
in effect (Choi and Kahyo 1991, Brennan et al 1995,  Lewin et al 1998).  Other risk 
factors for the development of OSCC include presence of premalignant oral lesions, 
betal quid chewing, age, diets lacking antioxidants, genetic factors, exposure to UV-
light, immunodeficiencies, anaemias and poor oral health (Reichart 2001). The human 
papilloma virus (HPV) has recently been identified in over 95% of invasive cervical 
cancers (Bosch et al 2002) and HPV has also been implicated as a risk factor for 
HNSCC (Ragin 2007).   Figure 1.4 shows a buccal intaoral squamous cell carcinoma. 
 
 
 
 
Figure 1.4 – Typical appearance of oral squamous cell carcinoma. 
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1.2.1 Current Management of Oral Cancers 
 
1.2.1.1 Imaging 
 
Combined with thorough physical examination, pan endoscopy and a tissue diagnosis, 
improvements in imaging techniques have lead to a huge increase in the accuracy of 
preoperative staging of patients with OSCC.  Current imaging modalities include 
computerised tomography (CT) and magnetic resonance imaging (MRI) with the 
choice of scan being determined by the location of the tumour and what information is 
being sought.  Newer spiral CT imaging allows for accurate three dimensional images 
which can be obtained in a shorter time period and are useful for guided biopsies of 
deep seated tumours. Positron Emission Tomography (PET)/CT combines image data 
from intravenously injected radioactive 2-[18F]-fluoro-2-deoxy- D-glucose (FDG) 
with anatomical data from the CT scan. By merging the excellent sensitivity of PET 
with the spatial resolution of CT, accurate images can be obtained of metabolically 
active tumours, especially in patients who have undergone therapy (Sachelarie et al 
2005). 
 
MRI is often used in place of CT when detailed soft tissue images are required as the 
modality offers improved contrast by which blood vessels, masses, and adjacent soft 
tissues are easily differentiated (Hoover et al 1987). Disadvantages of MRI include 
the length of time taken to obtain the images, often patients with OSCC have other co-
morbidities and cannot lie still for the required time period. Patients with cardiac 
pacemakers, metallic cochlear implants or cerebral artery aneurysm clips cannot be 
placed in the strong magnetic field of an MRI machine due to risk of implant 
malfunction (Pavlicek et al 1983, Klucznik et al 1993).  The use of contrast agents 
improves the efficiency of both CT and MRI scans and recently superparamagnetic 
iron oxide nanoparticles have been used to improve contrast in MRI imaging of 
cancers of the liver and lymph nodes. Contrast agents in current use are taken up non 
specifically either by tissues with a higher metabolic rate or simply accumulate in 
organs which are acting to remove them from the circulation (DeBondt et al 2007).  
Work continues to produce contrast agents which can be specifically targeted against 
cells or molecules produced by cancers to improve the efficacy of conventional 
imaging techniques (reviewed by Atri 2006). 
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1.2.1.2 Therapy 
 
A unifying thread in OSCC is the poor overall survival for those patients with 
advanced, recurrent or metastatic disease.  Oral cancers have been classified by the 
American Joint Committee on Cancers (AJCC) and is based on the Tumour Node 
Metastasis (TNM) system:  
 
Stage 0  Carcinoma in situ 
 
Stage I Tumour < 2cm diameter 
 
Stage II Tumour 2 – 4 cm in diameter 
 
Stage III Tumour > 4cm diameter 
 Tumour diameter <2cm with single ipsilateral lymph node  
(LN) <3cm in diameter 
 Tumour 2 – 4cm diameter with single ipsilateral LN <3 cm in 
diameter. 
Tumour > 4cm with single ipsilateral LN <3cm in diameter 
 
Stage IVa  Tumour invades adjacent structures 
Tumour invades adjacent structures with single ipsilateral LN 
<3cm 
Tumour of any size with ipsilateral LN 3-6cm diameter or 
multiple ipsilateral LNs all under 6cm or multiple 
bilateral/contralateral LNs all under 6cm diameter 
 
Stage IVb  Any tumour size with any LN >6cm in diameter 
 
Stage IVc  Any tumour, any nodal status with distant metastasis 
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Patients with stage I/II early disease can usually be cured with chemoradiotherapy and 
or surgery, however, by the time most patients present to their doctor, most will 
already have locally or regionally advanced disease (Cohen et al 2003). The treatment 
goal for patients with Stage III/IV locoregional disease is organ preservation and cure. 
One of the reasons patient’s with OSCC have such a poor prognosis is that at the time 
of presentation metastatic spread may have aready occurred and irrespective of 
therapy, locoregional failure is the most common pattern of disease progression. To 
improve the outcome for patients with OSCC, a multidisciplinary approach is adopted 
involving surgeons, oncologists, radiotherapists, occupational therapists, speech 
therapists, dieticians and other allied healthcare professionals.   
 
Although the outlook for patients with advanced OSCC remains poor, there has been 
some improvement with the use of new chemotherapy programs and of combined 
chemoradiotherapy regimens. The Meta-Analysis of Chemotherapy on Head and 
Neck Cancer (MACH-NC) Collaborative Group recently reported a 4% overall 
survival improvement in OSCC at 5 years compared to controls (Pignon et al 2000). 
More recently, a large phase 2 trial looking at combined chemotherapy regimen of 
cisplatin, fluorouracil and docetaxel in stage III/IV OSCC showed an improvement in 
median overall survival of 18.8 months, as compared with 14.5 months with cisplatin 
and fluorouracil alone (Vermorken et al 2007).  However, these are modest 
improvements and 5-year survival in OSCC remains at less than 50%, which comes 
with the heavy price to pay of all the acute side effects associated with chemo and 
radiotherapy (Cooper et al 2004, Bernier et al 2004).  
 
In OSCC, the median survival time for patients with metastatic disease is just 6-8 
months and in those with treatment-refractory disease the median survival time is just 
3 months, for these patients, the only treatment is palliative.  Several randomized 
clinical trials have shown a 30% to 40% response rate in stage IV disease (Forastiere 
et al 1992, Gibson et al 2004) however there has been no improvement in mean 
survival time. The standard treatment for recurrent and/or metastatic OSCC remains 
combination chemotherapy with either cisplatin/fluorouracil or a platinum/taxane 
regimen (Cohen et al 2003). 
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Research on new avenues of treatment in OSCC has focused on developing therapies 
against specific molecular targets that are over expressed in cancerous cells.  One 
such target is the Epidermal Growth Factor Receptor (EGFR) family which is 
upregulated in over 90% of head and neck SCC (Albanell et al 2001) and high 
expression levels are associated with adverse prognosis (Chung et al 2006, Mrhalova 
et al 2005, Smid et al 2006).  Cetuximab is a monoclonal antibody against the EGFR 
receptor and has been shown to improve the median duration of survival (49 months 
versus 29.3 months) in a large multicenter phase III trial. The trial involved 424 
patients with locoregionally advanced HNSCC who were randomized to receive either 
radiotherapy alone or radiotherapy in combination with weekly cetuximab during 
radiotherapy (Bonner et al 2006).  A smaller randomised phase III trial comparing 
cetuximab with cisplatin to cisplatin alone in patients with recurrent or metastatic 
HNSCC failed to show any significant increase in overall survival time (Burtness et al 
2005). 
 
Gefitinib and erlotinib are orally administered EGFR selective tyrosine kinase 
inhibitors (TKI) which are approved by the Food and Drug Administration for the 
treatment of Non-small cell lung cancers.  Knowledge that the EGFR is upregulated in 
HNSCC has lead to the use of these TKI’s in phase I/II clinical trials. Cohen et al 
(2003) set up a phase II trial, using gefitinib as a single agent in patients with 
recurrent or metastatic HNSCC and found overall survival to be 29% at 1 year and 
mean survival time was 8.1 months. Erlotinib has also been evaluated in a single 
agent phase 2 study in previously treated patients with stage IV HNSCC and showed 
a median overall survival of 6 months, and a 1-year survival of 20% (Soulieres et al 
2004).  These studies show a minimal increase in survival time compared to patients 
receiving standard therapy and as such do not represent a major improvement in 
prognosis. 
 
The Cyclooxygenase (COX) 2 receptor is known to be involved in tumour 
progression and is upregulated in several carcinomas including OSCC (Chan et al 
1999, Grau et al 2004). Celecoxib is a selective COX2 receptor inhibitor which has 
been shown to inhibit the proliferation of OSCC cells both in vitro and in vivo (Bock 
et al 2007). Vascular endothelial growth factor (VEGF) is another attractive target for 
anticancer therapies in a number of cancers including HNSCC.  Kyzas et al (2005) 
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found that high VEGF expression was associated with higher clinical stage and worse 
overall survival in retrospective review of 69 OSCC patients.  In vivo studies 
combining the monoclonal anti VEGF antibody Bevacizumab (Avastin) with the 
chemotherapeutic agent paclitaxel further showed a dramatic reduction in tumour size 
compared to when each agent was applied separately (Fujuita et al 2007).  
 
Other promising therapies are antibodies directed against the insulin like growth 
factor type 1 receptor (IGF-IR) (Garcia-Ecchevaria et al 2004) and immunotoxins 
which target the epithelial cellular adhesion molecule Ep-CAM (Stoecklein 2006). 
The therapeutic efficacy of the human anti IGF-IR monoclonal antibody IMC-A12 
alone and in combination with the EGFR blocking antibody Cetuximab has been in 
HNSCC tumor xenografts.  The study showed that use of IMC-A12 in combination 
with Cetuximab resulted in 44% of the tumour xenographs showing complete 
regression. (Barnes et al 2007).  
 
 
 
1.3 Non Melanoma Skin Cancers 
 
Non melanoma skin cancer (NMSC) is the most common human malignancy and can 
be divided into basal cell carcinomas (BCC) and SCC.  BCC is the most common 
human malignancy and although most are indolent and treated with simple excision 
there exists a small subset of Morphoeic type BCC which are highly aggressive, occur 
mainly in the head and neck region and are prone to recurrence (discussed in detail in 
chapter 3). In the UK, there are over 62,000 new cases of BCC and SCC registered 
per year although this number is thought to be much higher due to incomplete 
registration (Cancer Research UK, CancerStats: Incidence UK. 2004). SCC is the 
second most common type of skin cancer and is responsible for the highest number of 
deaths from cutaneous malignancy after melanoma (Weinstock1989, Bernstein et al 
1996).  Cutaneous SCCs are a heterogenous group of tumours with many distinctive 
characteristics that can affect diagnosis and appropriate patient management. Of 
interest are the premalignant skin conditions such as Actinic Keratosis or Bowens 
disease which may be described as SCC in situ or early SCC.  These early types of 
SCC have not yet invaded across the basement membrane and if left untreated it is 
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estimated up to 20% of these will become malignant (Callen et al 1997). There are 
multiple histologically distinct variants of true SCCs and the behaviour of these 
subtypes varies considerably, with some being relatively indolent and others 
exhibiting a high propensity for aggressive and frequently metastatic behaviour. (Barr 
1991, Lohmann and Solomon 2001).  Although the majority of cutaneous squamous 
tumours can be treated with simple excision, there is a subset of patients who either 
present with advanced disease or who have particularly aggressive phenotype of 
squamous tumour. 
 
For a Caucasian child born in the United States in 1994, the lifetime risk of 
developing NMSC was estimated to be 28% - 33% for BCC and 7% - 11% for SCC 
(Miller and Weinstock 1994).  The rates of cutaneous SCC appear to vary widely 
depending on skin type, geographical location and reporting levels by healthcare 
professionals.  Cutaneous SCC rates per 100,000 of population have been reported at 
1332 for males living in Queensland, Australia (Buettner and Raasch 1998) compared 
to 25 per 100,000 in Welsh men (Holme et al 2000).  
 
The incidence of NMSC is increasing rapidly. For Caucasians living in Europe, the 
U.S., Canada, and Australia there has been an annual increase of 3–8% per year in the 
rates of NMSC over the past 40 years (Green 1992).   The rates of SCC have also 
been shown to double with every 8-10 degree decline in latitude as one approaches 
the equator (Giles et al 1988) as the exposure to UV light also increases with 
proximity to the equator (Fears 1983).  As people age, the incidence of NMSC 
increases, possibly due to prolonged exposure to UV light – the risk of developing 
SCC for patients over 75 years old is approximately 35 times higher than for those 
aged 50 to 55 years old (Holme 2000). 
 
The increases in skin cancer rates seen over the past 40 years have been attributed to 
changes in lifestyle, increased sun exposure, aging populations, increased skin cancer 
awareness and depletion of the ozone layer through greenhouse gas emissions. It has 
been estimated that a 10% reduction in the thickness of the ozone layer results in a 
20% increase in UV-radiation and a corresponding 40% increase in skin cancers 
(Oikarinen and Raitio 2000).  Chronic UV exposure as a major risk factor for NMSC 
is further evidenced by the fact that over 80% of tumours arise on sun exposed areas 
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of the skin.  The commonest sites for NMSCs include backs of hands and forearms, 
lips, nose, upper aspect of the back, the face and tops of the ears (Buettner and Raasch 
1998). 
 
Other risk factors for NMSC include pale complexion, fair or red hair, skin types I 
and II (Fitzpatrick 1988), previously damaged skin areas such as burn scars. Chemical 
exposure such as arsenic, coal tar and tobacco, immunosuppression and genetic 
disorders such as xeroderma pigmentosum have all been linked with increased risk of 
SCC (Diepgen and Mahler 2002).  Patients who have already had a NMSC are at 
increased risk of developing a second tumour, as are those who have a premalignant 
lesion such as Actinic Keratosis (AK) or Bowens disease (SCC in situ).  A study by 
Frankel et al (1992) found that of all patients with NMSC, 52% developed a second 
lesion in the five years after the original diagnosis. It is also estimated that around 5–
20% of AKs will transform into SCC within 10–25 years (Marks et al 1988) and that 
the risk of malignant transformation for an average patient with AKs followed up for 
10 years would be 6-10% (Dodson et al 1991). 
 
 
1.4  Antibodies 
 
Antibodies are glycoprotein immunoglobulins that bind antigens and are produced by 
B-cells. An antigen can be defined as a substance that can be bound by an antibody 
molecule through its antigen-binding sites or epitopes.  The high specificity of 
antibodies for their target ligand raises the potential for their use as agents to deliver 
targeted cancer therapy.  This became a possibility when the fusion of cancer and 
immune cells to create hybridomas allowed for the production of designer cancer 
specific monoclonal antibodies (Köhler & Milstein, 1975) 
 
1.4.1 Antibody structure  
 
 
Antibodies have a basic structure of four polypeptide chains, two identical light (L) 
chains and two heavy (H) chains.  Each L chain is bound to a H chain by non-covalent 
interactions and disulphide bridges and the H chains are bound to one another by 
covalent disulfide bridges and non covalent hydrophilic and hydrophobic interactions 
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to form the classic Y shaped molecule (Poljak 1973, Davies et al 1975).  The five 
classes of human immunoglobulin IgM, IgG, IgD, IgA and IgE are defined by 
differences in their heavy chains. 
 
The H and L chains can be further divided into variable (V) and constant (C) regions 
(Dreyer and Bennet 1965; Hilschmann and Craig 1965) and these in turn are folded 
into globular domains (Poljak et al 1972).  The ligand specificity found on antibodies 
is due to complement determining regions (CDRs) located in the V region, three of 
which are found on the H chain (VH) and three on the L chain (VL).  These CDR loops 
are hypervariable in amino acid length and sequence, accounting for the huge 
diversity in ligand recognition seen with antibodies (Wu and Kabat 1970; Kabat and 
Wu 1971). 
 
Ryle and Porter (1959) further showed that digestion with the enzyme pepsin cleaves 
the Fc portion from the whole antibody.  The Fc portion is involved in complement 
fixation and interaction with other components of the immune response.  Between 
each Fab and Fc portion lies a proline rich "hinge" region, 25 amino acid residues 
long and containing interchain disulfides bridges (Dayhoff 1972). Proteolytic 
cleavage of the whole antibody with the enzyme papain releases two identical 
fragments (Fab) of around molecular weight 50,000 which contain the Antigen 
binding portion of the molecule (Porter 1959). The architecture of the Fab fragments 
is of a framework of fairly constant residues in a beta sheet formation that link the 
three CDR regions. 
 
 
 
1.4.2  Fv antibody fragments 
 
The antigen binding Fab fragments can further be digested by pepsin to produce Fv 
fragments of around molecular weight 30,000.  These Fv fragments consist of VL and 
VH chains held together by non covalent bonds and were shown have the same 
association constant as whole Fab suggesting the antigen binding ability of antibodies 
is independent of the Fc region (Inbar et al 1972).  The small size of Fv fragments and 
the retention of full antigen binding capabilities makes them an interesting tool in the 
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development of immunotherapeutic applications.  Furthermore, the small size of Fv’s 
allows greater tumour penetration, improved pharmacokinetics and a reduction in 
antigenicity of the fragments compared to whole antibodies (Sedlacek et al., 1983). 
Development of expression systems using E. coli has allowed for the production of 
fully functional Fv fragments (Skerra and Pluckthun 1988) with similar binding 
affinities to whole antibodies, however these early systems failed to produce 
fragments stable in physiological conditions.  Work to improve the stability of these 
Fv fragments lead to the introduction of chemical cross-linking of the variable 
domains and introduction of intermolecular disulfide bonds (Glockshuber et al 1990). 
 
 
 
1.4.3  scFvs 
 
Huston et al (1988) first utilised E. coli bacteria to produce recombinant VH - VL 
complexes joined by the synthetic polypeptide linker (Gly-Gly-Gly-Gly-Ser)3 and 
these complexes were termed single chain Fv’s (scFv’s). Bird et al (1988) also used 
synthetic flexible linkers joining the carboxyl terminus of VL to the amino terminus of 
VH to create scFv’s and found them to be comparable in antigen affinity and 
specificity to the monoclonal antibodies from which their sequences were derived. 
Since that time, scFv and Fab antibody fragments have been generated from many 
existing monoclonal antibodies (MAbs) and, due to their small size, have been shown 
to have improved tissue penetration and clearance (Colcher et al 1998).  Figure 1.5 
shows various designs of engineered antibodies. 
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Figure 1.5 - Schematic representation of various engineered antibody fragments A) scFv (25KDa), B) 
Diabody (55KDa), C) Minibody (80KDa), D) scFv-Fc (105KDa), E) Intact Ab (150KDa) 
 
 
The development of display techniques using filamentous bacteriophage technology 
allowed for the selection of high affinity scFv’s from a library of millions of scFv’s 
displayed on the coat proteins of bacteria (McCafferty et al 1990). Phage display 
involves the use of polymerase chain reaction to amplify VL and VH regions of 
antibodies, making it possible to create large numbers of different scFvs.  These 
regions are randomly combined and then used to construct to large repertoires of 
scFvs that are displayed on the surface of bacteriophage. The virus like phage 
particles can contain single stranded DNA encoding for bacterial coat proteins. When 
phage enters the bacteria, the DNA is replicated, phage particles assembled and 
secreted into culture media without lysis of the bacterial cell. Antibody fragment 
DNA can then be spliced to the gene sequence for a phage coat protein, resulting in a 
phage surface expressed scFv fusion protein. 
 
Clackson et al (1991) originally created phage display libraries from B cells extracted 
from the spleens of immunised mice and used these to successfully select antigen-
specific scFv’s. Subsequently, phage libraries have been made from human B cells 
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taken from individuals immunized with antigen (Persson 1991), exposed to infectious 
agents (Burton et al 1991), with cancer (Cai and Garen 1995) or even with 
autoimmune diseases (Graus et al 1997).  However, one of the most successful uses 
of phage display has been for the selection of antibodies recognising specific antigens 
which have similar affinity to antibodies developed from hybridoma techniques.  
Furthermore, by using the selected scFvs as the basis for new libraries, the affinity can 
be further increased to levels greater than would be naturally found in the immune 
system (reviewed by Adams and Schier 1999). 
 
There are two main types of phage library: naive or immune. The naive libraries are 
derived from natural unimmunised human rearranged V genes (Marks et al 1991, 
Sblattero and Bradbury 2000), synthetic human V genes (Griffiths et al 1994) or 
shuffled V genes (Soderlind et al., 2000). Immunised libraries are generated from the 
V genes from immunised humans or mice and tend to have much higher affinities for 
the antigen than when using naïve libraries (reviewed by Bradbury and Marks 2004).  
Refinements in the use of phage display technology have led to the production of high 
affinity, human scFvs directed against a wide range of antigens. 
 
Recently, human phage antibody libraries have been used in the production of a fully 
human anti TNF α antibody, Adalimumab (Humira) which is Food and Drug 
Administration (FDA) approved for the treatment of rheumatoid arthritis.  Currently, 
there are several other antibody constructs in advanced clinical trials which have been 
discovered using phage display technology (Hoogenboom et al 2005). 
 
 
1.4.4  Antibody Engineering for Therapy 
 
Antibodies can be used either to block biological functions, to trigger an immune 
response against a cell they are bound to or as delivery agents to target cytotoxic 
agents, drugs or radioisotopes against specific antigens (Wu and Senter 2005, Weiner 
2010).  To improve usefulness of antibodies in the treatment of disease, they have 
been manipulated to vary the molecular size, pharmacokinetics, immunogenicity, 
specificity, valency and effector functions (Batra et al 2002). Currently there are 32 
antibody-based products approved by the FDA for human use in the clinic, 85% were 
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the result of antibody engineering and of those, 90% were for the treatment of cancer 
or immunological disease (Dubel 2007). 
 
Antibody engineering began with the creation of Fab, Fv and scFv fragments as 
described in above. The benefit of these small fragments being reduced 
immunogenicity and their small size with rapid clearance made the fragments ideal 
for imaging modalities such as radioimmmunotherapy (reviewed by Wangler et al 
2007).  However the small size and the monovalency of scFvs has limited their 
therapeutic potential due to the rapid clearance of these antibody fragments from the 
circulation. To improve the clinical applications of scFv’s various strategies have 
been employed including the formation of dimers either spontaneously or through the 
use of covalent disulphide bonds or peptide linkers (Hollinger et al 1993, Wu et al 
1996, Goel et al 2000). 
 
The discovery that camels and llamas (sp Camelidae) have antibodies consisting only 
of heavy chains and that the variable region (VHH) is capable of independently 
binding antigen has led to the development of a further class of antibody fragment 
termed nanobodies.  Nanobodies are 15KDa in size and recognise antigen through 
long CDR loops which seek out cryptic epitopes inaccessible to larger VH VL pairings. 
In addition, the greater thermal and intracellular stability of nanobodies has led to 
their investigation as potential targeting agents (Muyldermans 2001, Revets et al 
2005) 
 
To improve the serum half life and stability of scFvs, they can be reinserted into 
whole antibodies or fused to Fc portions to enable the new complexes to bind 
complement and trigger host immune responses (Persic et al 1997, De Lorenzo et al 
2004). Much of the early work in designing antibodies for therapy was based on 
mouse antibodies which led to the development of Human-Anti-Mouse-Antibody 
response, particularly with repeated administrations.  To reduce the immune response, 
chimeric antibodies were developed in which mouse VH and VL domains were fused 
with human Fc portions. Unfortunately, although less immunogenic, these mouse-
human chimeric antibodies generated an immune response termed Human-Anti-
Chimeric-Antibody response (reviewed by Mirick et al 2004). Other options to limit 
human immune responses to engineered antibodies include grafting of murine CDR 
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regions onto human antibody frameworks (ie the amino acid sequences between the 
CDR regions in human antibodies)  
 
Another approach to ‘humanise’ engineered antibodies whilst maintaining efficacy 
and affinity is to exchange for human residues, only the external residues of the 
murine antibody, leaving the CDR and internal residues of murine origin. A 
successful approach to humanise the murine anti CEA antibody MFE-23 was 
employed by Graff et al (2004) who compared the crystalline structure of MFE-23 
with that of TR1.9 – a fully human antibody.  The group identified 28 human residues 
on TR1.9 that were >30% solvent accessible and substituted these residues into MFE-
23, the newly humanised hMFE-23 retaining full affinity for it’s ligand CEA. 
 
 
1.4.5 MFE-23 
 
Phage display has been used to produce the scFv MFE-23 which is directed against 
CEA, an oncofoetal protein expressed in several cancers including colon cancer 
(Chester et al 1994).  The scFv MFE- 23 was developed from a filamentous phage 
expression library of random murine VH VL domain pairings obtained from a CEA 
immunized mouse.  MFE-23 was also the first scFv to be used in patients and has 
been used in several clinical trials firstly to improve imaging of secondary tumour 
deposits in patients with colon cancer (Begent et al 1996).  A second clinical trial 
used radiolabelled MFE-23 and a hand held gamma radiation probe to detect the 
presence of liver metastases during surgery (Mayer et al 2000).  Furthermore, the 
scFv has been previously well characterised and it’s structure and behaviour in vitro 
and in vivo described (Boehm et al 2000, Lee et al 2002 and Sainz-Pastor et al 2006).  
 
 
1.4.6 Rational Structural Based Antibody Design 
 
With the advent of X ray crystallography it has become possible to study the 
macromolecular structure of proteins, enzymes and nucleic acids.  This ability has 
lead to the development of rational approaches to drug and antibody design based on a 
knowledge of the precise structure of therapeutic targets (Scapin 2006).  Combining 
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knowledge of the macromolecular structure with the ability to substitute amino acid 
sequences into precise positions within the CDR loops of scFv’s or Fab gives a 
further avenue of approach in antibody design. This technique of grafting peptide 
epitopes newly synthesised or cut from known antigens into antibody CDR loops is 
known as antibody antigenisation and was first described by Zanetti (1992).  This 
technique takes advantage of the fact that the Fv regions are held in β pleated sheet 
conformation principally by the framework regions (FRs) and the CDR loops often 
protrude beyond these confines.  Thus it is possible to insert novel peptides into the 
CDR loops without disturbing the overall conformation of the Fv region (Figure 1.6).   
 
 
 
 
Figure 1.6 - Ribbon model of shMFE-23 showing position of CDR3 loop and site for peptide insertion. 
 
 
This hypothesis was tested by inserting a B cell epitope for the malarial parasite into 
the third CDR loop of the VH chain of a murine antibody which was then used to 
successfully immunise rabbits and mice against the malarial parasite (Billetta et al 
1991).  Further examples of this approach include the insertion of RGD repeat loops 
into the CDR region of a chimeric mouse-human heavy chain immunoglobulin which 
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was subsequently shown to bind at RGD recognition sites on the αvβ3 integrin 
expressed on tumour cell lines (Lanza et al 1997). 
 
Taking a rational structural based approach to antibody design allows the alteration of 
the specificity of well-characterised whole antibodies or antibody fragments that are 
known to be safe in human trials and can speed the time taken from bench to bedside.  
 
 
 
 
1.5 Nanotechnology and Cancer  
 
 
 
1.5.1 Background 
 
 
Nanotechnology is a rapidly developing field involving the interdisciplinary study of 
materials that are between 100 to 10,000 times smaller than the size of a human cell.  
Collaborations between engineers, physicists, biologists and medics have led to some 
striking advances, particularly in the area of nanomaterial research. Advances in 
nanotechnology are providing us with unprecedented abilities to study and manipulate 
molecular interactions at a sub cellular level leading to the development of new 
strategies to image and treat human disease.  The past ten years have seen the 
establishment of specific centres for research into nanotechnology, such as the 
Nanotechnology Characterisation Laboratory in the USA and London Centre of 
Nanotechnology – a joint venture between University College London and Imperial 
College London. In America, an estimated $6 billion has been invested in 
nanotechnology research and this investment is beginning to show some returns (Cai 
and Chen 2007, Mazzola 2003).   
 
Nanotechnology has the potential to make the great advances in the arena of cancer 
research.  Current cancer therapies include aggressive surgery to excise the tumour 
and any known metastases combined with chemo or radiotherapy often with high 
associated morbidity.  In essence the problem of treating cancer is that it often is 
detected too late to provide treatment and the treatments we have do not differentiate 
sufficiently between healthy and cancerous cells.  The goal of cancer treatments is 
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therefore to detect cancers earlier before they have had chance to develop and spread 
to distant parts of the body then, when detected to treat only the cancerous cells, 
leaving as much normal tissue undisturbed as possible 
 
 
1.5.2 Nanoparticles for Targeted Cancer Theranosis 
 
The term theranosis is used to refer to molecular complexes that can be used for both 
therapy and diagnosis of disease.  Nanotechnology research has been focussed on 
producing devices capable of targeting cancerous cells and using these devices to 
improve cancer imaging and to deliver anti cancer therapies directly to the cancer 
cells.  Tumour targeting can be passive or active, for example the rapid growth of 
tumours often means they have a poorly developed vascular supply with leaky 
capillary beds and a poor lymphatic drainage (Maeda and Matsumura 1989, Jain 
1988). This is in comparison to the normal well organised functional tissue 
architecture of capillary arterioles and venules. Vessel wall structure is also abnormal 
in tumours (McDonald and Choyke 2003, di Tomaso et al, 2005). Large inter-
endothelial junctions, increased numbers of fenestrations, vesicles, and a lack of 
normal basement membrane are often found in tumour vessels (Dvorak et al 2000). It 
is becoming increasingly thought that the increased permeability of tumour 
vasculature compared to normal vasculature means circulating molecular complexes 
are more likely to leak from the circulation into the tumour (Fukumura and Jain 
2007).  Furthermore, the size of molecular complexes directly influences the 
biodistribution of these complexes (Schipper et al 2009). Linking toxic agents to 
suitable nanomaterials may thus increase the toxin’s uptake at the tumour and the 
reduced lymphatic drainage may further encourage accumulation of the agent at the 
tumour site.   
 
One problem with passive delivery of nanoparticles is that these particles are 
recognised as foreign and mopped up by the reticuloendothelial system (RES) and by 
macrophage phagocytosis.  Use of hydrophilic particle coatings such as polyethylene 
glycol (PEG) and dextran can minimise phagocytosis and maximise the time 
nanoparticles can remain in the circulation (Lin et al 2009, Hu et al 2006). 
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Other forms of passive targeting include ‘Tumour Activated Prodrug Therapy’ which 
uses enzymes present in the local tumour environment to activate an intravenously 
delivered prodrug complex.  An example of this is the use of doxyrubicin-human 
albumin conjugates which are activated by specific matrix metallo proteases produced 
by melanoma cells, causing the local release of activated doxyrubicin at the tumour 
site (Mansour et al 2003).  Direct intratumoural injection is another method of passive 
targeting and this has been used to deliver various toxic or imaging agents including 
mitomycin (Nomura et al 1998), the attenuated adenovirus ONYX-015 which kills 
cells with mutated p53 (Khuri et al 2000) and ferromagnetic nanoparticles (Johannsen 
M et al 2006).  Magnetic nanoparticles have been used to passively target tumours by 
attaching drugs to particles, delivering the complexes intravenously and using an 
externally placed magnet over the tumour to target the nanoparticles-drug complexes 
(Alexiou et al 2003).   
 
 
Active cancer targeting is an attractive concept which uses specific targeting agents 
such as antibodies to deliver nanoparticles directly to cancer cells which can then be 
used for cancer imaging and therapy.  This concept will be explored throughout this 
thesis. 
 
 
1.5.3 Magnetic Nanoparticles 
 
Magnetic nanoparticles are ferric particles between 5 – 100 nm in size (compared to 
the average cell diameter of 10000 nm) and have characteristics between molecular 
and solid states, combining chemical accessibility in solution with physical 
properties of the bulk phase (Siegel 1999). Most research has focussed on the use of 
iron oxide nanoparticles, made from magnetite (Fe304) or maghemite (γFe203) 
principally due to the biological stability and ease of manufacture of these particles.  
Magnetic nanoparticles of magnetite or maghemite are synthesized through the 
alkaline co-precipitation of Fe2+ and Fe3+ aqueous salt solutions.  The control of size, 
shape and composition of nanoparticles depends on the type of salts used, Fe2+ to Fe3+ 
ratio, and pH of the media (Sjogren et al 1994). The magnetic properties of 
nanoparticles can vary greatly and are dependent on the size and interactions between 
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the particles which is in turn dependent on the manufacturing conditions (reviewed by 
Boyer et al 2010).  
 
 The aim of the manufacturing process of magnetic nanoparticles is to produce a 
ferro-fluid whereby the particles are held in colloid form and retain fluid 
characteristics even in high magnetic fields (Charles and Poppelwell 1980).  To 
reduce hydrophobic interparticulate interactions, prevent aggregation and to ensure 
the particles are remain in suspension, the particles are given a stabilising surface 
coating.  Various coatings are available including polymeric complexes such as 
polyethylene glycol (Hu et al 2006), dextran (Berry et al 2003), polyvinylpyrrolidone 
(D’Souza et al 2004), fatty acids (Sahoo et al 2002) and inorganic materials such as 
the surfactants sodium oleate and sodium carboxymethylcellulose (Sun et al 2007) or 
silica (Tartaj et al 2002). 
 
The magnetic properties of material can be described by the relationship between the 
magnetic field (H) and the magnetic induction (B).  Ferromagnetism describes the 
phenomenon of permanent magnetism seen when unpaired electron spins align 
themselves spontaneously in the absence of a magnetic field. Iron is a ferromagnetic 
material however when it is ground down to tiny particles, less than 15nm in size, the 
particles no longer display ferromagnetism after removal of the magnetic field. 
Particles below the 15nm size are described as displaying paramagnetic properties in 
that they behave as ferromagnets when an external magnetic field is applied however 
on removal of the field, no permanent magnetism remains.  Superparamagnetic Ion 
Oxide Nanoparticles (SPIONs) are particles of magnetite or maghemite that are stable 
in and dispersed in solution until an external magnetic field is applied, at which point 
they become ferromagnetic in behaviour until the field is removed (Bonnemain 1998, 
Cantillon-Murphy et al 2010).  The precise behaviour of SPIONs when placed in a 
magnetic field depends on both the size and the temperature of the particles 
(Kallumadil et al 2009). 
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1.5.4 Nanoparticles for imaging 
 
 
Magnetic Resonance Imaging (MRI) exploits the magnetic properties of the large 
numbers of hydrogen ions present in the tissues of the body to provide high quality 
non invasive images. When a large pulsed radiofrequency magnetic field is applied to 
hydrogen ions in the body, changes in the alignment of hydrogen ions are detected by 
pick-up coils within the scanner and these are converted to images.  The different 
tissue types are distinguishable essentially due to the differences in water and hence 
hydrogen ion content between tissue types (Elster and Burdet 2001).  To improve the 
accuracy of MRI scanning, it is useful to be able to enhance the contrast between 
different tissue types using contrast agents.  SPIONs are now routinely used as 
contrast agents because of their superparamagnetic properties that cause a reduction in 
the signal generated by MRI, improving the contrast between different tissue types.  
 
Superparamagnetic iron oxide nanoparticles such as dextran magnetite have been used 
to provide negative contrast when imaging the liver using MRI scans as they have 
higher molar relaxivities and can be used at lower concentrations (Stark et al 1988).  
These agents are useful for imaging the liver and spleen as magnetic nanoparticles 
accumulate in the reticuloendothelial (RES) system of the liver and spleen which has 
been described as passive targeting.  The RES is defined as the cell family comprising 
bone marrow progenitors, blood monocytes and tissue macrophages, one function of 
which is to recognise and remove unwanted autologous or foreign material from the 
blood stream (Hume et al 2002).  This is done through opsonisation when circulating 
plasma proteins known as opsonins attach themselves to the surface of foreign 
material. The opsonins are then recognised by circulating monocytes or fixed 
macrophages within the RES causing phagocytosis/endocytosis of the foreign 
material, eliminating them from the circulation and causing the accumulation of 
foreign material within organs of high phagocytic activity. This is what happens when 
dextran coated paramagnetic particles are delivered intravenously leading to their 
accumulation within the liver and spleen and the improved imaging of these organs 
using MRI scanners. 
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There is minimal associated toxicity with iron accumulation and in vivo tests have 
shown that the iron oxide component of the nanoparticles will be naturally recycled. 
The human body contains around 3-4 g Fe, for example, in the proteins ferritin, 
hemosiderin, transferritin, and hemoglobin. As the magnetic nanoparticles start to 
break down, any soluble Fe becomes part of this normal Fe pool, and given that a 
clinical dose would likely include just a few milligrams of Fe per kilogram body 
weight, the prospect of Fe overload is highly unlikely.  
 
 
Active targeting of nanoparticles for imaging has also been achieved using particles 
conjugated to RGD peptides in integrin positive liver cancers (Chen et al 2010).  
Furthermore, Lee et al (2009) have successfully conjugated iron nanoparticles to 
RGD peptides and shown effective siRNA uptake in breast cancers which over-
express integrins demonstrating potential for both imaging and therapy.  Yang et al 
(2009) have used single chain epidermal growth factor receptor antibody conjugated 
nanoparticles for improving in vivo MRI imaging of mouse pancreatic tumours. 
 
 
 
1.5.5 Magnetic Fluid Hyperthermia 
 
‘Quae medicamenta non sanat; ferrum sanat. Uae ferrum non sanat; ignis sanat. 
Quae vero ignis non sanat; insanabilia reportari oportet’ 
 
‘Those diseases medicine cannot cure, the knife cures. Those diseases the knife cannot 
cure, fire cures; and those that fire cannot cure are to be reckoned totally incurable’ 
Hippocrates c.420 BC 
 
The earliest description of using heat as a therapy for breast tumours is a reference in 
the Egyptian Edwin Smith surgical papyrus dated 3000 BC, a more well known 
proponent of medical hyperthermia is Hippocrates (460-370 BC) who describes the 
use of cautery as a treatment (Breasted 1931).  Since the 17th century there have been 
numerous reports of tumour regressions in patients suffering with infectious fever 
(Storm 1983) and in 1898, Westermark described using temperatures of 42-44ºC to 
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treat inoperable carcinomas of the uterus. There has recently been an increase in 
interest shown in hyperthermia as a cancer therapy as evidenced by increasing 
numbers of randomised controlled trials looking at the effects of hyperthermia 
combined with either radio or chemotherapy (van der Zee 2002). 
 
Clinical hyperthermia can be delivered either locally, regionally or as whole body 
hyperthermia and heat can be induced by electromagnetic field technique, ultrasound, 
or perfusion methods. The rationale underlying clinical hyperthermia is the fact that 
temperatures over 42.5ºC are cytotoxic for tumour cells (Dewey 1977 and 1994), 
especially in the local environment of the tumour where there is low pO2 and low pH 
due to insufficient blood perfusion.  Orgill et al (2005) have shown that by heating 
cells to 45°C, intracellular proteins become unfolded, cell membranes are disrupted 
and cell death swiftly follows. Hyperthermia has been used successfully to treat 
localised prostate cancers using high intensity focused ultrasound (HIFU) (Chaussy 
and Thuroff 2001, Uchida et al 2002) and has been shown to improve survival in 
advanced head and neck cancers when combined with radiotherapy (Valdagni and 
Amichetti 1994). However, a major technical problem with hyperthermia is the 
difficulty of heating the local tumour region to the intended temperature without 
damaging normal tissue.   
 
The potential to use tiny particles of magnetic material and alternating magnetic fields 
to deliver clinical hyperthermia was first explored by Gilchrist et al. in 1957. The 
group injected microscopic particles of magnetite into primary tumours of the bowel 
in dogs, in the expectation the particles would accumulate in the lymph nodes which 
drained the tumour. The nodes were then dissected out and exposed to an alternating 
magnetic field of strength 200±240 Oersted (Oe). It was found that a concentration of 
5mg of magnetite per gram of lymph node tissue yielded a temperature increase of 
14ºC in 3 min. Two years later, the same group conducted an in vivo study using 
rabbits in which inguinal lymph nodes were successfully targeted with heat (Medal et 
al 1959). Total necrosis of the nodes was reported after 3 min of heating at 470 Oe. 
This early work, based on lymphatic uptake of microscopic ferromagnetic particles, 
clearly proved that it was possible to heat tissue in vivo using heat generated when 
magnetic particles are placed within alternating magnetic fields. 
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The mechanism by which heating takes place is by the power absorption of magnetic 
particles when they are exposed to an A/C magnetic field (Jordan 1993). The 
important factor for magnetic heating experiments is the specific absorption rate 
(SAR), which is determined by SAR = C × ΔT/Δt, where C is the specific heat 
capacity of the sample and T and t are the temperature and time, respectively. SAR is 
very sensitive to the material properties. While in multi-domain particles the dominant 
heating is hysteresis loss due to the movement of domain walls, this is not the case 
with small, single domain particles. The two main contributing mechanisms of SAR 
in single domain magnetic nanoparticles are the Brownian (rotation of the entire 
nanoparticle) and Néel (random flipping of the spin without rotation of the particle) 
relaxations (Kotitz 1995, Pakhomov 2005). The transition between the two 
mechanisms occurs between 5-12 nm for various materials, but it also varies with 
frequency (Mornet 2004). 
 
There are several alternative ways to deliver magnetic particles to tumours, either via 
an artery that feeds a tumour, intravenously or via direct injection into the tumour. In 
1976, Rand et al injected particles of iron oxide suspended in silicon into the renal 
arteries of dogs which were then sacrificed and the kidneys placed within a 570 Oe, 
20 KHz alternating magnetic field. Temperature measurements showed the ex vivo 
kidneys heated to 12ºC per minute. In 1994, Mitsumori et al tested dextran coated 
magnetite particles suspended in lipiodol or in a degradable starch microsphere. 
Earlier work had shown that such particles generated significant heat upon exposure 
to an alternating magnetic field (Tazawa et al 1988). The study reported an increase 
of over 12ºC after 10 min of heating, in vivo, in a rabbit kidney following direct 
arterial injection. 
 
The dextran coated particles used by Mitsumori et al were 75nm in diameter with a 
7.4 nm magnetite core. Suspensions containing particles less than 100nm in diameter 
are defined as magnetic fluids, can be heated by weaker magnetic fields and are 
generally less likely to cause heating of peripheral tissues. This may be an advantage 
over the use of larger multi-domain particles, which may require stronger field 
conditions for heating (Jordan et al 1997, Pankhurst et al 2009)). Advantages of 
delivering particles intra arterially is that the particles are more likely to be well 
distributed throughout the tumour, providing a uniform distribution of heat. Further, 
 58 
the poor venous drainage of tumours will favour retention of particles within the 
tumour for repeated hyperthermia therapies (Vaupel 2000, Lin et al 2010). 
 
Magnetic particles can also be directly injected into tumours, this was first 
investigated by Rand in 1982.  The group used ferromagnetic particles suspended in 
normal saline and directly injected these into the renal pelvis of 24 rabbits containing 
unilateral implanted renal carcinomas. On exposure to a magnetic field of 1000 Oe 
alternating at 2 kHz, tumour temperatures of 55ºC were obtained. Histological 
examination of the tumours 3 days after heating revealed complete tumour 
destruction. 
 
The direct intratumoural injection approach was used by Chan et al (1997), who used 
mice containing implanted subcutaneous hind-limb tumours and reported a 
tumour/body differential of 6.5-8.5ºC on exposure to a 7.15 kA/m magnetic field 
alternating at 0.85MHz. The tumours were infiltrated with supraparamagnetic 
colloidal iron oxide particles by direct intratumoural injection. It was found that a 
tumour iron concentration of only 0.5-1.0 mg/g was needed to produce this 
differential heating. 
 
An in vitro study by Hilger et al (2000) examined the effect of magnetic 
thermoablation in cow muscle. In this study, 50-180 mg of magnetite particles (1 
micron diameter) suspended in 0.3mL of physiologic saline containing 1% Tween 80 
were directly injected into prepared cylindrical cavities within samples of fresh cow 
muscle and exposed to a 6.5 kA/m magnetic field, alternating at 400 kHz. 
Temperature increases of up to 87ºC were recorded within 15mm from the particle 
deposits. It was suggested that lesions up to a volume of 0.131 cm3 could be treated 
using a dose of 180 mg of particles. Although the author was investigating the 
technique for use in the ablation of muscle lesions and the cooling effects of blood 
flow were absent, the principle of generating localized tissue heat with magnetic 
particles and externally applied magnetic fields was again demonstrated. Hilger et al 
(2001) have also tested direct intratumoural injection on immunosuppressed mice 
containing implanted human breast adenocarcinoma, as a model of the potential 
treatment of human breast cancer. In this work, a ferrofluid containing 10 nm 
magnetite particles was directly injected into the tumours, which were then exposed to 
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a 6.5 kA/m magnetic field alternating at 400 kHz. Mean tumour temperatures of 63ºC 
were recorded after 2-3 min of heating and all tumours showed histological evidence 
of necrosis. 
 
Recently, Balivada et al (2010) have compared the results of AMF exposure on mice 
with melanoma tumour xenographs using porphyrin coated magnetic nanoparticles 
which were delivered either intravenously or directly intratumorally.  The group 
found a significant reduction in tumour size in both groups after exposure to AMF 
suggesting the intravenous route may be a possibility however they also noted 
significant amounts of nanoparticles in the lungs and liver of the tumours. 
 
Since 2001, there have been several phase 1 clinical trials of magnetic fluid 
hyperthermia using direct injection of magnetic nanoparticles. In 2006, Johannsen et 
al reported promising results from a feasibility study involving 10 patients with 
locally recurrent prostate cancer treated with magnetic fluid hyperthermia. In 2007, 
Maier-Hauff and colleagues treated patients with recurrent glioblastoma multiforma 
using combination of radiotherapy and magnetic fluid hyperthermia.  Patients 
received 4-10 repeated hyperthermia treatments and a mean temperature increase of 
44.6°C was achieved intratumourally. There were signs of local tumour control, no 
toxic or adverse effects of the therapy and the study concluded that magnetic fluid 
hyperthermia can safely be used in glioblastoma multiforma patients. 
 
An advance on either intra vascular injection of particles or on direct tumour injection 
would be the use of targeted particles. This was first explored by Suzuki et al (1995) 
who described the attachment of monoclonal antibodies to magnetite particles, using 
polyethylene glycol with terminal carboxy or amino groups. Analysis of the cells after 
incubation determined that 90 pg of magnetite had been adsorbed per tumour cell, 
four times the amount compared to control cells.  
 
In 2005, deNardo et al attached 20nm poly ethylene coated nanoparticles to 
monoclonal antibodies and used these constructs in vitro and in vivo experiments. 
Using a 153KHz alternating magnetic field (AMF) at strengths of 700, 1000, 1300 Oe 
significant reductions in tumour growth were seen compared to controls with no 
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treatment.  This early work demonstrates the potential for developing a system using 
antibody-nanoparticle complexes to deliver targeted magnetic fluid hyperthermia.   
 
 
1.6 Research Aims 
 
 
The overarching hypothesis for this research is that the αvβ6 integrin is a clinically 
useful target in oral squamous cell carcinoma and non melanoma skin cancers. This 
thesis aims to test the hypothesis in several ways.  Firstly, expression levels of αvβ6 
in pre malignant actinic keratoses and basal cell carcinomas of the skin will be 
examined.  The clinical utility of αvβ6 will be tested by determining whether the 
integrin is an independent prognostic marker in oral squamous cell carcinoma.  
Finally, a single chain antibody fragment specific to αvβ6 will be designed, produced 
and tested for its ability to deliver nanoparticles to αvβ6 expressing cells for the 
delivery of targeted magnetic alternating current hyperthermia. 
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Chapter 2 
 
 
 
Materials and Methods 
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2.1  Materials and suppliers  
 
Buffers Formula 
Tris-borate (TBE) stock (10x) 100mM Tris, 10mM Boric acid, 1.25 mM EDTA 
10x DNA loading buffer for agarose gels  2.7 ml glycerol, 0.3 ml TBE buffer (10x), 1% SDS, 1ml 0.5 
M EDTA, pH 8.0 
DNA loading buffer 0.25% bomophenol blue, 0.25% xylene cyanol FF, 30% 
glycerol in dd H20 
DNA Markers in loading buffer Marker 10 µl, loading buffer 10 µl, dd H20 80 µl 
2 x SDS-PAGE loading buffer 1.25mM Tris-HCl, pH 6.8; 20% (v/v) glycerol, 2% (v/v) β-
mercaptoethanol; 0.1% (w/v) bromophenol blue; 0.1% 
(w/v) SDS 
1 x SDS PAGE running buffer 25mM Tris-HCl, 192 mM glycine, 20% (w/v) SDS 
5x SDS loading buffer 250mM TrisHCl pH6.8, 10%SDS, 30% Glycerol, 5% β-
mercapitalethanol, 0.02%bromophenol blue 
1 x transfer buffer 25 mM Tris-HCl, 192 mM glycine,, 20 % (v/v) methanol 
Coomassie gel stain 0.1% (w/v) Coomassie Blue R-250, 45% (v/v) methanol; 
10% (v/v) glacial acetic acid 
Coomassie gel destain 30% (v/v) methanol, 10% (v/v) glacial acetic acid 
NEBuffer 4 50 mM potassium acetate, 20 mM Tris-acetate, 
10 mM Magnesium Acetate, 1 mM Dithiothreitol 
Qiagen buffer P1 (resuspension) 50mM TrisCl, pH 8.0, 10mM EDTA, 100µg/ml Rnase A 
Qiagen buffer P2 (lysis) 200mM NaOH, 1% SDS (w/v) 
Qiagen buffer P3 (neutralisation) 3.0 M potassium acetate, pH 5.5 
Qiagen buffer QBT (equilibration) 750 mM NaCl, 50 mM MOPS, pH 7.0, 15% isopropanol 
(w/v), 0.15% Triton® X –100 (v/v) 
Qiagen buffer QC (wash) 1.0 M NaCl, 50mM MOPS, 15% isopropanol 
Qiagen buffer QF (elution) 1.25 M NaCl, 50 mM TrisCl, pH 8.5, 15% isopropanol 
(v/v) 
Direct Purification Buffer 
 
50mM KCl 
10mM Tris-HCl (pH 8.8 at 25°C) 
1.5mM MgCl2 
0.1% Triton® X-100 
 
TE Buffer 
 
10mM Tris-HCl (pH 7.5) 
1mM EDTA 
10X T4 ligation buffer 400 mM Tris-HCl, 100 mM MgCl2, 100 mM DTT, 5 mM 
ATP (pH 7.8 at 25°C). 
 
Table 2.1 – Solutions for protein manipulation and analysis 
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Media Formula 
2x YT broth 
 
16g tryptone, 10g yeast extract, 5g NaCl. Made up to 1l 
with dH20 then autoclaved.  For 2x YT Agar, add 15g agar 
prior to autoclaving 
Luria Bertani Broth (LB) 
 
10 g tryptone, 5 g yeast extract, 10 g NaCl. Complete to 1 
L with dH20. Autoclave. 
For LB Agar, add 15 g/L agar prior to autoclaving. 
 
Table 2.2 - Media for bacterial growth 
 
 
Media Formula 
Yeast Extract Peptone Dextrose Medium 
(YPD) 
 
Dissolve 10 g yeast extract and 20 g peptone in 900 ml 
dH20.  Autoclave. When cool add 100 ml 20% glucose 
solution.  Store at 4°C. 
For YPD agar add 20 g/L agar prior to autoclaving. 
YPD with sorbitol (YPDS)  
 
Dissolve 10 g yeast extract, 20 g peptone and 182.2 g 
sorbitol in 900 ml dH20.  Autoclave. When cool add 100 
ml 20% glucose solution.  Store at 4°C. 
For YPDS agar add 20 g/L agar prior to autoclaving.   
Buffered Methanol-complex Medium 
(BMMY)  
Dissolve 10 g yeast extract and 20 g peptone in 900 ml 
dH20.  Autoclave. When cool add 100 ml 1M potassium 
phosphate buffer, pH 6.0, 100 ml 13.4% YNB, 2 ml 0.02% 
biotin, 100 ml 5% methanol.    Store at 4°C. 
 
YPD medium/glucose primary culture 
medium 
Dissolve 4 g peptone, 4 g yeast extract, 3 g glucose into 
230 ml dH20.  Autoclave. 
Basic salt medium  Dissolve 5.4 g CaSO4 , 87.6 g K2SO4, 70.2 g MgSO4: 
7H2O,  54 g (NH4)2SO4 and 300 ml Glycerol into 5.0 L 
dH20.  Autoclave. 
Sodium hexametaphosphate  
 
Dissolve 150 g in 1 L dH20. Filter sterilise.  
Secondary culture medium 300 ml basic salt medium 30 ml sodium 
hexametaphosphate, 1 ml trace elements (see Table 2.6). 
Filter sterilise. 
Fermentation medium 4.7 L basic salt medium, 1 L sodium hexametaphosphate, 1 
ml anti-foam, 24 ml trace elements. Autoclaved in 
fermentor.  
Limited glycerol feed 300 ml glycerol, 300 ml dH20. Autoclave. Add 7 ml sterile 
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trace elements. 
Limited methanol feed 2 L methanol, 24 ml sterile trace elements. 
 
Table 2.3 – Yeast growth media and solutions 
 
Buffers Formula 
Keratinocyte Growth Medium (for VB6 
cells) 
450mls αMEM (Invitrogen), 50mls 10% Fetal calf serum, 
5mls Penecillin/streptokinase, 7.5mls 20Mmol Glutamine, 
250µl Insulin, 2mls Hydrocortisone, 500µl EGF, 5mls 
Adenine, 500µl Cholera Toxin  
 
A375B6 Culture Medium  500mls DMEM media (Lonza Biowhittaker, Woking, UK), 
10% FCS, Pen/Strep and 2mMol glutamine 
HT29 Culture Medium 500mls McCoys 5A media (Lonza Biowhittaker, Woking, 
UK), 10% FCS, Pen/Strep and 2mMol glutamine 
Trypsin Versene EDTA and trypsin 
Freezing Medium 1ml dimethyl sulphoxide (DMSO) with 9ml foetal calf 
serum 
  
Table 2.4 - Solutions for tissue culture 
 
 
Buffers Formula 
0.1 M Sodium hydrogen phosphate 
buffer pH 9.0 
14.1g Na2HPO4  dissolved in 1l dH20. Adjusted to pH 9.0 
with NaOH. 
Glycine 25mM Dissolve 0.18g glycine into 100mls 1xPBS 
MES buffer 0.5M Dissolve 106.6g 2-(4-morpholino)ethanesulphonic HCl in 
1l dH20. Adjust to pH 6.3 with Na2CO3 
MES buffer 0.1M Dissolve 21.3g 2-(4-morpholino)ethanesulphonic HCl in 1l 
dH20. Adjust to pH 6.3 with Na2CO3 
EDC/NHS activation buffer 
 
 
 
Dissolve 0.6mg 1-ethyl-3-(3-dimethlaminopropyl)-
carbodiimide hydrochloride and 1.2mg N-
hydroxysuccinimide in 200µl 0.5M MES buffer 
Activation Buffer for cyanogen bromide 
conjugation 
0.1M Sodium hydrogen phosphate buffer pH9. Filter to 
sterilise 
 
Table 2.5 – Solutions for nanoparticles-scFv conjugation 
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Buffers Formula 
FeCl3 standard Dissolve in 1 litre H20 
Lysis buffer 50 mM NaOH 0.2g dissolved in 100ml H20 
Iron Releasing Buffer Dilute 3.5ml of 4M HCl into 10ml H20. Add to 10ml 
solution of 0.45g KMnO4 dissolved in H20 
Iron Detecting Buffer Dissolve in 5mls H20 0.015g ferrozine, 0.015g 
neocuproine, 0.96g ammonium acetate and 0.9g ascorbic 
acid. 
 
Table 2.6  - Solutions for Ferrozine Assay 
 
 
All experiments were in accordance with HSE guidance on COSHH and carried out 
following standard guidelines for good laboratory practice.  The work was carried out 
within the Department of Oncology, Royal Free and University College Medical 
School, at The Cancer Institute, University College London and at the Centre for 
Tumour Biology, Institute of Cancer, Bart’s and the London School of Medicine and 
Dentistry, UK.  
 
 
2.1.1 Chemicals and reagents 
 
All chemicals were of AnalaR grade and purchased from VWR-BDH Ltd 
(Gillingham, Dorset, UK) or Sigma-Aldrich Company Ltd (Poole, Dorset, UK), 
unless otherwise stated.  Buffers, solutions and antibiotics were prepared using 
distilled de-ionised water (dH20; Elga, UK), unless otherwise stated.   
 
2.1.2 Superparamagnetic Nanoparticles 
 
Chemicell FluidMAG-DX® magnetic nanoparticles were purchased from Chemicell 
GmbH, Berlin, Germany.  Resovist® nanoparticles were purchased from Bayer 
Schering Pharma, Newbury, UK. 
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2.1.3 Glassware and disposables 
 
All glassware used was washed with tap water and detergent followed by rinsing with 
dH20.  All plastic-ware was purchased from VWR-BDH Ltd (Gillingham, Dorset, 
UK), unless otherwise stated.   
 
 
2.2 Methods 
 
2.2.1 Manipulation of bacterial DNA 
 
 
2.2.1.1 Expression Vectors and Primers 
 
The plasmid hsMFEpCTCON (C.P. Graff et al Protein Eng.Des.Sel. 2004, 17, 293-
304, available in the laboratory) was used as template for PCR amplification. The 
bacterial expression vector pUC119HIS was a kind gift from the MRC Laboratory of 
Molecular Biology, Cambridge, UK. Primers were obtained from MWG Biotec 
(Ebersberg, Germany), dissolved at concentrations of 100pM/µl and stored at –20ºC. 
 
 
2.2.1.2 PCR  
 
PCR reactions were carried out using the Taq PCR Master Mix Kit (Qiagen GmbH, 
Hilden, Germany) kit. 
 
Template    40 µl 
Primers  – forward 0.5µl 
- back  0.5 µl 
PCR Master mix   50 µl 
dd H20    9 µl 
Total reaction volume  100 µl 
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Cycling carried out using Biometra Personal Cycler in steps as follows :  Initial, 94ºC 
for 2 minutes; Denaturing, 94ºC for 30 seconds, Annealing 50ºC for 60 seconds, 
Elongation 72ºC for 7 minutes cycled 30 times with final elongation step 72 ºC for 7 
minutes. 
 
First PCR reaction amplified the 5’end of the 6.2.2. DNA sequence using primers 
hsMFE sense  and 6.2.2. antisense with hsMFEpCTCON plasmid as template. The 
second PCR reaction amplified the 3’ end of the 6.2.2. DNA sequence using primers 
hsMFE antisense and 6.2.2. sense with plasmid hsMFEpCTCON. 
 
PCR reactions were carried out using varying amounts of template which had been 
diluted 1:1000.   Amounts used were 1µl, 2µl, 3µl, 4µl, 5µl. 
 
Following purification of the PCR products (see below), the 5’ end of the 6.2.2. DNA 
sequence was diluted to 1:100 and the 3’ end of the 6.2.2. DNA sequence was diluted 
to 1:1000 with dd H20. A third PCR reaction was set up to assemble the whole 6.2.2. 
DNA sequence using the partly overlapping products from the first two reactions as 
templates with the primers hsMFEsense and hsMFE antisense.  This reaction used 
varying amounts of 2µl, 5µl and 10µl of both templates.  The resulting PCR product 
was then purified using the Wizard Purification Kit (Promega, Madison, WI, USA) 
following the manufacturer’s instructions. 
 
300µl of PCR product was transferred to a 1.5ml microcentrifuge tube and 100µl of 
direct purification buffer was added and mixed with 1ml of purification resin by 
vortexing three times over 1 minute.  The mixture was transferred to a Wizard PCR 
Prep Minicolumn then 2ml of 80% isopropanol was added and the slurry pushed 
through the column with a syringe plunger.  The Minicolumn was then transferred to 
a 1.5ml microcentrifuge tube and centrifuged for 2 minutes at 10,000 x g before 50µl 
of water was added to elute the DNA by final centrifugation for 20 seconds at 10,000 
x g. 
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2.2.1.3 PCR for site-directed mutagenesis 
 
Site-directed mutagenesis was performed using the QuikChange® Site-Directed 
Mutagenesis Kit (Stratagene, Cambridge, UK) using a set of complementary primers 
overlapping the region to be mutated.  Melting temperatures (Tm) of the primers to 
determine annealing temperatures in PCR amplifications were estimated using the 
following equation: 
 
 
Tm=81.5 + 0.41(%GC) -675/N-%mismatch 
 
Where N is the primer length in bases, and % GC and % mismatch are whole 
numbers. 
 
Amplification was carried out according to manufacturer’s protocols in 600 µl snap-
fit thin-walled tubes (Bio-Rad Laboratories, UK).  Briefly, 5 µl (5 ng) of template 
plasmid DNA was added to 5 µl 10 X reaction buffer (consisting of 100 mM KCl, 100 
mM (NH4)2SO4, 200 mM Tris-HCl (pH 8.8), 20 mM MgSO4, 1% Triton® X-100, 1 
mg/ml nuclease-free bovine serum albumin), 1 µl dNTP mix, 1.25 µl each 
oligonucleotide (125 ng), and sterile dH2O to 50 µl. One microlitre of PfuTurbo® 
DNA polymerase (2.5 U/ µl) was then added to each reaction.    Reactions were 
incubated at 95°C for 30 s followed by 12 cycles of PCR as follows:  95°C for 30 s, 
55°C for 1 min, 68°C for 2 min/kb plasmid length (reaction times were between 12-
13.2 min).  
 
 
2.2.1.4 Agarose Gel Electrophoresis 
 
For agarose gel electrophoresis, Agarose MP was supplied from Roche Diagnostics 
(Lewes, East Sussex, UK).  DNA Molecular Weight Markers II (Hind III-digested λ 
DNA) and IX (Hae III-digested φx174 DNA) were purchased from Roche 
Diagnostics Ltd (Lewes, East Sussex, UK).  Figure 2.1 shows sizes of standards. 
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Figure 2.1 - DNA Markers II and IX shown run on 1% agarose gel with relative sizes and ng of DNA 
in 4µl 
 
Gel electrophoresis was conducted using 1% horizontal slab gels run on a Hi-Set mini 
electrophoresis unit (Anachem, UK).  Gels were made up using 0.5mg of agarose MP 
(Roche Diagnostics, UK) dissolved in 50ml 1x TBE buffer (Table 2.1) by microwave 
heating.  5 µl ethidium bromide was added to the solution after cooling to a 
temperature that allowed the glassware to be comfortably handled and the gel poured 
into the electrophoresis unit with appropriate well forming units. 
 
For agarose gel electrophoresis, 10x DNA loading buffer (Table 2.1) was added to the 
DNA at a ratio of 2µl buffer to 8 µl DNA and this solution was applied to the gel.  In 
all cases, electrophoresis was carried out using 1x TBE buffer at a constant 50 mV 
powered with the Pharmacia LKB-GPS 200/400 powerpack (Pharmacia, UK).  Bands 
were visualised using a UVP transilluminator (Genetic Research Instrumentation Ltd, 
Essex, UK) prior to photography using a DS34 polaroid direct screen instant camera 
(Genetic Research Instrumentation Ltd, Essex, UK) and black and white Polaroid film 
type 667.  
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2.2.1.5 Purification of DNA from Agarose 
 
DNA was extracted using the QIAEX II Agarose Gel Extraction Protocol (Qiagen 
GmbH, Hilden, Germany).  After agarose gel electrophoresis desired DNA bands 
were excised with a scalpel and the gel was placed in a 1.5ml microcentrifuge tube. 
The gel was then weighed and Buffer QX1 (Table 2.1) was added to the tube at a ratio 
of 1:3 volumes which was then incubated at 50ºC for 10 minutes with vortexing every 
2 minutes.  The sample was then centrifuged for 30s at 10,000 x g, supernatant 
removed and the pellet washed once with Buffer QX1 then twice with Buffer PE 
(Table 2.1) to remove residual salt contaminants.  The pellet was air dried for 30 
minutes until white.  The DNA was eluted in 20µl dH20 prior to centrifuging for 30 
sec and the supernatant then pipetted into a 1ml tube. This final step was repeated 
once. 
 
 
 
2.2.1.6 PCR Product and Plasmid Digestion 
 
Restriction site enzymes were used to cut the 6.2.2. PCR product and the plasmid 
vector VLpuc119 (available in the laboratory).  To test the enzymes, a small scale 
digestion was carried out using 1µl plasmid (3.8µg), 0.5µl NcoI, NotI digestion 
enzymes (New England Biolabs, Ipswich, MA, USA), 1µl NEBuffer 3, 1µl BSA 
(10%) and 6µl dd H20.  All digestion took place at 37°C over 4 hours using the PCR 
personal cycler.  Successful digestion was verified by 1% Agarose Gel 
electrophoresis. 
 
Large scale digestion was then performed using 5µl plasmid (19µg), 2.5µl NcoI, NotI 
digestion enzymes (New England Biolabs), 5µl NEBuffer 3, 5µl BSA (10%) and 30µl 
dd H20.  PCR product digestion was conducted using 35µl PCR product, 2.5µl NcoI, 
NotI digestion enzymes (New England Biolabs), 5µl NEBuffer 3 and 5µl BSA (10%). 
Purification of digestion products was performed using 1% agarose gel 
electrophoresis and DNA eluted from the gel using Qiagen Gel Extraction Kit as 
above. 
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2.2.1.7 Protein Ligation 
 
Ligation of digested PCR product and digested VLpuc119 vector was performed at 
differing ratios of vector to insert 1:1, 1:3, 1:5, 3:1 and a control of vector only.  In 
each case, 10ng of vector were used, with the appropriate amount of digested PCR 
product,  2µl 5x DNA buffer was added to the reaction mixture and the volume made 
up to 10µl with ddH2O, then 10µl T4 DNA Ligation Buffer was added followed by 
1µl T4 DNA Ligase.  The mixture was then incubated for 30 minutes at room 
temperature. 
 
 
2.2.1.8 Phenol Extraction of DNA from Ligation Mixture 
 
In a 1.5ml microcentrifuge tube, 21µl ligation mixture was added to 81µl dd H20 and 
to this, a further 100µl of Phenol:Chloroform Isamyl alcohol were added.  The sample 
was vortexed for one minute and then centrifuged for 3 minutes, 14,000 x g at room 
temperature.  The upper aqueous phase was then carefully transferred to a clean tube 
to which 100µl dichloromethane was added, the sample vortexed then again 
centrifuged at 14,000 x g for 3 minutes.  The DNA containing upper phase was taken 
and 1/20 vol of 3M NaAc (pH5.6) added prior to DNA being precipitated by adding 1 
vol of isopropanol.  The whole mixture was then vortexed for 1 minute and 
centrifuged for 10 minutes at 14,000 x g before discarding the supernatant.  The 
sample was then washed with 70% ethanol, supernatant carefully removed and the 
DNA pellet allowed to air dry overnight.  The following morning, the sample was 
solubilized in 5µl dd H20. 
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2.2.2 Bacterial Protein Production 
 
2.2.2.1 Microbial strains 
 
The bacterial strain TG1 was a kind gift from Professor Robert Hawkins (Cancer 
Research UK Department of Medical Oncology, Paterson Institute of Cancer 
Research, Manchester, UK). TOP10F’ and the wild-type yeast strain X-33 were 
obtained from Invitrogen (UK).   
 
 
2.2.2.2 Transformation of phenol extracted ligation mixture by electroporation 
 
Electrocompetent TG1 cells were defrosted on ice.  1 µl of plasmid (1:1000 dilution) 
was added to 50 µl of thawed cells and the sample then transferred into 0.2 cm 
cuvettes (BioRad Laboratories, Hemel Hempstead, UK) pre chilled on ice.  Cuvettes 
were then individually pulsed at 2.5kV, 25 µFD, 200 Ω using the Bio-Rad 
Micropulser (Bio-Rad Laboratories - as above) and after electroporation, 0.5 mls 
2YT, 1% glucose (no ampicillin) was added and the cuvettes incubated at 37 ºC for 1 
hr.  Following this, 100 µl of the culture was plated onto agar with 2YT, 1% glucose, 
100µg/ml ampicillin and plates were then incubated overnight at 37ºC. 
 
 
 
 
2.2.2.3 PCR Colony screening 
 
Individual bacterial colonies were picked from agar plates using autoclaved wooden 
sticks and split half to grow in 2x YT/1% glucose/100µg/ml ampicillin and half for 
PCR colony screening.  For screening, cells were suspended in 50 µl dd H20, heated at 
100ºC for 10 minutes, centrifuged and 40 µl were used in PCR reaction as above with 
primers hsMFE sense and hsMFE anti-sense.  However, for this PCR reaction we 
used a total volume of 50µl only.  
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2.2.2.4 Plasmid Extraction 
 
This was carried out using the QIAGEN Plasmid Midi Extraction Kit (Qiagen GmbH, 
Hilden, Germany).  Cells were grown overnight at 37ºC shaking at 300 x g from 60 µl 
starter culture in 30 mls 2xYT, containing 1% glucose and 100µg/ml ampicillin 
contained in sterile 250 ml flasks.  Bacterial cells from culture were centrifuged at 
6000 x g for 15 minutes at 4ºC and the pellet re-suspended in 4ml Buffer P1 (Table 
2.1) before adding 4mls Buffer P2 and incubating at room temp for 5 min.  Next, 4mls 
chilled Buffer P3 was added and the mixture incubated on ice for 15 min before 
centrifuging at 20,000 x g for 30 min at 4 ºC and removing the plasmid containing 
supernatant.  Centrifugation was repeated at 20,000 x g for 15 min at 4ºC and the 
supernatant was immediately applied to QIAGEN-tip 100 columns which had been 
primed using 4ml Buffer QBT.  The column was next washed twice with 10mls 
Buffer QC prior to DNA elution using Buffer QF and the eluate collected in a clean 
15ml centrifuge tube.   
 
To precipitate DNA, 3.5mls isopropanol was added to the elute and the sample 
centrifuged at 15,000 x g for 30 min at 4ºC.  The supernatant was carefully removed 
and the pellet washed with 70% ethanol at room temperature by centrifugation at 
15,000 x g for 10 min before again removing the supernatant and air drying the DNA 
pellet overnight.  Finally the DNA was dissolved in 100 µl dH20. 
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2.2.2.5 Determination of DNA yield after purification  
 
This was quantified using optical density measurements on a spectrophotometer 
(CECIL CE2041 2000) at wavelength of 260 nm using a quartz cuvette.  The 
spectrophotometer was zeroed using dd H20 and samples of purified DNA diluted 
1:1000 before taking readings at 260 nm.  DNA purification was calculated using the 
following formula: 
 
[DNA] = (Optical Density260 x 50 x dilution factor) µg/ml 
 
Optical Density260 of 1.0 is equivalent to [DNA] of 50 µg/ml 
  
2.2.2.6 Protein Expression 
 
Single colonies from transformed E.coli cells were selected from agar plates and 
cultured overnight at 37ºC, 225 x g in 5mls 2YT, 1% glucose, 100µg/ml of ampicillin.  
Cells were harvested by centrifuging at 3,900 x g for 20 min then re-suspended in 
5mls 2YT, 100µg/ml ampicillin, 5µl β-D-thiogalactoside (IPTG) (1M stock) and 
grown overnight at 30ºC with shaking at 225 x g.  The culture was again centrifuged 
at 3,900 x g and the supernatant containing expressed protein decanted into clean 
polypropylene tubes. 
 
 
2.2.2.7 Protein Concentration 
 
500µl supernatant following protein expression was loaded onto Vivaspin 500 
centrifugal concentrators (Sigma Aldridge, UK) with membrane pore size of 10,000 
Da MWCO. This was centrifuged at 15,000 x g for 20 minutes and the protein 
concentrated to a volume of 5µl prior top loading for SDS-PAGE electrophoresis or 
Western blot analysis. 
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2.2.2.8 SDS PAGE Electrophoresis 
 
Samples for electrophoresis were made up using 200 µl of supernatant containing the 
expressed protein and this was mixed with 67µl of 5x SDS PAGE reducing buffer in 
1ml microcentrifuge tubes.  Protein denaturation was achieved by heating for 10 min 
at 99.9ºC in the Biometra Personal Cycler.  Samples were loaded onto two 12% Tris-
Glycine pre-cast mini gels (Invitrogen, Paisly, UK) and run on an Xcell II™ Mini-
Cell system (Invitrogen) in 1 x SDS PAGE Running Buffer at a constant 35mA 
(125V, 5W) for 1.5 hrs using a PowerEase® 500 power supply (Invitrogen).  Protein 
molecular weight marker (See Blue®) was obtained from Invitrogen and run in lane 1 
(figure 2.2).  After electrophoresis, one gel was stained using Coomassie blue and one 
loaded for Western blot analysis.  Gels for staining were soaked for one hour in 
Coomassie blue at room temperature on a shaker then transferred into Destain to soak 
overnight. 
 
 
 
Figure 2.2 :-See Blue® marker after subjection to SDS- PAGE with apparent molecular weights (From 
Invitrogen catalogue). 
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2.2.2.9 Western blot analysis 
 
Gels from electrophoresis were transferred onto 0.45 µm polyvinylidene difluoride 
(PVDF) membrane (Bio-Rad Laboratories, as above) which had been pre-soaked in 
methanol.  The gel was placed next to the membrane and inbetween eight sheets of 
blotting paper (Whatman, Maidstone, UK) pre soaked with 1x Transfer buffer and 
then into an XCell II Blot Module (Invitrogen, as before).  The Module was placed in 
the XCell Mini Cell System and run at 125 mA (25V, 17W) for 1.5 hrs using 1x 
transfer buffer. 
 
Following protein transfer from gel to membrane, the membrane was removed and 
blocked for 1hr at room temperature in 5% Marvel (Marvel, UK) dried milk powder 
made up with PBS.  After 1 hr on the shaker, membrane was washed three times in 
0.1% (v/v) Tween-20 in PBS followed by three times with PBS.  Next, the membrane 
was stained with 20 µl mouse anti-tetra-His antibody (Qiagen, 100µg/1ml stock) in 
20mls 1% Marvel in PBS for one hour under shaking, then washed four times in 
Tween/PBS followed by four times in PBS.  Secondary staining was achieved using 
20µl sheep anti-mouse IgG antibody (GE Healthcare) again dissolved in 20mls 
1%Marvel/PBS and left for 1 hour at room temperature under shaking. 
Finally, the membrane was washed again four times in Tween/PBS and proteins 
visualised using DAB solution (0.25 mg/ml 3,3’- Diaminobenzidine 
tetrahydrochloride, 0.5µl/ml H202 in dH20).  When protein bands became visible after 
20mins, the reaction was stopped by rinsing the membrane in dH20 and membrane 
was then air dried.  
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2.2.3 Protein Production in Yeast 
 
2.2.3.1 Linearisation of plasmids for homologous recombination with X-33 
yeast genome 
 
pPICZα-B based plasmids (or modified pPicZαB vector) containing insert DNA were 
linearised for transformation into the X-33 yeast genome.  10 µg (approx. 10 µl) of 
plasmid DNA was digested with 4 µl Pme I (40 units; New England Biolabs) for 2 h 
at 37°C in the presence of 5 µl 10 X NEBuffer 4 (Table 2.1), 5 µl BSA (10 x BSA; 
final concentration 100 µg/ml),  and completed to 50 µl with sterile dH20.    Reactions 
were stopped by heat inactivation at 65°C for 20 min and digested DNA was purified 
by phenol:chloroform extraction and precipitated 
 
 
2.2.3.2 Preparation of electro-competent yeast cells 
 
Yeast wild-type X-33 strain was purchased from Invitrogen (UK) and prepared for 
electroporation following protocols by Invitrogen (UK).  Five millilitres of YPD 
media (Table 2.3) was inoculated with X-33 cells picked from agar stabs 
(EasySelect™ Pichia Expression Kit; Invitrogen, UK) and the inoculated culture was 
grown overnight at 30°C, 250 x g in an orbital shaker.  The next day, 500 ml YPD 
was inoculated with 0.5 ml overnight culture and grown at 30°C, 250 x g until an 
OD600 of between 1.3-1.5 (~16 h). 
 
Cultures were centrifuged at 1,500 x g for 5 min at 4°C and pellets resuspended in 
500 ml ice-cold sterile dH2O.   Cells were centrifuged as before, followed by 
resuspension of the pellet in 250 ml ice-cold sterile dH2O.  The cells were again 
centrifuged and the pellet resuspended in 20 ml ice-cold sterile 1 M sorbitol.  The 
process was repeated once more and cells resuspended in 1 ml ice-cold sterile 1 M 
sorbitol.  The cells were stored on ice and used the same day. 
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2.2.3.3 Electroporation of electro-competent yeast cells 
 
Eighty microlitres of freshly prepared X-33 electrocompetent cells were added to 10 
µl of linearised plasmid DNA and incubated on ice for 1 min.  Cells were transferred 
to a pre-chilled 0.2 µm cuvette (Biorad) and pulsed once using the pre-set ‘Pic’ setting 
on BioRad MicroPulser™ (Bio-Rad Laboratories Ltd., Hemel Hempstead, U.K.) for 5 
ms at 2000 V.  One millilitre of ice-cold, sterile 1 M sorbitol was immediately added 
to the mixture, the contents of the cuvette were transferred to a sterile 15 ml tube and 
the cells were incubated at 30°C for 2 h with no shaking.  Transformed cells were 
spread onto YPDS plates (Table 2.3) containing Zeocin™ (100 µg/ml) in 10, 25, 50, 
100, and 200 µl aliquots and incubated at 30°C for 4-5 days until colonies formed.  At 
this time, ten clones were picked and streaked onto fresh YPDS Zeocin™ plates and 
incubated for 2-3 days until colonies formed. 
 
 
2.2.3.4 Protein expression in yeast  
 
Individual colonies were picked from YPDS plates (Table 2.3) containing 100 µg/ml 
Zeocin and inoculated into 5ml BMGY medium (Table 2.3) and grown until an OD600 
of 2-5 at 30°C, 250 x g (approximately 16 h).  Overnight cultures were centrifuged for 
5 min at 3,000 x g (room temperature) and pellets were resuspended in BMMY (Table 
2.3) with the addition of 1 % casamino acid, pH 6.0 medium to a final OD600 = 1 
(approximately 50 ml).  Cultures were expressed at 30°C, 250 x g with the addition of 
100% methanol for a final concentration of 0.5% (v/v) every 24 h for a total of 96 h.  
At this time cultures were centrifuged for 10 min at 3,000 x g and supernatants were 
filtered through 0.2 µm Nalgene filters and stored at either 4°C for immediate 
purification or at -80°C.  Glycerol stocks were made for high expressers by mixing 
900 µl of culture with 100 µl sterile glycerol, followed by storage at -80°C. 
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2.2.3.5 Seed lot preparation for P. pastoris fermentation 
 
Single colonies growing on YPDS-zeocin plates were streaked out onto the freshly 
prepared YPDS-zeocin plates and grown at 30°C until colonies formed (1-2 days) in 
an empty incubator which had been sprayed with 80% (v/v) ethanol in sterile dH20.  
Colonies were picked from the plates and used to inoculate 50 ml sterile YPDS-
zeocin.  The culture was grown at 30°C, 250 x g in an empty incubator which had 
been sprayed with 80% (v/v) ethanol until an OD600 = 15-25 (approximately 48 h).  At 
this time the culture was centrifuged in a sterile centrifuge tube for 10 min at 3,000 x 
g and moved into a laminar flow cabinet.  The pellet was resuspended in 25 ml sterile 
YPD and dispensed in 1 ml aliquots into cryovials (Nunc) for storage at -80°C. 
 
 
2.2.3.6 Fermentation of P. pastoris X-33 cells  
 
Fermentations of P. pastoris X-33 cells were carried out with the help of Dr. Berend 
Tolner (UCL Cancer Institute, London) using a Bioflo 3000 Batch/Continuous 
Bioreactor (New Brunswick Scientific, Edison, NJ, USA).  One frozen vial containing 
1 ml of seed lot was used to inoculate a 250 ml primary culture of YEPD Glucose 
medium (Table 2.3) and the culture was grown overnight at 30°C at 180 x g 
(OD600=12).   Concomitant with this, fermentation medium was prepared by mixing 5 
L basic salt medium in the fermentor and 1 L sodium hexametaphosphate (see Table 
2.4). 
 
Five millilitres of the primary culture was used to inoculate a 0.2 µm filter-sterilised 
(Nalgene Ltd., UK) secondary culture comprised of 300 ml basic salt medium, 30 ml 
sodium hexametaphosphate, and 1 ml trace elements (Table 2.3).  The secondary 
culture was grown overnight at 30°C at 180 x g (OD600=5).   The 10 L fermentor, with 
remaining basic salt medium, was autoclaved and the remaining sodium 
hexametaphosphate was added, along with 1 ml anti-foam (Sigma-Aldrich Ltd., UK) 
and 24 ml trace elements.  The fermentor pH was set to 5.0, regulated by a base 
solution of 100% NH4OH and an acid solution of 10% ortho phosphoric acid.  The 
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dissolved oxygen probe was set to 40%. The run was started upon addition of the 
complete secondary starter culture. 
 
A limited glycerol feed (made up of an autoclaved mixture of 300 ml 100% glycerol 
with 300 ml water and 7 ml trace elements) was started immediately upon a sharp 
increase in dissolved oxygen (approximately 23-24 h) and the pH was reset to 6.5. 
One hour after the start of the limited glycerol feed, 11 ml of limited methanol feed 
(made up of 2000 ml methanol and 24 ml trace elements) was directly injected into 
the fermentor. Flow rates of glycerol and methanol feeds were altered during the run 
and are given in Table 2.7.  The fermentation run was stopped after approximately 72 
h post inoculation, at which time the cells were harvested by centrifugation at 11,300 
x g for 1 h.  Cleared supernatants were filtered through 0.2 µm Nalgene vacuum filters 
(Millipore UK) and either immediately purified or stored at -80°C. 
 
Time post limited feed start 
(h) 
Flow rate glycerol 
(ml/h) 
Flow rate methanol 
(ml/h) 
0 120 0 
1.0 120 0 
1.5 100 0 
2.0 80 0 
2.5 60 0 
3.0 40 0 
3.5 20 0 
4.0 0 10 
6.0 0 20 
8.0 0 30 
10.0 0 42-45 
 
Table 2.7 - Flow rates for addition of glycerol and methanol during yeast fermentation 
 
 
2.2.3.7 Purification of scFv after large scale Pichia production 
 
Supernatant from the Pichia fermentation was purified using expanded bed adsorption 
immobilised metal affinity chromatography IMAC (GE Healthcare)).  
 
Firstly, the expanded bed adsorption column was connected to the spectrophotometer 
and zeroed with water. Next, the column was charged with 0.1 M copper sulphate 
solution at flow rate of 300 cm/h. Unbound ions were washed off with dH2O until 
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UV signal returned back to baseline. Ten column volumes of loading buffer (Table 
2.1) were then run through the column.  
 
Before application to the column, the Pichia supernatant diluted 1:1 with 2 M NaCl in 
2x PBS, then loaded onto the charged EBA column at flow rate 300 cm/h. Following 
this, loading buffer was run through until the UV signal reached baseline. To remove  
contaminants, 40 mM Imidazole wash buffer was applied to the column at a flow rate 
300 cm/h. Next, the column flow was reversed and the target histidine-tagged scFv 
proteins were eluted from the column by application of 200 mM Imidazole elution 
buffer to the column at flow rate 150 cm/h fraction. Peak fractions were analysed on a 
spectrophotometer at OD280, those containing protein were further concentrated by 
application to a 1 ml Ni2+ charged HiTrap IMAC HP column (GE Healthcare).   
 
 
 
2.2.3.8 Size exclusion chromatography 
 
Purification of the concentrated scFv fractions continued using size exclusion 
chromatography with an AKTA™ FPLC system (GE Healthcare) loaded with a 
Superdex 75 column (125 ml bed volume) (GE Healthcare). Protein samples were 
loaded via the 2 ml injection loop at a constant flow rate of 2 ml/min PBS, fractions 
were collected and peak fractions pooled prior to western blot analysis as in section 
2.2.2.9. 
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2.2.3.9 Quantification of protein post purification 
 
Protein concentration was determined spectrophotometrically on a Cecil CE2041 
2000 series spectrophotometer using the equation: 
 
A280=ε280 x c x l 
 
• A280 is the absorbance of protein samples at 280 nm  
 
• ε280 is the extinction coefficient (0.1%, 280 nm, 1 cm path length) of the 
protein calculated based on the protein primary amino acid sequence using the 
Expasy Protparam web tool (http://www.expasy.ch/tools/protparam.htlm) 
 
• c is the protein concentration, 
 
• l is the path length of the cuvette (cm).  
 
• For B6.3 ε280 = 1.9 
 
 
2.2.4 Human Cell Lines 
 
2.2.4.1 Antibodies and reagents.  
 
The monoclonal antibodies (mAb) used in this study were as follows: 10D5,anti-αvβ6 
integrin, from Chemicon International; 2G2, and 6.3G9, anti-human αvβ6 integrin 
generously provided by S Violette (Biogen Idec). 53a2 rat mAb against human αvβ6 
was produced in-house. Anti-c-Met from Invitrogen, anti-E-cadherin from Santa Cruz 
Biotechnology, anti-HGF/SF from R&D Systems.  IA4, anti-smooth muscle actin and 
AE1/AE3, anti-cytokeratin were from Dako.  Polyclonal antibody C-19, anti-human 
integrin β6 was from Santa Cruz Biotechnology. Human type 1 collagen was obtained 
from Sigma, Matrigel from BD Biosciences and MET kinase inhibitor SU11274 from 
Calbiochem. 
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2.2.4.2 Immunohistochemistry 
 
Antibodies used were anti-αvβ6, 62G2 (0.5µg/ml; Biogen Idec)), anti-smooth muscle 
actin (SMA), IA4 (1;100; Dako), anti-c-Met (1:50; Zymed)  anti-HGF/SF (1:10; R&D 
Systems), anti-cytokeratin, AE1/AE3 (1:50; Dako), or anti-E-cadherin (1:50; Santa 
Cruz Biotechnology), phospho-Smad2 (Cell signalling) and Smad4 (sc-7966, Santa 
Cruz Biotechnology). Immunohistochemistry was performed on 4µm, formalin fixed, 
paraffin embedded serial sections of tumor blocks. Samples were dewaxed and 
brought to absolute alcohol using Xylene 5mins x2, 100% EtOH 2mins x2, 95% 
EtOH 2mins x2, 50% EtOH 2mins, ddH2O 2mins.  Antigen retrieval varied according 
to primary antibody; 0.1% α-chymotrypsin 0.1% calcium chloride pH 7.8 for 20 min 
at 37°C (AE1/AE3); Digest-All™ 3 Pepsin Solution (Zymed® Laboratories, USA) for 
5 min at 37oC (6.2G2), microwaving for 30 minutes in 0.1M citrate buffer, pH 6 (c-
Met, SF/HGF, E-cadherin). Endogenous peroxidase was neutralized with 0.45% 
hydrogen peroxidase in methanol for 15 min and primary antibodies applied in TBS 
(pH 7.6) for 1 hour. Anti-mouse IgG biotinylated secondary antibody (Vectastain 
Elite ABC Reagent, Vector Laboratories) was applied for 30 min followed by 
peroxidase-labelled streptavidin (Vectastain Elite ABC Reagent; Vector Laboratories) 
for 30 min. Peroxidase was visualized using DAB+ (Dako) for 7 min and 
counterstained in Mayer’s hematoxylin (Sigma, UK).  Slides were dehydrated and 
cleared then mounted using permount (Fischer SP15-500). 
 
 
2.2.4.3 Human Tissue 
 
Ethical approval was obtained from the National Research Ethics Committee 
reference number 07/Qo4o5/8.  Skin samples were chosen at random from pathology 
records at Mt Vernon Hospital, Northwood, UK and stained for αvβ6, SMA, c-Met, 
HGF/SF, E-cadherin and cytokeratin.  Samples were scored according to the 
quickscore method (Detre et al 1995).  The staining intensity of αvβ6 and SMA was 
scored out of 3 (0= none, 1=weak, 2=moderate, 3=strong), and the proportion of cells 
staining positively was scored out of 4 (0=no staining, 1=1-25%, 2=25-50%, 3=51-
75%, 4=76-100%).  The score for intensity was added to the score for proportion to 
 84 
give a score in the range of 0-7 and grouped as low (score=0,1), medium (score=1-3), 
or high (score 4-7). 
 
OSCC samples were obtained from pathology storage at UCLH and Barts Hospitals, 
London, UK with OSCC patient details obtained from medical records at the relevant 
hospitals.  Patient mortality data were obtained from the Thames Cancer Registry and 
confirmed with patient records. Patients whose tissue samples were unobtainable were 
excluded from the study. 
 
 
2.2.4.4 Cell culture 
 
All cell culture procedures were carried out in a class II hood with humidified air and 
5% CO2. Culture medium (Table 2.4 ), PBS and Trypsin/EDTA were pre-warmed to 
37°C before use.  Cell lines were stored in frozen aliquots and brought into culture 
having been thawed to 37°C and resuspended by drop wise addition of 10 ml culture 
medium (Table 2.4). The cells were then centrifuged at 1300 x g for 3 min and 
resuspended in 5 ml of culture medium prior to seeding into T25 culture flasks.  
 
Once confluent, cells were sub-cultured routinely twice weekly; culture medium was 
poured off and cells washed once in 10 ml PBS and the cells released from the flask 
with 5 ml trypsin/EDTA for 5 min at 37°C. Next, cells were resuspended in fresh 
culture medium before 2 ml was drawn off and centrifuged at 1300 x g for 3 min. 
These cells were then seeded into T75 flasks. 
 
If cells were to be stored, a confluent flask was selected, cells washed and released 
from the flask as before then centrifuged and resuspended in 5mls freezing medium 
(Table 2.4).  Cells were then aliquoted into 1ml cryovials (Nalgene) and stored at -
80°C. 
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2.2.4.5 Preparation of NTGLi1 and NTGLi2 cell lines 
 
NT-Gli1 cells were generously donated by Dr Graham Neill (Centre for Cutaneous 
Research, Barts and The London School of Medicine and Dentistry, London, UK). 
NTGli1 and NTGli2 cell lines were used as a BCC model.  Briefly, the coding 
sequences of GLI1 and an active mutant of GLI2 (DN-GLI2b) were cloned into 
pBabePuro and retroviral particles made using the Phoenix (amphotropic) packaging 
cell line as described previously (Regl et al 2002). NTert-1 keratinocytes (NTGli1, 
NTGli2) were selected with puromycin (1 ug/ml) 48 hr after retroviral transduction 
(for 72 hr) and Gli expression was confirmed by Western Blot analysis (Santa Cruz 
GLI-1 C18 and GLI-2 H-300 abs).  Cells were grown in keratinocyte growth medium 
(KGM) (Table 2.4). Human Foreskin Fibroblasts (HFF2) were obtained from ATCC 
(Teddington, Middlesex, UK) and maintained in fibroblast growth medium (DMEM 
supplemented with 10% fetal calf serum) at 37oC in a humidified atmosphere.  
 
2.2.4.6 RNAi 
 
RNAi SMART pool reagents targeting β6 control (random) sequences were obtained 
from Dharmacon (Chicago, USA) and used as described previously (Nystrom et al 
2006). Cells were seeded into 6-well plates and left for 24 hours until approximately 
40% confluent, then transfected with 100nmol/ well of the relevant duplex pool using 
Oligofectamine transfection reagent (Invitrogen, Paisley, UK). Cells were used in 
assays after 24-48 hours. Cells were also lyzed and used to verify protein knock-down 
by Western blotting analysis. These experiments were kindly carried out by Professor 
Gareth Thomas, Centre for Tumour Biology, Institute of Cancer, Bart’s and the 
London School of Medicine and Dentistry,UK. 
 
 
2.2.4.7 Flow cytometry 
 
Subconfluent cells were washed twice with PBS and harvested by trypsin/EDTA 
(0.25% w/v, 5 mM). Cells were washed once in PBS containing 10% FCS then 
resuspended to give concentration of 2.5x106 per ml.  200µl added to each FACS tube 
(5x105 per tube). FACS media was Dulbecco’s modified Eagle’s medium (DMEM) 
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supplemented with 0.1% (w/v) Bovine Serum Albumin (BSA) and 0.1% (w/v) 
sodium azide (DMEM 0.1/0.1). Next, cells were incubated with primary antibody for 
40 min at 4°C and washed twice with PBS. FITC conjugated secondary antibody was 
applied to the cells for 30 min at 4°C. Cells were washed twice with PBS and 
resuspended in 0.5 ml PBS with 10% FCS. Labelled cells were analysed on an LSR-1 
FACS flow cytometer (Becton Dickinson, Oxford, UK) using CellQuest software, 
acquiring 1x104 events. 
 
 
Antibodies used were the anti-αvβ6 antibody (10D5; Chemicon International, 
Harrow, UK), anti-c-Met antibody (Invitrogen), Alexa 488-conjugated secondary 
antibody (Dako), rabbit anti human IgG 2.3mg/ml (Jackson ImmunoResearch 
Laboratories, West Grove, USA),  Mouse Tetra-His antibody (Qiagen, Crawley, UK) 
diluted 1:100 in DMEM. Negative control used secondary antibody only. Results 
show mean fluorescence (arbitrary units, log scale).  
 
 
2.2.4.8 TGF-β bioassay 
 
Mink lung epithelial reporter cells (MLEC) stably expressing a TGFβ-responsive 
luciferase reporter construct (Abe et al 1994) were plated overnight in 96-well plates 
in DMEM, 10% FCS (5 x 104 cells/well). The medium was changed to serum-free α 
MEM, and NTGli1 or NTGli2 cells (2.5 x 104 cells/well) were added to each well in 
serum-free α MEM containing anti-αvβ6 antibody (10µg/ml; 10D5; Chemicon) or ctl 
antibody (10µg/ml; anti-α4 integrin).  The cells were co-cultured overnight, washed 
once in PBS and lysed in reporter lysis buffer (Promega). Luciferase assay buffer 
(Promega) was added to the supernatant and the luminescence measured using a 
Wallac platereader. These experiments were kindly carried out by Dr Sarah 
Dickinson, Centre for Tumour Biology, Institute of Cancer, Bart’s and the London 
School of Medicine and Dentistry, UK. 
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2.2.4.9 Co-culture experiments 
 
HFF2 Fibroblasts and NTGli1 or NTGli2 cells were plated in 6-well dishes (2.5 x 105 
cells per cell type) or on to 13mm glass coverslips in 24 well plates (2.5 x 104 cells of 
each cell type). Cells were seeded in DMEM, 10% FCS ± antibodies (as above) or 
TGF-β1 (1ng/ml; R&D Systems) and left to attach. The medium was then changed to 
serum-free DMEM containing antibodies or TGF-β and cultured for a further 48 
hours. The cells were either lyzed for analysis by Western blotting or fixed and 
processed for immunoflourescence.  The supernatant was analyzed by ELISA for 
HGF/SF.  
 
 
 
2.2.4.10 Western blot analysis following cell culture experiments 
 
Cells were lyzed in NP40 buffer (Biosource).  Samples containing equal protein were 
electrophoresed under reducing conditions in 12% SDS-PAGE gels. Protein was 
electro-blotted to nitrocellulose membranes (Amersham Biosciences). Blots were 
probed with antibodies against αvβ6 (Santa Cruz) or SMA (Dako). Horseradish 
peroxidase-conjugated anti-goat or anti-mouse (Dako) were used as secondary 
antibodies. Bound antibodies were detected with the ECL Western blotting detection 
kit system (Amersham). Blots were probed for HSP70 (Santa Cruz) as a loading 
control.  Exposures of blots in the linear range were quantified by densitometry 
software (Scion Corp.).  
 
 
2.2.4.11 Preparation and use of medium conditioned by fibroblasts and 
myofibroblasts 
 
5x105 fibroblasts were plated in fibroblast growth medium in 75cm2 culture flasks for 
24 hours then washed twice with PBS.  To induce a myofibroblastic phenotype cells 
were incubated for 48 hours in medium containing recombinant TGF-β1 (1ng/ml; 
R&D Systems), which was acid-activated prior to use (4mM HCl/ 0.1% BSA).  
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Control cells were cultured in medium alone.  After 48 hours the cells were washed 
twice with PBS, and cultured for a further 72 hours in α-MEM.  The control fibroblast 
(FCM) or myofibroblast-conditioned medium (MCM) was collected, clarified by 
centrifugation and the cells detached and counted.   The volumes of FCM and MCM 
were corrected for cell number, adjusted to a total volume of 500µl and used in the 
lower chamber of a Transwell invasion assay as a chemoattractant.   
 
 2.2.4.12 Transwell invasion assays 
 
Cell-invasion assays were performed over 72 hours using Matrigel-coated 
polycarbonate filters (Transwell®, BD Biosciences, Oxford, UK). Matrigel (70 ml, 
1:2 dilution in α-MEM) was added to the upper chamber and allowed to set for 1 hr at 
37°C. To act as a chemotactant, 500 µl of KGM was placed in the lower chamber. 
Cells were plated in the upper chamber of quadruplicate wells at a density of 5x104 in 
200 ml of α-MEM and incubated at 37°C for 72 hrs. For blocking experiments anti-
αvβ6 antibody (6.3G9; 10µg/ml) or control antibody (7.2; 10µg/ml), were added to 
the cells for 30 minutes at 4°C prior to seeding. For c-Met inhibition, cells were 
treated with c-Met kinase inhibitor, SU11274 (5µM; Calbiochem) for 24 hours prior 
to use, and the inhibitor was present throughout the experiment. After 72 hr, cells in 
the lower chamber (including those attached to the undersurface of the membrane) 
were trypsinised and counted on a Casy 1 counter (Sharfe, Reutlinger, Germany). 
Experiments were repeated a minimum of 3 times in quadruplicate.  
 
 
 
 2.2.4.13 Organotypic culture  
 
To prepare collagen gels, 7 volumes of collagen type 1 (4 mg/ml, Upstate, Lake 
Placid, NY) were mixed on ice with 1 volume 10× DMEM, 1 volume FCS and 1 
volume FGM in which HFF had been suspended at a concentration of 0–5 × 106 ml−1. 
Then 1 ml of this solution (5 × 105 HFF unless otherwise stated) was aliquoted into 
wells of a 24-well plate and allowed to polymerise for 30 min at 37°C. After 
polymerization, 1ml of FGM was added per well and gels were left for 18 h at 37°C 
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to equilibrate. Concurrently, a fibroblast-free collagen gel mix was used to coat sterile 
nylon discs (100 µm pore size; Tetko Inc, New York, USA) which after 
polymerization at 37°C for 10 min were fixed in 1% glutaraldehyde for 1 h, washed 
(four times in phosphate-buffered saline (PBS), twice in KGM) and stored at 4°C. 
Next day, medium was aspirated from the wells of the 24-well plates and 5 × 105 
NTGli1 cells (suspended in α-MEM supplemented with 10% FCS and glutamine) 
were added to each well. The following day, gels were removed from the 24-well 
plate and placed on to individual collagen coated nylon discs resting on steel grids. 
These steel grids were made from 2.5 cm2 squares of stainless steel mesh with the 
edges bent down to form 4–5 mm high ‘legs’. This initial time-point was defined as 
day 1 of organotypic culture. The steel grids were placed in six-well plates and 
sufficient KGM (minus the cholera toxin) added to reach the undersurface of the grid, 
allowing the epithelial layer to grow at an air–liquid interface.  
 
For inhibition studies, the met kinase inhibitor SU11274 (5µM) was added to the 
KGM. The medium was changed every two days. After six days the gels were 
bisected, fixed in formal-saline, and processed to paraffin. 4µm sections were 
immunostained with the pan-cytokeratin antibody AE1/AE3 (Dako) as described 
previously. 
 
 
2.2.4.14 Confocal microscopy 
 
Cells were fixed for 10 minutes in 4% formaldehyde in cytoskeletal buffer (10 mM 
MES, 3 mM MgCl2, 138 mM KCl, 2 mM EGTA, pH 6.1) with 0.32 M sucrose. Cells 
were permeabilised for 5 minutes with 0.2% Triton X-100 and incubated for 30 
minutes in DMEM, 0.1% BSA, 0.1% sodium azide. Non-specific staining was 
blocked by incubation in 5% normal goat serum. Cells were then incubated with anti-
SMA (IA4; Dako) and anti-αvβ6 antibodies (53a; in-house) for 1 hour, and binding 
detected by incubation with secondary antibodies conjugated with FITC or Cy3 
(Jackson ImmunoResearch) for 45 minutes. Nuclei were visualised using DAPI 
(Invitrogen).  Coverslips were mounted onto glass slides using mowiol. All dilutions 
were in DMEM, 0.1% BSA, 0.1% sodium azide and incubations were at room 
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temperature. Images were recorded and processed with a confocal laser scanning 
microscope (Zeiss LSM510). Confocal microscopy was kindly carried out by Dr 
Sarah Dickinson, Centre for Tumour Biology, Institute of Cancer, Bart’s and the 
London School of Medicine and Dentistry,UK 
 
 
2.2.5 Preparation of scFv-nanoparticle conjugates 
 
2.2.5.1 Resovist to scFv conjugation 
 
This carbodiimide attachment method was adapted from the method used by De 
Nardo et al (2005) for attachment of available COO- groups on Resovist particles to 
the NH2 groups on scFvs. Firstly, the scFvs were dialysed into 1L 0.1M MES buffer 
pH 6.3 (=19.5g in 1l ddH20) for 6hrs at 4ºC using dialysing cassette (3,500MW), 3 
buffer changes performed. Next, 1ml of 10mg/ml particles in MES buffer was 
activated by adding 200µl EDC/NHS activation buffer 1hr at room temp. Activation 
reaction stopped by running particles through a PD10 desalting column (Amersham 
Bioscience UK). Next, the particles were eluted off the column with 0.1M MES 
buffer pH 6.3. To eluted particles 200µl of 1mg/ml scFv/MES added and mixed 
overnight at room temperature. To block unbound active sites, 100µl 25mM 
glycine/PBS added and mixed at room temperature for 60 minutes.  ScFv-
nanoparticles were then washed to remove unbound glycine by running through PD-
10 desalting column and particles eluted off with 0.1M MES buffer.  Finally, the 
scFv-Resovist particles were concentrated using Vivaspin 15R concentrators before 
purification by size exclusion chromatography (section 2.2.3.8).  
 
 
 
 2.2.5.2 Chemicell DX to scFv attachment 
 
Attachment of scFvs to the dextran coating of the Chemicell particles was achieved 
using a two step procedure whereby particles were first ‘activated’ with cyanogen 
bromide. Briefly, 10mg Chemicell FluidMAG-DX particles were washed x1 with 1 
ml 0.1 M Sodium hydrogen phosphate buffer pH 9.0 using the magnetic separator 
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(Dynal A.S, Oslo, Norway) and resuspended in 0.25 ml 0.1 M Sodium hydrogen 
phosphate buffer pH 9.0.  50µl Cyanogen Bromide in 5 M Acetonitrile was added to 
the particles and mixed by vortex. The tube was then placed in ice cold water for 10 
minutes. 
 
After incubation, the activated particles were washed x2 with 1 ml PBS using the 
magnetic separator and resuspended in 0.25 ml ice cold PBS.  Next, 200µl of 1mg/ml 
scFv (in PBS) was added to the activated particles and mixed overnight at room 
temperature.  Excess reactive sites blocked with 100µl 25mM glycine/PBS and finally 
particles washed x3 with PBS using the magnetic separator and resuspended in 1ml 
PBS. Figure 5.24 depicts the steps required for particle attachment. 
 
 
2.2.5.3 Purification of nanoparticle-scFv conjugates 
 
scFv-nanoparticle conjugates were separated from unbound scFvs and unbound 
nanoparticles by size exclusion chromatography using an AKTA FPLC system (GE-
Healthcare, Amersham, UK) and a 30ml Sephacryl 300 high resolution column (GE 
Healthcare). The column was calibrated using the Gel Filtration Standard Kit (Bio-
Rad) and conjugated particles were loaded onto the column at a constant flow rate of 
0.5ml/min in PBS and fractions collected throughout for storage at 4°C. 
 
 
2.2.5.4 Analysis of scFv – nanoparticle conjugation: The Bradford Assay 
 
The concentration of scFv-nanoparticle conjugates was estimated using the Bradford 
assay.  Firstly, standards of scFv alone were prepared in PBS buffer at concentrations 
of 0, 2.5, 5, 7.5 and 10µg/ml. 500µl Bradford Reagent (Sigma) was added to 500µl of 
each standard and samples left to equilibrate to room temp for 15mins. Using a Cecil 
CE4041 2000 series spectrophotometer, the absorbance of each standard was 
measured at OD 595nm in quartz cuvettes allowing a plot to be made of the 
absorbance vs. standard protein concentration. 
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The concentration of scFv in the scFv-nanoparticle fractions obtained after size 
exclusion chromatography could then be calculated by repeating the Bradford assay 
as above then measuring the OD at 595nm and comparing this reading to the 
calibration curve.  
 
 
2.2.5.5 Estimation of nanoparticle concentration post scFv-nanoparticle 
conjugation  
 
The concentration of nanoparticles in the fractions obtained after purification could 
also be estimated using a spectrophotometer.  Nanoparticle concentration standards 
for both Resovist and Chemicell particles were prepared in PBS at concentrations of 
0, 0.125, 0.25, 0.375, 0.5mg/ml.   The absorbance was measured at OD 490 on the 
Cecil CE4041 2000 series spectrophotometer. A plot was then made of the 
absorbance v. standard nanoparticle concentration. Measuring the OD at 490 and 
comparing this reading to the calibration curve then allowed the nanoparticle 
concentration in the scFv-nanoparticle fractions to be calculated. 
 
 
2.2.6 Analysis of scFv-nanoparticle conjugates in vitro 
 
Standard cell culture techniques were followed as set out in section 2.2.2.4.  Three 
αvβ6 expressing cell lines were used for the experiments set out below. VB6 cells 
were a kind gift from Professor Gareth Thomas, Barts and the London Medical 
School.  HT29 cells were a purchased from ATCC- Promochem, Teddington, UK. 
A375B6 cell line is a transfected melanoma cell line and was a kind gift from Dr John 
Marshall, Barts and the London Medical School. 
 
 
2.2.6.1 Estimation of cellular uptake of nanoparticles: The Ferrozine Assay 
 
The Ferrozine Assay uses an iron detection buffer to form a complex with ferrous iron 
that absorbs strongly at 550 nm that can be read on a microplate reader – so allowing 
the detection of small changes in iron concentration within solutions.  By using the 
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assay with a range of standards with known iron concentrations it is possible to 
prepare a graph from which unknown iron concentrations can be read when the same 
assay is performed. 
 
100µl FeCl3 standards were prepared at 0, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 7.5 and 10 
µg/ml in 10 mM HCL which were then incubated with 100 µl 50 mM NaOH and 
100µl iron releasing buffer (Table 2.6) at 60°C for 2 hrs. Once the samples had cooled 
to room temperature, 30µl iron detection buffer (Table 2.6) was then added and the 
samples incubated at room temperature for a further 30 min.   The iron detection 
buffer produces a colour change in the solution which was then read by the Opsys 
MR™ Microplate Reader (Dynex Technologies), absorbance readings taken at 
550nm. The absorbance vs. the Fe2+ concentration for each standard was plotted. This 
assay was then performed for both Resovist and Chemicell nanoparticles at 
concentrations 0, 0.5, 1, 2.5, 5, 10, 2.5, 5, 10, 25, 50 and 100 µg/ml in 10 mM HCL. 
The absorbance vs. the nanoparticle concentration for each standard was plotted and 
the nanoparticle concentration was then plotted against its corresponding Fe2+ 
concentration 
 
For analysis of iron uptake by cells after incubation with nanoparticles or 
nanoparticle-scFv initially cells were seeded in 24 well plates at 5x104/ml, 2mls per 
well and incubated in culture medium for 5 days. On day 5, the culture media was 
replaced with either 1ml filter sterilised scFv-nanoparticle conjugates or 1ml of 
nanoparticles alone at varying concentrations in culture media. Cells were incubated 
overnight followed by 3 x washes in cold PBS. Next, cells were released from the 
wells, a haemocytometer cell count performed and remaining cells lysed with 300 µl 
50 mM NaOH for 2 hrs on a shaker at room temperature.   
 
Following this, cell lysates were transferred to 1.5 ml eppendorf tubes, mixed with 
300 µl of 10 mMHCL and 300µl of the iron releasing reagent (Table 2.6).  The 
samples were then incubated for 2 hrs at 60°C on a heating block. Addition of iron 
detection buffer and colour change detection at 550nm then allowed the microplate 
readings to be referenced against the standard nanoparticle concentration curves, 
giving an estimate of the relative iron uptake. 
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2.2.6.2 Estimation of cell death after exposure to MACH: The MTT Assay 
 
Cell survival after incubation with nanoparticles and exposure to MACH was assessed 
using a cell viability assay based on 3-(4,5- Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) (Mosmann 1983).  
 
Cells were seeded on 96 well plates at a density of 1x105 cells/ml, 200µl/well and 
incubated for a minimum of 16 hours to allow adherence of the cells. Once adherent, 
100µl culture medium containing either nanoparticles alone, scFv-nanoparticle 
conjugates or culture media only as a control was added per well.  The nanoparticles 
were added at a range of concentrations, cells returned to the incubator for 1 hr before 
being exposed to MACH for 20 minutes.  In each case, ambient temperature was 
maintained at 37°C using the Air Therm.  Following this, cells were washed and 
incubated for a further 96hrs with fresh culture media. 
 
20µl of MTT (5mg/ml) was then added to each well and plates returned to the 
incubator for a further 4hrs. Then, culture media was removed and purple formazan 
crystals were added to each well along with 100µl of DMSO. The crystals would then 
induce a colour change indicating cell viability which could be read by the Opsys 
MR™ Microplate Reader at 550nm as before. Percentage cell survival was then 
estimated by comparison with untreated control wells. All tests were performed in 
triplicate. 
 
 
2.2.7 Statistical Analysis 
 
Statistical analysis was carried out using IBM’s SPSS software version 18. Data are 
expressed as the mean ± SD of a given number of observations. Figures show 
representative examples of independent repeats with error bars representing SD. 
Where appropriate, one-way ANOVA was used to compare multiple groups; 
comparisons between groups were made with Fisher's exact test or the student’s T 
test. P < 0.05 was considered to be significant. Five-year survival rates were 
calculated according to the Kaplan–Meier method using the logrank test with the 
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endpoint for survival analysis being death from disease. Univariate and multivariate 
analysis of overall and disease-free survival was performed according to Cox 
proportional hazard models.   
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Chapter 3 
 
 
 
Expression of αvβ6 in non-melanoma skin cancers 
and the role of SMA in morphoeic type basal cell 
carcinoma 
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3.1 Introduction 
 
The αvβ6 integrin has previously been shown to be over expressed in various 
epithelial derived malignancies including skin SCC (Thomas et al 2005).  As 
previously discussed in the introduction to this thesis, αvβ6 has been implicated in the 
malignant transformation of oral SCCs from leukoplakia, a premalignant oral lesion 
(Hamidi et al 2000).  It is proposed therefore that αvβ6 may be expressed in the 
premalignant skin lesion Actinic Kerastosis (AK) and that it may play a part in the 
development of the most common non melanoma skin cancer, basal cell carcinoma. 
 
Although most BCCs (80%) may be described as belonging to the nodular subset that 
is relatively indolent, there exists a smaller subset that are the highly aggressive 
morphoeic type (6%) and these are found mostly in the head and neck region 
(Scrivener et al 2002; Walling et al 2004). These two subsets may be differentiated 
histologically; morphoeic type BCCs have an infiltrative growth pattern with small 
islands of tumour cells in a densely fibrous stroma, whereas nodular type BCCs have 
pallisading cells arranged as nests within the relatively normal dermal stroma. 
 
To further study the role of αvβ6 in BCCs, cell culture experiments will be carried out 
using keratinocytes transfected with the Gli-1 transcription factor as currently there 
are no BCC cell lines available.  This model was chosen as BCCs have been shown to 
develop due to disruption of the sonic hedgehog signalling (Shh) pathway, leading to 
upregulation of the glioma-associated (Gli) family of transcription factors (Dahmane 
et al 1997). In human BCCs, disorders in the Shh pathway are usually due to 
mutations in the hedgehog receptor and antagonist Patched 1 (Ptch1) (Evangelista et 
al 2006).  Transgenic mouse models have been developed showing the loss of Ptch1 
function from the basal keratinocytes of mouse skin is sufficient to induce BCC-like 
tumour formation (Adolphe et al 2006). The importance of the Shh pathway in BCC 
development has further been confirmed with the development of BCC like tumours 
in mice which over-express constituents of the abnormal Shh pathway, including Shh, 
Gli-1 and Gli-2 (Oro et al 1997, Grachtchouk et al 2000, Nilsson et al 2000).  
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3.2 Aims and Objectives 
 
 
The aim of this chapter is to determine whether αvβ6 could have potential for future 
use as a molecular target in patients with non melanoma skin cancers.  The objectives 
of this chapter are to measure αvβ6 expression levels in tissue samples from patients 
with normal skin, AKs, skin SCCs and BCCs.  This chapter’s further objectives are to 
examine the role of αvβ6 in BCCs using transwell invasion assays, confocal 
microscopy and cell culture experiments. 
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3.3 Results 
 
 
3.3.1 Expression of αvβ6 in non-melanoma skin cancers and actinic keratoses 
 
Sections of NMSC, AKs and normal skin were obtained from Mt Vernon Hospital 
Pathology Dept, subjected to immunohistochemical staining and scored as set out in 
Chapter 2.  For the initial analysis 8 sections of normal skin, 19 AKs, 19 BCCs and 19 
SCCs were examined. Table 3.1 shows the differences in expression levels of αvβ6 
between the different tissue types, examples of which are shown in Figure 3.1.  
 
 
αvβ6 expression (no of samples)  
Tissue 
 
No of Specimens Low or Negative Medium High 
Normal skin 8 8 0 0 
Actinic Keratosis 19 0 13 6 
BCC 19 3 10 6 
SCC 19 0 4 15 
 
Table 3.1 - Tissue sections were scored using the quickscore method and the sections were then 
grouped according to whether the αvβ6 expression was negative/low, medium or high. Equal numbers 
of AK, SCC and BCC samples were scored.  
 
 
Figure 3.1 - Immunohistochemistry images showing αvβ6 staining (brown).  A negative expression in 
normal skin, B low expression of αvβ6 in Actinic Keratosis, C high αvβ6 expression in SCC at x100 
magnification, D high αvβ6 expression in SCC at higher magnification. 
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One of the aims of this chapter is to determine whether premalignant AKs also 
express αvβ6 and whether the expression level is part way between normal skin and 
SCC as is found in oral leukoplakia.  The results here show that when comparing 
tumours with high levels of αvβ6 expression, 79% of skin SCCs were found to have 
high expression levels, compared to just 32% of AK and 0% of normal skin samples.  
αvβ6 was found to be expressed at high level in 32% of the BCC sections examined 
(Figure 3.2)   
 
 
Figure 3.2  - Graph showing percentage of tissue samples with high expression levels of αvβ6.   
 
 
 
3.3.2 αvβ6 expression in BCC 
 
Although overall only 32% of BCC samples showed high expression levels of αvβ6 
which is comparable to the expression seen in AKs, there was a striking difference in 
αvβ6 expression seen between morphoeic and nodular type BCC (Figure 3.3).  
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Figure 3.3 - Examples of immunohistochemical staining for αvβ6 expression (brown colour) at x100 
and x200 magnification.  A,B:  Nodular type BCCs showing typical pallasading cells and islands of 
tumour with low levels of αvβ6 expression.  This is contrasted to morphoeic type BCC (C,D) with 
fibrotic stroma pattern and high levels of expression of αvβ6. 
 
Of the 19 BCCs initially examined, 16 were of the nodular type and 3 morphoeic. To 
investigate the differing αvβ6 expression levels seen between nodular and morphoeic 
BCCs, a further 9 morphoeic BCC specimens were examined giving a total of 12 
morphoeic and 16 nodular. In the 16 nodular type, high expression of αvβ6 was 
present in only 13% of tumours. In contrast, expression of αvβ6 in morphoeic BCC 
was significantly higher (p= < 0.001) with 9 of 12 tumours (75%) expressing the 
integrin strongly (Figure 3.4). 
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Figure 3.4 - Percentage of BCCs expressing high levels of αvβ6 
 
 
3.3.3 Generation of the BCC model – NTGli1 
 
The marked differences in αvβ6 expression between nodular and morphoeic BCC 
variants raises the possibility that the αvβ6 integrin plays a role in generation of the 
more aggressive tumour phenotype.  To further investigate the role of αvβ6 in BCC a 
BCC model was generated using retrovirally transfected keratinocytes.  Abnormal 
activation of the Shh signaling pathway has been shown to be a major contributing 
factor in the development of BCCs (Dahmane et al 1997).  cDNA encoding the Shh 
transcription factor Gli1 (DN-GLI1b) was retrovirally transduced into NTert-1 skin 
keratinocytes (Dickson et al 2000) to produce the cell line NTGli. Expression of the 
proteins was confirmed using Western blotting (Figure 3.5).  
 
 
 
 
 
 
Figure 3.5 - Western blot showing expression of Gli-1 transcription factor in NTert keratinocytes 
transfected with Gli-1 transcription factors compared to non transfected NTert controls 
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Flow cytometry and confocal microscopy confirmed that NTGli1 cells expressed 
αvβ6 (Figure 3.6,3.7).   
 
 
Figure 3.6 - Flow cytometry showing αvβ6 expression on NTGli1 keratinocytes.
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Figure 3.7 - Confocal microscopy of NTGli1 cells showing A expression of αvβ6 (green), B actin (red) 
and C merged image 
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3.3.4 Role of αvβ6 in invasion of NTGli1 in Transwell assays 
 
To investigate whether αvβ6 directly promoted invasion of NTGli1 and NTGli1 cells, 
Transwell assays were run comparing invasion of cells alone with αvβ6 blocking 
antibodies (Figure 3.8).  
 
 
 
Figure 3.8 - Transwell assays showing inhibition of αvβ6 by the antibody 6.3G9 did not have any effect 
on invasion of Gli-1 transfected N/tert keratinocytes. 
 
 
Further Transwell assays comparing antibody 6.3G9 inhibition of αvβ6 with β6 RNAi 
did not demonstrate suppression of invasion of NTGli1 cells (p=0.834, p=0.718 
respectively; Figure 3.9). In contrast, as has been shown previously, αvβ6 inhibition 
of carcinoma cells from the head and neck (VB6), breast (BT20) and lung (H441) 
significantly reduced invasion (p= 0.0035, p=0.005; p=0.002 respectively).  Since it 
has also been suggested that αvβ6 may promote invasion directly through modulating 
TGF-β1-dependent EMT, assays were repeated, either adding TGF-β1 or inhibiting 
TGF-β1 signalling using recombinant soluble TGF-β receptor II (TGF-βrii).  Neither 
treatment had an effect on NTGli1 invasion (Figure 3.9; p=0.52, p=0.47 
respectively).  
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Figure 3.9 - Relative invasion of NTGli1 and comparable SCC cell lines VB6 (head and neck), BT20 
(breast), H441 (lung) in Transwell assays alone (ctl) variously following incubation with αvβ6 blocking 
antibody 3G9, β6 RNA inhibition, TGFβ 1  and recombinant soluble TGF-β receptor II (TGF-βrii). 
Transwell invasion of NTGli1 cells was not inhibited by blockade of αvβ6 integrin (6.6.3G9) or by 
transient transfection of cells with β6 RNAi.  Treatment of NTGli1 cells with TGF-β1 or inhibition of 
TGF-β1 using recombinant soluble TGF-β receptor type II (TGF-βRII) did not affect invasion.  
 
 
 
3.3.5 αvβ6 mediated TGF-β1 activation in NTGli1 cells 
 
 
αvβ6 has been shown to modulate several other cell functions, including activation of 
TGF-β1 (Munger et al 1999). To investigate whether αvβ6 activated TGF-β in 
NTGli1 cells, a TGF-β bioassay was carried out as previously described (Abe et al 
1994). Inhibition of αvβ6 using antibodies (10D5) or β6 RNAi significantly reduced 
TGF-β1 activation (by 59% and 37% respectively; p=<0.0001, p=0.0006; Figure 
3.10).  NTGli2 cells activated TGF-β1 similarly (Figure 3.11).   
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Figure 3.10  - TGF-β activation co-culture assay.  Co-culture of NTGli1 with MLEC promoted TGF-β 
activation, which was suppressed by antibody blockade of αvβ6 integrin (10D5) or by transient 
transfection of cells with β6 RNAi.  Control antibody was anti-β4 integrin, 7.2 
 
 
 
 
Figure 3.11 - TGF-β activation co-culture assay of NTGli1 with MLEC promoted TGF-β activation, 
which was suppressed the anti αvβ6 antibody 10D5. 
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A common finding in many types of carcinoma is that stromal fibroblasts become 
‘activated’ myofibroblasts and express a number of contractile proteins, particularly 
α-smooth muscle actin (SMA) (Tlsty and Hein 2001). TGF-β1 is considered to have a 
central role in inducing the myofibroblastic phenotype (Tuxhorn et al 2001). To 
determine whether NTGli1 cells could induce myofibroblast differentiation, co-
culture experiments were carried out with HFF2 fibroblasts.  Co-culture of HFF2 with 
NTGli1 cells induced myofibroblast transdifferentiation, producing a significant 
increase in SMA expression (Figure 3.12, 3.13).   SMA was associated with 
cytoplasmic stress fibres (Figure 3.13).  To demonstrate myofibroblast generation was 
αvβ6-dependent, co-culture assays were repeated in the presence of either 10D5, a 
αvβ6 inhibitory antibody or a non αvβ6 binding antibody, 7.2 (Figure 3.13).  When 
the anti αvβ6 antibody was included, SMA expression was inhibited significantly.  
This was confirmed by Western blotting (Figure 3.14; p= 0.006).  These experiments 
suggest αvβ6 is important in driving the phenotypic conversion of fibroblasts to 
myofibroblasts. 
 
 
 
Figure 3.12 - Histogram showing Western blot densitometric expression of SMA in NTGli1 cells alone 
(1), co-cultures of HFF and NTGli1 cells (2) and after incubation with 10D5 αvβ6 blocking antibody 
(3) 
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Figure 3.13 - Confocal microscopy of αvβ6-positive NTGli1 cells (red) co-cultured on glass cover slips with HFF2 fibroblasts (blue), showing production of SMA (green). 
Panal A shows cells cultured in presence of 7.2 (a non αvβ6 binding control antibody). Addition of 10D5 αvβ6 blocking antibody reduces SMA production (panel B), 
suggesting αvβ6 promotes fibroblast to myofibroblast transition. 
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Figure 3.14 - Western blot showing SMA expression in HFF2 fibroblasts alone (1), co-cultures of HFF 
and NTGli1 cells (2) and suppression of SMA in co-cultures after incubation with 10D5 αvβ6 blocking 
antibody 
 
 
3.3.6 Myofibroblast content within the stroma of morphoeic BCC 
 
Morphoeic BCCs are characterised by an infiltrative growth pattern and a densely 
fibrous stroma.  To determine whether this stroma contained myofibroblasts, samples 
of nodular and morphoeic BCCs were stained and scored for the myofibroblast 
marker SMA expression using immunohistochemistry (Figure 3.15).     
 
 
 
Figure 3.15 - A, B Nodular BCC showing tumour islands and low levels of SMA expression (brown 
staining) C, D Morphoeic BCC with fibrotic stroma and high SMA expression. 
 
Similar to αvβ6 expression, expression of SMA was significantly higher in 
morphoeic BCCs (p=0.0041) with 10 of 12 tumours (83%) having stroma with strong 
SMA expression, indicating myofibroblastic differentiation.  In contrast, only 6 of 16 
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nodular BCC (37.5%) showed strong expression (Table 3.2).  No SMA staining was 
observed in the dermis of normal skin. 
 
 
αvβ6 and SMA expression  
Negative Low Medium High %High 
 Cases αvβ6 SMA αvβ6 SMA αvβ6 SMA αvβ6 SMA αvβ6 SMA 
Nodular 
BCC 
16 1 2 5 1 8 7 2 6 13 37.5 
Morphoeic 
BCC 
12 0 0 1 0 2 2 9 10 75 83 
 
Table 3.2 - Expression of SMA and αvβ6 in nodular and morphoeic BCC 
 
 
3.3.7 Effect of myofibroblasts on NTGli1 invasion 
 
Previously it has been shown that myofibroblasts promote invasion of SCC cells 
through the paracrine secretion of growth factors (Lewis et al 2004).  Although 
expression of αvβ6 did not directly modulate Transwell invasion of NTGli1 cells, it 
can be postulated that generation of a stromal myofibroblastic phenotype would have 
an invasion-promoting effect. To determine the effect of myofibroblasts on NTGli1 
cell invasion, Transwell – Matrigel assays were set up.  Myofibroblasts were 
generated by treating HFF2 fibroblasts with TGF-β1 and cultured for 72 hours in α-
MEM.  The myofibroblast-conditioned media (MCM) was used as a chemoattractant 
in the lower chamber of the Transwell, and NTGli1 cells were allowed to invade 
towards this stimulus for 72 hours before being counted. Untreated fibroblast 
conditioned medium (FCM) was used for comparison. MCM was found to 
significantly promote invasion of NTGli1 cells compared with FCM (p=<00001; 
Figure 3.16).  Addition of αvβ6 inhibitory antibody (6.3G9) into the assay still did not 
inhibit invasion. 
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Figure 3.16  - Transwell – Matrigel migration assay comparing migration of NTGli1 cells through 
Matrigel towards either fibroblast conditioned medium (FCM) or myofibroblast conditioned medium 
(MCM) with addition of 10D5 αvβ6 blocking antibody. Blockade of αvβ6 (6.6.3G9) did not inhibit 
invasion MCM-induced invasion. Results are expressed relative to VB6 invasion using SCCM-
generated myofibroblast conditioned medium. 
 
 
To further investigate the interaction between NTGli1 and HFF2 cells in the invasive 
process, organotypic experiments were set up. In contrast to Transwell invasion, 
transient transfection of NTGli1 cells with β6 RNAi markedly suppressed invasion 
(Figure 3.17). 
 
 
Figure 3.17 - NTGli1 cells were transiently transfected with random or β6 RNAi and then grown in 
organotypic culture with HFF2 fibroblasts for 6 days. In contrast to Transwell invasion, inhibition of 
αvβ6 suppressed invasion of NTGli1 cells 
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3.3.8 Role of myofibroblast secreted HGF/SF in NTGli invasion 
 
Previously, studies have demonstrated that myofibroblasts secrete HGF/SF (Goke et 
al 1998). This cytokine promotes epithelial cell growth and migration and has been 
shown to stimulate invasion in squamous carcinoma cells (Lewis et al 2004).  To 
determine whether induction of a myofibroblastic phenotype was associated with 
increased production of HGF/SF, medium from co-cultures of NTGli1 and HFF2 cells 
treated with control or anti- αvβ6 inhibitory antibodies was examined. Figure 3.18 
shows that co-culture of NTGli1 and HFF2 induces HGF/SF production which is 
suppressed when αvβ6 is inhibited.  
 
Figure 3.18 - ELISA showing production of HGF when NTGli1 cells are co-cultured with HFF2 cells 
and the reduction in HGF levels when αvβ6 blocking antibody is added. 
 
 
To determine whether the invasion-promoting effect of MCM was modulated through 
HGF/SF, HGF/SF signalling pathway in NTGli1 cells was inhibited using the Met 
kinase inhibitor, SU11274 (5µg/ml).  Flow cytometry confirmed that NTGli1 cells 
expressed the HGF/SF receptor, c-Met (Figure 3.19). 
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Figure  3.19 - Flow cytometry demonstrating c-Met expression by NTGli1 cells 
 
 Inactivation of c-Met significantly reduced invasion of NTGli1 cells towards MCM 
(p=0.00002).  Following c-Met inhibition, the level of invasion was similar to that 
produced by FCM suggesting that the invasion-promoting effect of MCM was 
mediated by HGF/SF (Figure 3.20).   
 
 
Figure 3.20  - Transwell invasion assay following treatment of NTGli1 cells with Met kinase inhibitor 
(SU11274) and using conditioned medium from fibroblasts (FCM) or myofibroblasts (MCM).  
 
 
 
 
 
 115 
3.3.9 Expression of c-Met and HGF/SF in morphoeic BCCs 
 
Immunochemistry confirmed that c-Met was expressed strongly (+++) or moderately 
(++) expressed by all morphoeic BCCs and that HGF/SF was commonly detected in 
myofibroblasts in the desmoplastic stroma (Figure 3.21). Interestingly, all the nodular 
BCC also expressed c-Met strongly and expression did not differ significantly from 
the morphoiec variants (p=0.69; Figure 3.22).  Normal epidermis was negative for E-
Cadherin or showed weak expression in basal keratinocyes only (Figure 3.22). 
 
 
 
 
Figure 3.21 - Immunohistochemistry showing representative c-Met (upper panel) and HGF/SF (lower 
panel) expression in morphoeic BCC.  Strong c-Met expression was observed in most tumours.  
HGF/SF expression was present in stromal cells 
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Figure 3.22 - Immunohistochemical staining for E-Cadherin in normal epidermis (A), morphoeic (B,C) 
and nodular BCCs (D) 
 
 
3.4 Discussion 
 
The results presented in this chapter show that the integrin αvβ6 is expressed at 
significantly higher levels in aggressive, infiltrative morphoeic BCC compared with 
more common nodular BCC. Using Gli-transfected, NTert human skin keratinocytes 
as a BCC model, the effects of αvβ6 expression in these cells were examined. 
Antibody inhibition of αvβ6 had no direct effect on cell invasion.  However, on co-
culture assays, NTGli1 cells seemingly modulate human myofibroblast 
transdifferentiation through αvβ6-dependent activation of TGF-β1. Data presented 
here shows that the fibrotic stroma of morphoeic BCC is myofibroblast-rich compared 
with nodular BCC, and that myofibroblasts promote BCC invasion through secretion 
of HGF/SF.    
 
Morphoeic BCC account for around 6% of BCCs, and are so-called because of their 
fibrotic (desmoplastic) stroma.  Unlike the more common nodular BCC variant, 
morphoeic BCCs are aggressively infiltrative, resulting in greater depth of invasion, 
tissue destruction and recurrence (Walling et al 2004).  Since 95% of these tumours 
are located on the face or head this causes significant morbidity (Scrivener et al 
2002).  Immunohistochemical staining of BCC samples showed that 77% of 
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morphoeic BCC strongly expressed αvβ6.  This was similar to expression levels in 
cutaneous SCC (79% high expression; 15/19 tumours), but was significantly higher 
than nodular BCC (7%, 2/16 tumours).  Interestingly the histological growth pattern 
of morphoeic BCC more closely resembles SCC than nodular BCC.  
 
Expression of αvβ6 is increasingly described in numerous carcinoma types, often 
correlating with poor prognosis (Bates et al 2005, Elayadi et al 2007, Hazelbag et al 
2007).  Workers have shown previously that αvβ6 promotes invasion of head and 
neck SCC in vitro and in vivo (Thomas et al 2001, Nystrom et al 2006). These data 
suggest that αvβ6 is an attractive tumour target, and several studies have now 
successfully inhibited tumour growth in vivo using treatments directed against the 
integrin (Zhou et al 2004, Koopman et al 2007). Surprisingly, inhibition of αvβ6 had 
no effect on NTGli1 cell Transwell invasion (Figure 4.8).  However, αvβ6 modulates 
several other cell functions including activation of TGF-β1 (Munger et al 1999), and 
these data show that activation of TGF-β1 in NTGli1 cells was αvβ6-dependent 
(Figure 3.11).  The role of TGF-β1 in tumour biology is complex, having both 
suppressive and promoting effects (Elliot and Blobe 2005).  This is explained in part, 
by observations that most carcinomas become refractory to the anti-proliferative 
effect of TGF-β1 (Elliot and Blobe 2005).  TGF-β1 also has direct pro-oncogenic 
effects on tumour cells, including promotion of motility through modulating 
epithelial-to-mesenchymal transition (EMT). However, treatment of NTGli1 cells 
with recombinant TGF-β1 or inhibition of TGF-β1 signalling using recombinant 
soluble TGF-βRII receptor had no effect on invasion. These data suggest that 
activation of TGF-β1 did not promote NTGli1 cell invasion directly. 
 
Another mechanism by which αvβ6-dependent activation of TGF-β1 could promote 
tumour progression is by modulating the tumour stroma. TGF-β1 is considered to 
have a central role in inducing the myofibroblastic phenotype, and αvβ6-dependent 
activation of TGF-β1 results in the pathological fibrosis of several epithelial organs 
(Munger et al 1999, Hahm et al 2007). There is now abundant evidence that tumour 
stroma promotes tumour progression (Liotta and Kohn 2001, Pupa et al 2002, De 
Wever and Mareel 2003), and workers have previously shown a pro-invasive, 
paracrine interaction between myofibroblasts and head and neck SCC cells (Lewis et 
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al 2004). Transdifferentiation of myofibroblasts is frequently observed associated 
with the edge of an actively expanding tumour mass, and it is common to find αvβ6 
expressed most strongly at this invasive margin (Lewis et al 2004, Nystrom et al 
2006, Koopman et al 2007). Co-culture assays suggested that NTGli1 cells modulated 
myofibroblast transdifferentiation through the αvβ6-dependent activation of TGF-β1, 
and that conditioned medium from myofibroblasts promoted NTGli1 Transwell 
invasion.  Immunochemistry confirmed that the stroma of morphoeic BCCs is 
myofibroblastic-rich compared with nodular BCCs. Additionally, although inhibition 
of αvβ6 had no anti-invasive effect in Transwell assays, when NTGli1 cells were 
admixed with fibroblasts in organotypic culture, β6 RNAi knockdown markedly 
reduced invasion.  It may be postulated that this effect is modulated through 
suppression of myofibroblast transdifferentiation.  
 
Myofibroblasts may promote tumour progression in a number of different ways 
including secretion of proteases, matrix proteins and cytokines (De Wever and Mareel 
2003).  Co-culture of NTGli1 and HHF2 cells resulted in upregulated secretion of 
HGF/SF which was suppressed when αvβ6 was inhibited (Fig 3.18).  HGF/SF acts 
through the c-Met tyrosine kinase receptor, and misregulated expression of both 
cytokine and receptor is a common finding in many tumour types (Peruzzi and 
Bottaro 2006), although expression has not been described in BCC previously. These 
data show that inhibition of HGF/SF signaling suppressed the invasion-promoting 
effect of myofibroblast-conditioned medium in Transwell assays (Figure 3.20). De 
Wever and colleagues (2004) found that myofibroblasts stimulated invasion of colon 
carcinoma cells through secretion of a combination of HGF/SF and Tenascin C, and it 
is possible that a similar mechanism promotes invasion of NTGli1 cells.  
Immunochemistry showed that morphoeic BCC express both c-Met receptor and 
stromal HGF/SF (Figure 3.21).  Interestingly, c-Met expression was also present in 
nodular BCC at similar levels, although expression in normal epidermis was negative 
or weakly basal (Fig 3.21 upper panels).   
 
HGF/SF may induce invasive growth through several mechanisms, including 
regulation of the expression and function of cadherins, integrins and matrix 
metalloproteinases (Birchmeier et al 2003). It has previously been shown that 
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HGF/SF promotes invasion of head and neck SCC cells and induces expression of the 
type IV collagenases MMP-2 and –9 (Lewis et al 2004, Bennett et al 2000). This 
latter observation suggesting a possible mechanism for the HGF/SF-dependent 
invasion through Matrigel (which is composed of predominantly type IV collagen) 
described in this study. HGF/SF stimulation also promotes tyrosine phosphorylation 
of b-catenin, resulting loss of E-cadherin binding and nuclear translocation of b-
catenin (Monga et al 2002). Nuclear localization of b-catenin has been reported to be 
significantly higher in morphoeic BCC compared with nodular BCC (El-Bahrawy et 
al 2003).  Although Gli-1 has been reported to downregulate E-cadherin expression in 
BCC through induction of the E-cadherin repressor, Snail (Li et al 2006), 
immunochemistry showed that E-cadherin expression was maintained in morphoeic 
BCC (Figure 3.22).  However, there was less membranous and more cytoplasmic 
staining compared with normal epidermis.  These data raise the possibility that altered 
E-cadherin function may play a role in the morphogenesis of morphoeic BCC, and 
that this may be modulated through stromal-derived HGF/SF.  
 
 
3.5  Summary 
 
The aim of this chapter was to examine the expression of αvβ6 in non melanoma skin 
cancers and in premalignant skin lesions in comparison to normal skin.  These results 
show the novel finding that premalignant AKs express higher levels of αvβ6 than 
normal skin and lower levels than are seen in skin SCC.  These findings can be 
compared to the expression of αvβ6 seen in leukoplakia, a premalignant oral lesion 
which can progress on the SCC (Westernoff et al 2005) suggesting αvβ6 may be 
important for the progression of premalignant disease. 
 
The immunohistochemistry revealed that αvβ6 is expressed at significantly higher 
levels in aggressive morphoeic BCC compared with nodular BCC.  Further cell 
modelling then demonstrated an indirect invasion-promoting effect modulated 
through stromal cells; αvβ6-dependent TGF-β1 activation induces a myofibroblastic 
phenotype resulting upregulated HGF/SF secretion which promotes tumour cell 
invasion.  Data here shown also confirms that morphoeic BCC are myofibroblastic-
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rich and express HGF/SF and c-Met.  These clinical observations support the 
suggestion that the paracrine interactions observed in vitro between BCC cells and 
fibroblasts may also occur in vivo, and may explain the morphological appearance of 
morphoeic BCCs.  As well as emphasizing the importance of the stromal contribution 
to tumour development, the data show that that αvβ6 may promote tumour invasion 
through both direct and indirect mechanisms. 
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Chapter 4 
 
 
 
αvβ6 as a prognostic indicator in oral squamous 
cell carcinoma 
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4.1 Introduction 
 
Amongst the commonest major cancers, oral SCC has one of the lowest overall 5-year 
survival rates and there has been no improvement in this over the past two decades 
(Stewart and Kleihues 2003, Parker et al 1996). The standard treatment for patients 
with this cancer is surgery, radiotherapy, or multiple modalities for high risk patients. 
For patients with early (stage I or II) disease, these treatments are often successful 
however 20-30% of these patients will go on to suffer either local tumour or lymph 
node recurrence (Vikram 1994; Clayman et al 1996). For patients with advanced oral 
carcinoma (stage III or IV), the recurrent rate is approximately 50–60% and 20–35% 
of these patients will have metastatic disease at first presentation (Clayman et al 
1996). Furthermore, patients with advanced disease often suffer substantial functional 
and cosmetic morbidity, which decreases the quality of life. The identification of 
prognostic factors that may affect disease outcome may lead to improvements in 
adjuvant systemic therapy and a reduction in the morbidity associated with the 
disease. 
 
OSCC is usually histological classified as well, moderately or poorly differentiated 
and this tumour grade is based on degree of squamous differentiation (keratinisation, 
pearl formation and intercellular bridges), degree of cellular pleomorphism and 
mitotic index (number of visible mitotic figures). Other histopathologic features have 
been shown to provide statistically significant prognostic information include the 
pattern of tumour invasion within the stroma (cohesive or non-cohesive), the 
maximum depth of tumour invasion and the presence of nodal extracapsular spread 
(Thomas et al 2006). 
 
At present the outcome in patients with OSCC is directly related to the stage at 
diagnosis and this in turn is related to how early the disease is detected.  It is also 
important to predict which patients are at significantly higher risk of disease 
recurrence after the primary treatment and the present gold standard for this is clinical 
stage following the initial endoscopy. Currently, the most significant prognostic 
indicator of survival in patients with OSCC is the presence of extracapsular spread in 
cervical lymph node metastasis (Greenberg et al 2003, Puri et al 2003).  Other 
important factors include tumour size (Tytor and Olofsson 1992), positive margins 
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after surgical excision (Sutton et al. 2003) and the presence of perineural and 
perivascular invasion (Rahima et al. 2004). However, there is no clear consensus 
however regarding the relative importance of these features and, although attempts 
have been made to combine various parameters into defined scoring systems, their use 
has produced unsatisfactory inter-observer agreement. 
 
Numerous molecular markers have been studied in the hope that they may be able to 
provide more accurate prognostic information for the staging of OSCC. A review by 
Thomas et al (2005) discusses the conflicting evidence that the cell cycle regulators 
P16, P53 and CCND1 are shown to be both prognostic and not prognostic in OSCC.  
Thus there is a marked need to develop new accurate diagnostic tools that can 
accurately identify aggressive disease, preferably at an early stage, so that patient 
management can be adjusted accordingly. 
 
 
 
 
4.2 Hypothesis and Aims 
 
The hypothesis proposed in this chapter is that αvβ6 is an independent prognostic 
marker in OSCC. This will be tested using immunohistochemical staining on tumour 
specimens from patients with OSCC.  Building on results from the previous chapter, 
the myofibroblastic marker SMA will also be examined as to whether it may yield 
prognostic information.  The aims are to compare selected molecular markers 
including αvβ6 and SMA with other standard histo-pathological parameters currently 
used to predict prognosis in OSCC. 
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4.3 Results 
 
 
 
4.3.1 Patient Data 
 
282 consecutive patients were identified from the records at 2 London hospitals (107 
patients from University College Hospital (UCL)/Eastman Dental Hospital (EDH), 
and 175 from Barts and the London Hospital (BLT)). These patients underwent 
surgery between 1992 and 2005 (UCL/EDH, 1992-2004; BLT, 2000-2005). All 
patients were treated with surgery with or without radiotherapy and none received 
chemotherapy.  Data were available on age, sex, tumour stage (I-IV), metastatic 
disease, lymph node status and presence of extracapsular spread.  Data were collected 
also for depth of invasion (mm), tumour grade (well, moderately, poorly 
differentiated), pattern of invasion (cohesive or discohesive), surgical margins 
(positive = ≤1mm, close = >1-<5mm, clear = ≥5mm) (Woolgar 2006), inflammation 
(low, medium or high) and whether patients received radiotherapy. Date of death data 
were obtained through the Thames Cancer Registry and cases were excluded if 
complete survival data or pathological archival material were not available. 
Appropriate ethical approval was obtained (REC reference 07/Q0405/1).  The median 
follow up was 6.4 years (25th-75th centile 4.4-8.2 yrs), with a total of 14,714 person-
years. Of the 282 patients, 120 were known to have died from OSCC. 
 
Patient characteristics are summarized below in Table 4.1. 
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Characteristic Number of patients (%) 
N= 282 
Number who died from OSCC 
N=120 
(% dying from OSCC within group) 
Sex   
 Male 179 (63) 77 (43) 
 Female 103 (37) 43 (42) 
   
Age (yrs)   
  <50 49 (17) 16 (33) 
  50-60 75 (27) 36 (48) 
  61-70 78 (28) 32 (41) 
   >70 79 (28) 36 (46) 
   
Disease Stage   
 1 98 (35) 21 (21) 
 2 43 (15) 20 (47) 
 3 15 (5) 8 (53) 
 4 125 (44) 70 (56) 
   
Radiotherapy   
  Yes 117 (42) 63 (54) 
  No 162 (58) 56 (35) 
   
Surgical Margins   
Clear (>5mm) 85 (30) 23 (27) 
Close (1-5mm) 82 (29) 36 (44) 
Involved (<1mm) 113 (40) 61 (54) 
   
Metastasis   
Yes 92 (33) 54 (59) 
No 190 (67) 66 (35) 
   
Extracapsular spread   
Yes 40 (14) 25 (63) 
No 242 (86) 94 (39) 
   
Cancer site   
Tongue 106 (38) 44 (42) 
Floor of Mouth 39 (14) 17 (44) 
Buccal Mucosa 30 (11) 13 (43) 
Lip  24 (9) 5 (21) 
Other 83 (29) 41 (49) 
   
   
 
Table 4.1 – Patient characteristics for entire cohort of 282 OSCC patients 
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4.3.2 Pathological Data 
 
Immunohistochemistry analysis was carried out on the tumour specimens as described 
in Chapter 2. Tumours were classified as cohesive (Bryne patterns 1 and 2) or 
discohesive (Bryne patterns 3 and 4) according to their pattern of invasion (Bryne 
1992). The inflammatory infiltrate was scored as diffuse (=3), patchy (=2) or 
weak/absent (=1). Initially, 107 cases were examined for αvβ6, SMA, EGFR and P53; 
the sections were scored on the basis of extent of staining within the tumor mass 
(<5%=1 [low], 5-50%=2 [moderate], >50%=3 [high]).  To look at activation of the 
TGF-β pathway, sections were also stained for Smad 4 and Smad 2; these were scored 
using the same method however were not investigated as potential prognostic 
indicators. Based upon the findings from the first 107 cases, a further 111 tumour 
sections were stained for αvβ6 and another 175 cases for SMA, giving a total of 282 
for the final analysis. To allow for accurate assessment of staining, scoring was 
carried out independently by 2 consultant histopathologists (Dr Kim Piper and 
Professor Gareth Thomas from Barts and The London NHS Trust). Concordance was 
>95%, the remaining cases were re-analysed and a consensus score agreed. 
 
The table below (Table 4.2) shows the breakdown of the pathological data for the 
total 282 cases.   
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Characteristics Number (%) 
N =282* 
Number who died from OSCC 
N=120* 
(% dying from OSCC within group) 
   
Grade   
Well differentiated 53 (19) 14 (26) 
Moderately differentiated 169 (60) 72 (43) 
Poorly Differentiated 59 (21) 34 (58) 
   
Depth of Invasion (mm)   
<2.0 17 4 (24) 
2.0-3.9 43 11 (26) 
4.0-8 96 29 (30) 
>8 126 76 (60) 
   
Pattern of Invasion   
Cohesive 162 (57) 51 (31) 
Discohesive 120 (43) 69 (57) 
   
Extracapsular Spread   
Yes 40 (14) 25 (63) 
No 242 (86) 94 (39) 
   
Inflammation   
Low 138 (49) 74 (54) 
Moderate 85 (30) 32 (38) 
High 59 (21) 14 (24) 
   
αvβ6   
Low 56 (26) 24 (43) 
Medium 48 (22) 15 (31) 
High 114 (52) 60 (53) 
   
SMA   
Low 130 (46) 33 (25) 
Medium 74 (26) 34 (46) 
High 78 (24) 53 (68) 
   
EGFR   
Low  49 (46) 18 (37) 
Medium  26 (25) 14 (54) 
High 31 (29) 17 (55) 
   
P53   
Low 67 (63) 27 (40) 
Medium 25 (23) 15 (60) 
High 15 (14) 7 (47) 
   
*except for αvβ6 (218 pts, 99 deaths);EGFR and p53 (107 pts, 49 deaths) 
 
Table 4.2 - Pathological characteristics for patient cohort 
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4.3.3 Statistical Analysis 
 
The endpoint for survival analysis was death from OSCC.  Survival time was 
measured from the date of diagnosis until the time of death or until the time last seen 
alive. Patients who died from causes other than OSCC were censored at the date of 
death. Survival analysis using Cox proportional hazards regression was used to 
examine the association between the risk of dying from OSCC and each of the factors 
taken independently and together. To evaluate the predictive performance of each 
factor (i.e. the 1- and 3-year OSCC death rates), the detection rate (DR; also known as 
sensitivity) and false-positive rate (FPR; also known as 1 minus specificity) was 
calculated. DR is the proportion of patients who have died by one year with test 
positive results; FPR is the proportion of patients alive at one year with test-positive 
results. Likelihood ratios (DR/FPR) were obtained for each marker, which quantifies 
among patients with a specified characteristic how many times more likely it is that 
patients will die from OSCC at 3 years compared to those who have not died. The 
minimum patient follow up was 3.67 years.  
 
To examine the factors in combination and allow for associations between them, a 
prognostic model was developed using a Cox regression modelling, in which the 
dataset of 282 patients was divided into two groups in a 2:1 ratio (Royston 2009). 
Group 1 had patients diagnosed up to and including 9 October 2002, because the first 
two-thirds of all OSCC deaths occur in this group (these were used as the ‘training’ set 
to develop the prognostic model). Group 2 had patients diagnosed after 9 October 
2002, ie the last third of OSCC deaths, and these formed the ‘validation’ set in which 
the prognostic model was tested. A Cox regression with backward selection and 5% 
level of statistical significance (Royston 2009) was applied to Group 1, and the 
parameter estimates were used as scores based on the group of factors that together 
had the most efficient predictive ability. These scores were then applied to patients in 
Group 2, in which the predictive performance of the model was evaluated by 
estimating DR and FPR for censored time-to-event data with 3-year mortality as the 
time point (Lu 2006 and Heagerty 2000). This receiver operating curve (ROC) 
analysis also produced an estimate of the area under the curve. Kaplan- Meier survival 
estimates were also used to provide survival plots. All statistical methods and results 
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in this chapter were reviewed Dr Alan Hackshaw, Statistician and Deputy Director 
UCL Cancer Trials Centre). 
 
 
4.3.4 αvβ6 expression in OSCC 
 
A total of 218 cases were examined for αvβ6 expression and of these cases, 56 
(25.7%) were found to have low expression, 48 (21.9%) moderate and 114 (52%) had 
high expression levels.  From the patients with high levels of αvβ6, 52.6% (60 
patients) died from OSCC and from the group with low expression levels 42.9% (24 
patients) died.  The expression levels of αvβ6 was found to be similar to that reported 
previously in OSCC (Thomas et al 2001) and figure 4.1 below shows the typical 
appearance of sections stained for αvβ6. 
 
 
Figure 4.1 – Typical OSCC section stained for αvβ6 at x100 and x200 magnification showing strong 
intratumoural staining. 
 
Kaplan-Meier plots (figure 4.2) suggested patients with high αvβ6 expression had a 
poorer prognosis than those with low αvβ6 expression and survival analysis for the 
total 218 cases showed there to be a 30%  (confidence interval 0.84-2.05) increased 
risk of death with a high level of αvβ6 expression compared to low expression (table 
4.5).  However these data failed to reach significance on unadjusted or adjusted Cox 
regression analysis (p=0.029 and p=0.16 respectively). 
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Figure 4.2 – Kaplan-Meir plot showing risk of dying from OSCC against time from diagnosis for 
patients with strong, moderate and low expression levels of αvβ6. 
 
 
Table 4.3 below displays the correlation of αvβ6 expression with other pathological 
factors examined.  αvβ6 was found to significantly correlate with depth of invasion 
(p= 0.013), presence of metastasis (p=0.048) and just failed to reach significance with 
the correlation with SMA expression (p=0.055).  Survival analysis did not reveal any 
significant association between αvβ6 expression levels and death from OSCC (table 
4.5) 
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αvβ6   
Low 
N=56 
Medium 
N=48 
High 
N=114 
P-value for the 
association between 
the risk factor and 
αvB6 
      
Age 
Mean age, years 62.9 59 60.4 0.296 
Depth of invasion Mean value, mm 7.4 7.6 9.8 0.013 
  Percentage*  
Sex Male 64 69 66 0.888 
 Female 36 31 34  
      
Disease stage 1 38 40 19 0.106 
 2 13 13 19  
 3 5.4 4.2 4.4  
 4 45 43 57  
      
Radiotherapy No 61 77 56 0.049 
 Yes 38 23 43  
      
Grade Well differentiated 27 17 15 0.120 
 Moderately 
differentiated 
45 65 65  
 Poorly differentiated 29 19 20  
      
Surgical margins Clear 30 27 27 0.878 
 Close 30 38 30  
 Involved 39 35 43  
      
Metastases No 77 71 59 0.048 
 Yes 23 29 41  
      
ECS No 91 92 84 0.278 
 Yes 9 8 16  
      
Pattern of 
invasion 
Cohesive 63 56 49 0.244 
Discohesive 37 44 51   
      
Inflammation Low 54 42 54 0.488 
 Medium 29 31 31  
 High 18 27 16  
      
SMA Low 52 58 40 0.055 
 Medium 32 19 27  
 High 16 23 33  
*expressed as a percentage of low, medium and high αvβ6 expression respectively. 
 
 
Table 4.3 – αvβ6 correlation with common pathological indices in OSCC. 218 patients included in 
analysis. 
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4.3.5 SMA expression in OSCC 
 
SMA staining was performed on all 282 cases, the numbers staining low, moderate 
and high were 130 (46.1%), 74 (26.2%) and 78 (27.7%) respectively.  Looking at 
death from OSCC, there were 33 (25.4%), 34 (45.9%), and 53 (67.9%) deaths in the 
Low, Moderate and High SMA groups respectively.  Figure 4.3 shows OSCC section 
with strong stromal staining for SMA. 
 
 
 
 
Figure 4.3 – Stromal staining for SMA at x100 and x200 magnification 
 
Ten lymph node metastases were also examined for SMA expression using 
immunohistochemistry and all were all found to be strongly positive for SMA (figure 
4.4).  
 
 
 
Figure 4.4 – SMA staining showing early invasion with blood vessels identified and LN stromal 
reaction 
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Survival analysis revealed a significantly increased risk of death for those patients 
with tumours showing high stromal levels of SMA expression (figure 4.5).  Cox 
regression analysis confirmed a 4.26 times increased risk of dying from OSCC 
(unadjusted, confidence interval 2.74-6.61) for those patients with high SMA levels 
compared to those with low SMA expression (p= 0.002) and a 3.06 times increased 
risk (confidence interval 1.65 – 5.66) when adjusted for other pathological markers 
(p=0.002).  Data shown in table 4.5. 
 
 
 
Figure 4.5 – Kaplan-Meir analysis for 282 cases of OSCC examined for SMA expression showing the 
increased risk of death when tumour stroma has moderate or high levels of SMA expression. 
 
SMA expression correlated strongly with increased depth of tumour invasion 
(p=<0.001), disease stage (p=<0.001), degree of differentiation (p=0.01), presence of 
metastasis (p=<0.001), extracapsular spread (p=<0.001) and inversely correlated with 
inflammation (p=<0.001) (table 4.4). 
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SMA   
Low 
N=130 
Medium 
N=74 
High 
N=78 
P-value for the 
association between 
the risk factor and 
SMA 
      
Age 
Mean age, years 62.3 58.5 61.5 0.40 
Depth of invasion Mean value, mm 5.3 9.8 
 
12.6 <0.001 
  Percentage*  
Sex Male 55 72 70 0.11 
 Female 45 28 30  
      
Disease stage 1 56 19 15 <0.001 
 2 15 18 13  
 3 6 5 4  
 4 23 58 68  
      
Radiotherapy No 65 58 47 0.86 
 Yes 35 42 53  
      
Grade Well differentiated 22 24 8 0.01 
 Moderately 
differentiated 
64 49 64  
 Poorly differentiated 14 27 28  
      
Surgical margins Clear 40 22 22 0.048 
 Close 29 35 25  
 Involved 31 43 53  
      
Metastases No 83 62 47 <0.001 
 Yes 17 38 53  
      
ECS No 98 85 68 <0.001 
 Yes 2 15 32  
      
Pattern of 
invasion 
Cohesive 69 50 46 0.02 
Discohesive 31 50 54   
      
Inflammation Low 30 53 77 <0.001 
 Medium 33 35 21  
 High 37 12 2  
      
αvβ6 Low 28 31 16 0.055 
 Medium 28 16 19  
 High 44 53 65  
      
*expressed as a percentage of low, medium and high SMA expression respectively 
 
Table 4.4 – correlation of SMA expression with αvβ6 and other pathological markers examined. 282 
patients included in analysis. 
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4.3.6 EGFR expression in OSCC 
 
A total of 107 cases were examined for EGFR expression and of these cases 49 had 
low expression, 26 medium expression and 31 high expression.  Of the patients who 
died from OSCC, 37% had low expression levels, 53% medium and 55% high EGFR 
expression levels.  On Cox regression analysis, although there was an increased risk 
of death associated with high level of EGFR expression (Hazard Ratio 1.96 for high 
vs low EGFR expression (unadjusted)) this did not reach significance.  Figure 4.6 
shows typical staining for EGFR in OSCC and figure 4.7 shows the Kaplan Meier 
plot for EGFR expression in OSCC. 
 
 
 
Figure 4.6 – OSCC staining showing medium EGFR expression levels. 
 
 
Figure 4.7 – Kaplan Meier plot for EGFR expression in OSCC.  No significant difference is seen in 
survival when comparing patients with low, medium and high levels of EGFR expression.  
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4.3.7 P53 expression in OSCC 
 
 
Of the 107 cases examined for p53 expression, 67 were found to have low expression, 
25 moderate expression and 15 cases showed strong expression.  Percentage of deaths 
from OSCC in patients with low, medium and high p53 expression levels was 40, 60 
and 47% respectively.  There was no significant correlation between level of p53 
expression and risk of death from OSCC in the 107 cases analysed.  Figure 4.8 shows 
a Kaplan Meir survival plot for p53 expression with sample p53 staining shown in 
Figure 4.9.  
 
 
 
 
 
Figure 4.8 – Kaplan Meier plot showing risk of death from OSCC and p53 expression level.  
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Figure 4.9 – OSCC sections stained for p53 
 
 
 
 
4.3.8 Smad4 and Smad2 expression in OSCC 
 
 
107 cases were stained for Smad4 and 40 cases for Smad2.  Stromal myofibroblasts 
were highly positive for both markers and there was a strong correlation between 
SMA expression and phosphorylated Smad2 and 4 (p<0.001 for both).  Figure 4.10 
shows normal mucosa with nuclear positivity for Smad4 compared to OSCC sample 
showing strong Smad4 expression 
 
 
 
 
Figure 4.10 – Smad4 staining in normal mucosa showing nuclear Smad4 only (A) compared with 
smad4 stromal and cytoplasmic upregulation in OSCC. 
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4.3.9 Comparison of prognostic indictors in OSCC 
 
 
Table 4.5 shows the hazard ratios for the chance of dying from OSCC for standard 
clinicopathological indices, SMA and αvB6. Looking at each factor independently 
(the unadjusted column), risk of death from OSCC was significantly increased with 
advanced tumour stage, positive resection margins, high tumour grade, an infiltrative, 
discohesive pattern of invasion and the presence of lymph node metastasis. Again 
looking at the unadjusted figures, the presence of a strong inflammatory host response 
conferred a significant survival advantage; patients with a high inflammatory response 
had a 68% reduction in OSCC mortality (HR=0.32 [95% CI=0.18-0.57]). There was 
also a weak association between increasing age and poorer prognosis in OSCC. 
Although extracapsular spead was a significant risk factor for early death from OSCC 
in the unadjusted column, surprisingly this factor loses significance when adjusted for 
all the other factors in the table. Patient sex, tumour site, p53, EGFR and αvβ6 
expression levels did not have any affect on prognosis in OSCC. 
 
There was a clear association between high stromal SMA expression and increased 
risk of OSCC death by over 4-fold (HR 4.26 [95% CI= 2.74-6.61], p=<0.001). After 
adjusting for known risk factors and all other variables considered in this analysis, the 
risk remained raised and statistically significant (HR 3.06 [95% CI=1.65-5.66; 
p=0.002]), showing that SMA is an independent risk factor for OSCC mortality. In 
fact, strong SMA expression had the highest hazard ratio of all the parameters 
examined in univariate and multivariate analysis, and even medium expression was 
associated with a significant increase in mortality (HR 2.01; table 4.5). There was also 
strong correlation between SMA expression and tumour stage, depth of invasion and 
extracapsular spread (p<0.001 for each) and inverse correlation with inflammation 
(p<0.001). 
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Unadjusted 
 
Adjusted 
(for all other factors in table) 
 
 
Characteristic Hazard Ratio (95% CI) P value Hazard Ratio (95% CI) P value 
     
Age* 1.04 (0.97-1.11) 0.04 1.08 (0.99-1.16) 0.07 
      
1.0 
  
1.0 
 Sex 
Male 
Female 0.96 (0.66-1.40) 0.72 1.43 (0.94–2.18) 0.10 
      
1.0 
 
<0.001 
 
1.0 
 
0.20 
2.61 (1.41-4.82)  1.90(0.99-3.66)  
3.02 (1.34-6.82)  1.62 (0.65-4.03)  
Disease Stage 
I 
II 
III 
IV 3.64 (2.24-5.94)  1.21 (0.62-2.33)  
      
1.0 
 
0.002 
 
1.0 
 
0.41 
Radiotherapy 
No 
Yes 1.88 (1.31-2.70)  1.18 (0.80-1.75)  
      
1.0 
 
0.004 
 
1.0 
 
0.04 
1.81 (1.07-3.05)  1.98 (1.16-3.38)  
Surgical Margins 
Clear (>5mm) 
Close (1-5mm) 
Involved (<1mm) 2.58 (1.60-4.17)  1.68 (0.97-2.93)  
      
1.0 
 
<0.001 
 
1.0 
 
0.05 
Metastasis 
No 
Yes 2.31 (1.61-3.32)  1.76 (1.00-3.11)  
      
1.0 
 
<0.001 
 
1.0 
 
0.70 
Extracapsular Spread 
No 
Yes 2.54 (1.63-3.96)  1.12 (0.63-1.98)  
      
1.0 
 
0.015 
 
1.0 
 
0.94 
1.82 (1.03-3.22)  1.07 (0.51-2.21)  
Grade 
Well differentiated 
Mod differentiated 
Poorly differentiated 2.96 (1.59-5.52)  1.11 (0.58-2.12)  
     Depth of Invasion ** 1.40 (1.23-1.59) <0.001 0.96 (0.78-1.19) 0.70 
      
1.0 
 
<0.001 
 
1.0 
 
0.001 
Pattern of Invasion 
Cohesive 
Discohesive 2.46 (1.71-3.54)  2.07 (1.33-3.24)  
      
1.0 
 
<0.001 
 
1.0 
 
0.55 
0.58 (0.38-0.88)  0.88 (0.55-1.42)  
Inflammation 
Low 
Medium 
High 0.32 (0.18-0.57)  0.69 (0.36-1.35)  
      
1.0 
 
0.029 
 
1.0 
 
0.16 
0.66 (0.35-1.27)  1.09 (0.66-1.78)  
αvβ6 
Low 
Medium 
High 1.43 (0.80-2.30)  1.00 (0.95-1.04)  
      
1.0 
 
<0.001 
 
1.0 
 
0.002 
2.18 (1.35-3.51)  2.01 (1.14-3.52)  
SMA 
Low 
Medium 
High 4.26 (2.74-6.61)  3.06 (1.65-5.66)  
* For increases of 5 years ** for increases of 5mm 
 
Table 4.5 – Hazard ratios for each potential prognostic factor in the cohort of 282 patients studied. 
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The data show that although αvβ6 is not an independent prognostic marker in OSCC, 
a high level of SMA expression within the tumour stroma is associated with an 
increased risk of dying from OSCC. At 3 years, the risk (95% CI) of dying from 
OSCC was 26% (18-34), 44% (32-56) and 74% (63-85) in the low, medium and high 
SMA groups respectively. The median OSCC-specific survival of the patients whose 
cancers expressed high levels of SMA was only 22 months (95% CI 13-22), the 
lowest of all other risk factors other than extracapsular spread (15 months). The 
median OSCC specific survival for other recognised risk factors were: metastatic 
disease (25 months), discohesive pattern of invasion (26 months), poorly 
differentiated tumours (28 months), stage IV disease (32 months) and positive 
surgical margins (43 months).  Table 4.6 shows the OSCC death rates at 1, 2 and 3 
years from diagnosis for patients with low, medium and high SMA expression and the 
median survival times for each group. 
 
 
 
SMA Expression 
 
 
 
Low 
 
Medium 
 
High 
1 year 
 
12% (7-18) 22% (12-32) 37% (26-48) 
2 years 
 
21 % (14-28) 36% (25-47) 65% (54-76) 
3 years 
 
26% (18-34) 44% (32-56) 74% (63-85) 
Median survival (95% CI) 
 
Not reached 93 months (40-not 
estimable) 
22 months (13-22) 
 
Table 4.6 – OSCC death rates (95% confidence intervals) according to SMA expression 
 
The Kaplan –Meier curves in Figure 4.11 below show that high SMA levels are 
associated with poor survival irrespective of whether the patients have advanced 
disease or not.   
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Figure 4.11 – Kaplan –Meier survival curves for varying SMA levels comparing patients with early 
and advanced disease.  Blue line is high SMA, red medium and black low. High SMA is associated 
with significant OSCC mortality regardless of whether the disease is advanced or not. 
 
The sensitivity and specificity of each predictive marker can also be assessed by 
generating a ‘likelihood ratio’ which is the detection rate (DR) divided by the false 
positive rate (FPR). DR is the percentage of those who have died with the specified 
characteristic (sensitivity) and FPR is the percentage of those still alive with the 
specified characteristic (1-specificity) (Deeks and Altman 2004).  Table 4.7 shows the 
DR, FPR and likelihood ratios for each potential prognostic indicator at 1 and 3 years 
– the higher the likelihood ratio, the more powerful the marker. 
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1 year status 3 year status  
 
Characteristic and 
definition of test 
positive 
DR%  
(60 
deaths) 
FPR% 
(214 
alive 
Likelihood 
ratio (LR) 
DR%  
(99 
deaths) 
FPR% 
(164 alive) 
Likelihood 
ratio (LR) 
       
Age (years)       
≥45 95 90 1.05 95 88 1.1 
≥50 85 82 1.04 87 79 1.1 
≥55 73 69 1.06 74 67 1.1 
≥60 57 56 1.02 58 55 1.1 
             Sex 
Male 68 63 1.1 64 64 1.0 
             
93 57 1.6 88 52 1.7 
75 43 1.7 69 39 1.8 
Disease Stage 
≥II, III, IV 
≥ III, IV 
≥ IV 71 37 1.9 62 34 1.8 
             Radiotherapy 
Yes 50 39 1.3 53 35 1.5 
             
87 66 1.3 83 62 1.3 
Surgical Margins 
Close, Involved  
Involved 62 35 1.8 54 32 1.7 
             Metastasis 
Yes 55 36 1.5 48 23 2.1 
             Extracapsular Spread 
Yes 27 10 2.7 24 7 3.4 
             
88 79 1.1 90 76 1.2 
Grade 
Moderate, poor 
Poor 33 17 1.9 31 15 2.1 
       Depth of Invasion        
≥ 4.0 mm 88 75 1.2 89 71 1.2 
≥ 5.0 85 65 1.3 85 60 1.4 
≥ 6.0 73 59 1.2 76 52 1.5 
≥ 10.0 60 30 2.0 59 23 2.6 
             Pattern of Invasion 
Discohesive 72 35 2.1 66 30 2.2 
             
92 75 1.2 90 71 1.3 
Inflammation 
Low, Medium 
Low 63 43 1.5 65 37 1.8 
       N=27 N=164  N=81 N=125  
83 72 1.2 78 72 1.1 
αvβ6 
Medium, high 
High 69 47 1.5 65 43 1.5 
       SMA       
Medium, high 73 47 1.6 73 40 1.8 
High 47 22 2.1 47 13 3.6 
        
Table 4.7 – Prognostic value of each baseline patient characteristic (for the death rate at 1 and 3 years) 
 
At 3 years from diagnosis, only SMA and extracapsular spread have a likelihood ratio 
greater than 3 with SMA at 3.6 and extracapsular spread at 3.4.  From this analysis, 
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other important prognostic indicators are depth of invasion >10mm (2.6 LR), presence 
of metastases (2.1 LR) and poor tumour grade (2.1 LR).  Applying the likelihood ratio 
rather than simply looking at the % of patients dead at 1 or 3 years with a particular 
prognostic indicator adjusts for the % patients with a prognostic factor who remain 
alive at 1 or 3 years (i.e. the false positive rate).  In the case of patients with high 
SMA levels, at 3 years from diagnosis 47% had died and only 13% of those still alive 
had high SMA expression levels.  Contrast this with other factors such as stage IV 
disease which is seen in 62% of patients who die at 3 years, however there is also a 
high false positive rate with this indicator as of those left alive at 3 years, 34% had 
stage IV disease.  Taking this into consideration, within this patient cohort, SMA is 
seen to be the most powerful prognostic indicator of those considered. 
 
To assess the validity of the finding that SMA was an independent prognostic marker 
in OSCC, data from the first 163 cases (80 OSCC related deaths) was used to produce 
a model to apply to the second data set of 116 patients (40 OSCC deaths). Cox 
regression modelling with backward elimination selected the most efficient group of 
prognostic indicators from the first data set.  Of all the factors considered, only age, 
metastatic disease, discohesive growth pattern and SMA expression were selected.  
The regression parameter estimates were 0.0226 (age), 0.585 (metastatic disease), 
0.899 (discohesive pattern of invasion), and 0.731 and 1.186 for medium and high 
SMA expression.   
 
Using these parameter estimates, a score for each patient in the independent validation 
set was derived and a ROC analysis performed using time to event data with 
censoring.  Figure 4.12 shows the ROC analysis showing the combined prognostic 
factors were highly predictive of death from OSCC at 3 years with an area under the 
curve of 77%.  Also from the curve it can be seen that using these factors around 70% 
of patients who die from OSCC were test positive (DR=0.7) but only 20% of those 
still alive were test positive (FPR =0.2). 
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Figure 4.12 – ROC curve for 3-year OSCC mortality derived using a model containing age, metastatic 
disease status, pattern of invasion and SMA expression, when applied to the independent validation 
dataset. The dashed line is the line of no effect.  
 
 
 
 
4.4 Discussion 
 
 
Currently in OSCC, patient management is based on the tumor-node-metastasis 
(TNM) system, which usually is supplemented with additional histopathological 
information from the primary tumor and loco-regional lymph nodes (Woolgar 2006). 
Although patients with advanced stage IV disease and extracapsular spread clearly 
have a poorer prognostic outlook than those with early disease, there is no clear 
consensus regarding the relative importance of other tumor features in determining 
patient prognosis.  Most prognostic studies report using relatively low patient 
numbers and this has hindered the identification of useful biomarkers, limiting the 
discovery of potential new prognostic markers. Thus there is a marked need to 
develop new diagnostic tools that can accurately identify aggressive tumours early, so 
that management can be adjusted accordingly. 
 
In this chapter, the significance of αvβ6, stromal SMA, EGFR and p53 expression in 
282 patients with OSCC is analysed, in relation to conventional prognostic indices 
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and mortality from OSCC. SMA was investigated to follow on from the findings set 
out in Chapter 3 and based upon evidence that the tumour stroma promotes tumour 
progression in other tumour types (Liotta and Kohn 2001, Pupa et al 2002, De Wever 
and Mareel 2003, DeWever et al 2008), and in in-vitro findings that myofibroblasts 
promote cell motility in OSCC cell lines (Lewis et al 2004).   
 
Results have shown that although αvβ6 is expressed at high levels in OSCC, it is not 
an independent prognostic marker as has been suggested in colon, cervical, non small 
cell lung and gastric cancers (Bates et al 2005, Hazelbag et al 2007, Elayadi et al 
2007, Zhang et al 2008).  Interestingly though, high levels of stromal SMA are seen to 
be an independent indicator of poor prognosis, and this finding is more significant 
than any of the other primary tumor indices used currently.  The data clearly show 
that in the OSCC patient cohort analysed, stromal SMA expression is the most 
significant independent prognostic marker, and is highly predictive of early death. In 
fact, only patients with extracapsular metastatic spread in the neck had a shorter 
median survival than those with high stromal levels of SMA (15 months verses 22 
months).  
 
As well as being associated with early mortality, SMA expression within the primary 
tumor correlated significantly with other indicators of adverse outcome including 
increased depth of tumour invasion advanced disease stage and poor tumour 
differentiation.  Furthermore, high SMA expression correlated with both presence of 
lymph node metastasis and extracapsular spread.  Immunohistochemical staining of 
lymph node metastases also revealed high levels of SMA, suggesting that 
myofibroblasts may help promote tumour dissemination.  
 
Expression of EGFR was also examined and not found to be significantly associated 
with prognosis in OSCC in this patient cohort. Although EGFR overexpression has 
been reported to be associated with higher grades or reduced survival in a numerous 
epithelial cancers including HNSCC (Salomon et al 1995, Kiyota et al. 2000; Putti et 
al. 2002, Laimer et al 2007), the clinical relevance of the findings varies. For 
example, Storkel et al (1993) found that overexpression of EGFR was associated with 
shortened survival whereas Christensen et al (1995) and Khan et al (2002) could not 
find significant correlation of EGFR with clinicopathological features or prognosis.  
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Others have looked specifically at tumour depth, lymph node status, extracapsular 
invasion, recurrence and survival in specimens from patients with HNSCC and found 
no significant correlation. (Partridge et al 1988, Ishitoya et al 1989, Frank et al 1993).   
 
The well-known tumour suppressor p53 was also examined as a potential prognostic 
marker in this OSCC cohort. Previously Nylander et al (2000) have shown that p53 is 
mutated in over 50% of human HNSCC specimens however again there are 
conflicting reports about the link between p53 expression and mortality in OSCC 
(Boslooper et al 2008, Gasco and Crook 2003). Results in this chapter show that 
although p53 was upregulated in OSCC, there was no significant correlation between 
p53 levels and mortality.  The reasons for this may be manifold but may include that 
the detection of p53 by immunohistochemistry is not always synonymous with the 
presence of p53 mutations. 
 
 
The analysis of 282 OSCC patients has revealed that tumour stage, grade, discohesive 
growth pattern, depth, incomplete surgical excision, metastatic disease and 
extracapsular spread are significant risk factors for mortality, which is consistent with 
previous studies (Brandwein-Gensler et al 2005, Woolgar 2006).  However, of all the 
prognostic indicators looked at, SMA was the single most significant independent 
predictor of mortality from OSCC and interestingly high SMA levels were indicative 
of poor outcomes irrespective of disease stage.  This is important, as it would allow 
high risk patients to be identified at the stage of initial biopsy, as SMA expression 
levels seen on the initial biopsy were consistent with those seen in the subsequent 
resection specimen.  
 
 
It is not immediately clear why certain tumours develop with a fibroblast rich stroma.  
The fibroblasts seen within tumours have an activated phenotype and are similar to 
those seen within healing wounds however they may be distinguished from normal 
fibroblasts by the fact they are perpetually activated, neither reverting to a normal 
phenotype nor undergoing apoptosis and elimination.  These tumour fibroblasts can 
be identified within the tumour stroma by the expression on SMA.  Activation of 
fibroblasts to become SMA positive myofibroblasts is proposed to take place by 
several mechanisms including activation of a tissue resident fibroblast, local cancer 
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cells or epithelial cells undergoing epithelial-to-mesenchymal transition (EMT), or the 
migration and activation of a marrow-derived cell.  
 
TGF-β has previously been shown to be the most potent cytokine driving 
myofibroblast transdifferentiation (DeWever et al 2008) and high levels of Smad2 and 
Smad4 seen in OSCC specimens along with the strong correlation with SMA 
expression would seem to confirm the relationship here. It is likely that a supportive 
SMA-positive stroma is generated because subsets of tumours are particularly 
effective at activating TGF-β1 (and probably refractory to its growth-suppressive 
effect). However, it is also possible that stromal cells from different individuals may 
vary in their ability to transdifferentiate into myofibroblasts. 
 
 
TGFβ exists in a latent form and may be activated through several mechanisms, 
including binding to the αvβ6, which has been shown to be a prognostic marker in 
several types of carcinoma (Bates et 2005, Hazelbag et al 2007 and Elayadi et al 
2007). αvβ6 expression has been shown to be increased in OSCC and to promote 
tumour invasion both directly and indirectly through stimulating TGF-β-dependent 
myofibroblastic transdifferentiation (Marsh et al 2008, Nystrom et al 2006). αvβ6 did 
not correlate significantly with SMA expression on multivariate analysis, nor was 
αvβ6 an independent prognostic marker in this OSCC patient cohort which suggests 
that either alternative mechanisms may be more important in activating TGFβ in 
OSCC, or that the stromal response to TGF-β varies between individuals.  
 
One other interesting finding was that SMA expression correlated inversely with 
inflammation (p=<0.001). The lack of a lymphocytic response in SMA-positive 
tumours may also be modulated through TGF-β, since this cytokine has also been 
shown to be a potent immune suppressor (Yang and Moses 2008). SMA expression 
also significantly correlated with depth and a discohesive pattern of invasion 
(p<0.001, p=0.02 respectively). Myofibroblasts have previously been shown to have 
an invasion promoting role in several tumour types through the upregulation of HGF 
(Lewis et al 2004, Marsh et al 2008). This growth factor promotes tumor cell motility, 
in part through downregulating cell cohesion and remodelling the extracellular matrix 
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(Birchmeier et al 2003), and it is possible a similar mechanism may modulate OSCC 
invasion in vivo.  
 
SMA status was also associated significantly with metastasis and extracapsular spread 
(both p<0.001). These data raise the possibility that SMA-positive stroma may be 
involved directly in disease progression and actively promote metastasis. There could 
be several explanations for this. Conceivably SMA-positive cells within lymph nodes 
could represent tumour cell EMT, or SMA-positive myofibroblasts may metastasise 
along with tumour cells. It is more likely that myofibroblasts are generated from local, 
or circulating mesenchymal cells and support disease progression by generating a 
supportive environment conducive to disease dissemination and that certain 
individuals may be more prone to stromal activation by TGFβ. 
 
 
4.5 Summary 
 
These data suggest that SMA may be the most significant independent prognostic 
indicator yet identified in OSCC.  High SMA is shown here to identify those patients 
most at risk in OSCC and more importantly identifies aggressive tumours even in 
patients with early stage disease or at the initial biopsy.  Although αvβ6 itself was not 
found to be an independent prognostic marker, there was a significant correlation 
between high αvβ6 expression, presence of metastases and depth of invasion 
suggesting the integrin may have a pro-invasive role in OSCC. 
 
Clearly there needs to be further prospective analysis of the natural progression of 
SMA positive tumours before suggesting that SMA scoring should take precedence 
over well established clinicopathological prognostic markers.  However the data from 
this large series of patients suggests that SMA scoring should be added as part of the 
routine assessment of samples from OSCC patients as those with high SMA scores 
should perhaps be managed more aggressively than those with low SMA scoring 
tumours. 
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Chapter 5 
 
 
 
Production of B6.3, a recombinant Ab to αvβ6 for 
the delivery of targeted magnetic alternating 
current hyperthermia  
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5.1 Introduction 
 
The murine scFv MFE-23 is a well characterised anti CEA antibody fragment which 
has previously been used in clinical trials (Begent et al 1996). To minimise the human 
anti mouse antibody response seen with repeated doses, MFE-23 has been humanised 
through the replacement of solvent exposed murine residues with human homologues 
(Graff et al 2004).  This new humanised scFv (hMFE-23) was then further stabilised 
by the same group using affinity maturation and termed shMFE-23. Furthermore, 
introducing a Tyrosine-H100b to Proline mutation in the H3 loop of VH domain has 
been shown to prevent MFE-23 binding to CEA without affecting the overall structure 
of MFE-23 (Boehm et al 2000). 
 
The integrin αvβ6 is utilised by the Foot and Mouth Disease Virus (FMDV) serotype 
O1 BFS as a vector by which to enter bovine epithelial cells (Monaghan et al 2005). 
FMDV is an RNA virus that is replicated in epithelial cells of domestic livestock and 
the primary route of infection is through epithelial cells in the animal’s oropharynx.  
The FMDV capsid consists of 60 copies each of the proteins VP1-VP4 which 
surround a single stranded positive sense RNA genome.  Crystal structures of these 
have shown the VP1 peptide contains a surface exposed conformationally flexible 
loop, the GH loop which has at its apex a highly conserved RGD motif (Acharya et al 
1989).  In cattle, the cells targeted by FMDV during the acute phase of infection have 
been shown to constitutively express αvβ6 suggesting that the integrin is important for 
the uptake of FMDV into cells (Monaghan et al 2005).  Binding of RGD motifs on 
the VP1 capsule peptide to αvβ6 stimulates a clathrin dependent uptake of the 
integrin-FMDV complex into cytoplasmic endosomes prior to transfer of the viral 
RNA into the cytoplasm (Berryman et al 2005).   
 
Although many integrins have RGD as a ligand, not all will recognise FMDV and 
there is evidence that other amino acids either side of the RGD sequence are 
important for intracellular uptake of FMDV. Consistently across FMDV strains, a 
leucine residue is seen at the RGD+1 and RGD+4 positions which is similar to the 
RGDLXXI sequence found in the LAP peptide associated with TGFβ (Munger et al 
1999). Mateu et al (1996) showed that substituting various amino acids at the RGD+1 
and RGD+4 sites of synthetic peptides derived from the GH loop of VP1 of a 
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particular FMDV strain reduced the ability of the peptides to inhibit infection of cells 
by the same strain of the FMDV. More recently, alanine substitution of the residues at 
RGD+1 and RGD+4 sites in a 17-mer peptide corresponding to the GH sequence of 
the VP1 loop of FMDV reduced the ability of the peptide to bind αvβ6 (Burman et al 
2006).  Although the contribution made by each individual residues of the GH loop to 
binding of αvβ6 is not fully understood, it is clear that residues either side of the RGD 
are also important for high affinity binding to αvβ6. A recent study looking at 
peptides generated from αvβ6 specific ligands with the sequence RGDLXXL (ie 
Leucine at RGD +1 and +4) and analysis of their binding to αvβ6 shows that the 
sequence is important for formation of a post RGD helix in the secondary structure of 
the peptide.  This helix is shown to be functionally important for stabilising the 
interaction of the RGD containing ligand with αvβ6 and for maintaining high affinity 
binding (DiCara et al 2007) 
 
 
The CDR3 loop of the VH domain of antibodies has previously been used as a site for 
insertion of peptides to successfully alter the specificity of a human/mouse chimeric 
heavy chain antibody (Lanza et al 1997).   The conformationally exposed position of 
the CDR3 loop within the VH domain of shMFE-23 also means it is an ideal site for a 
similarly structural based approach of peptide insertion to alter the specificity of the 
scFv.  Knowledge of the sequence of the VP1 peptide and evidence that it shows high 
affinity for αvβ6 gives rise to the possibility that by grafting the peptide into the 
CDR3 loop of shMFE-23, we can create a new scFv specific for αvβ6. Furthermore, 
by mutating the H3 loop with substitution of tyrosine residue for a proline residue, the 
new scFv should not bind to CEA. 
 
Ferric nanoparticles have been shown to generate heat when placed within an 
alternating magnetic field (Kallumadil et al 2009, Cantillon-Murphy et al 2010) and 
magnetic alternating current hyperthermia (MACH) has been successfully used in 
vivo to reduce tumour bulk (Jordan et al 1997, deNardo et al 2005, Balivada et al 
2010).  Single chain antibody fragments have previously been conjugated to many 
types anticancer therapies, including to nanoparticles (deNardo et al 2005, Dobson 
2010).  
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5.2 Aims and Objectives 
 
Work in this chapter builds upon previous data on magnetic alternating current 
hyperthermia and the chapter aims are to produce novel αvβ6 specific scFv in large 
scale and to attach commercially available magnetic nanoparticles to the αvβ6 
specific scFv.  The objective is to determine whether the scFv-nanoparticle conjugates 
can then be used to deliver targeted hyperthermia against αvβ6 expressing cell lines. 
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5.3  Results 
 
5.3.1 Insertion of VP1 peptide into CDR3 loop of shMFE-23 
 
DNA encoding the 17- mer peptide sequence from A140 to A156 of VP1 was inserted 
at the tip of CDR-H3 of MFE-23, between T98 and G99 (Kabat nomenclature). This 
was done using overlapping PCR reactions as described below. The first PCR reaction 
was designed to produce N terminus of desired sequence and to include Nco1 
restriction enzyme site in final product (CCATG). Primers used were shMFE sense 
(51CATGCCATGGCCCAAGTTAAACTGGAACAGTCC31) andVP1 antisense 
(51GAGCCAGCACCTGCAGATCACCTCGCAGATTCGGAACTGCAGTTGGTG
TCCCTTCGTTGC 31) Figure 5.1 shows the results of the PCR reaction run on 1% 
agarose gel. 
 
 
 
Figure 5.1 - 1% agarose gel showing PCR products from first PCR reaction to generate N terminal end 
of shMFE with varying amounts of plasmid template (1µl – 5µl) diluted 1:1000 and molecular weight 
markers II, IX. 
 
 
The second PCR reaction was designed to produce C terminus of desired sequence 
using primers shMFE antisense (51ATAGTTTAGCGGCCGCAGCCTTGATTTC31) 
and VP1 sense (51CTGCGAGGTGATCTGCAGGTCGTGGCTCAGAA 
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AGTTGCAGGTCCTTACCCTTTCGACTACTGGGGACAAGG 31). Figure 5.2 
shows the PCR products run on agarose gel. 
 
 
Figure 5.2 - 1% agarose gel showing PCR products from second PCR reaction to generate C terminal 
end of shMFE with varying amounts of plasmid template (1µl – 5µl) diluted 1:1000, MFE as control 
and molecular weight markers II, IX. 
 
The two separate PCR reactions have generated N and C terminal ends of B6.3 which 
were then combined in a third PCR reaction using primers shMFE sense and shMFE 
antisense to produce sequence coding for shMFE-23 with VP1 peptide in the CDR3 
region of VH chain as shown in figure 5.3. 
 
 
Figure 5.3 - 1% agarose gel showing PCR products from third PCR reaction at 2,5,10µl to produce 
DNA sequence encoding desired product B6.3, MFE as control and molecular weight markers II, IX. 
 
Having produced the sequence for B6.3, restriction enzymes Not1 and Nco1 were 
used to cut the PCR product and the E. coli vector puc119 (figure 5.4) prior to ligation 
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of digested B6.3 and puc119 vector, phenol extraction of the DNA and 
electroporation into TG1 E. coli cells. 
 
Figure 5.4 - 1% agarose gel showing PCR products and puc119 vector after digestion with enzymes 
Nco1 and Not 1 as compared to the un-cut control puc119 vector. 
 
Transformed cells were plated and left to grow overnight, from these plates, 20 
colonies were selected for PCR screening using primers shMFE sense and shMFE 
antisense. Five colonies were found to be positive for the insert B6.3 on colony 
screening; these were then selected for plasmid extraction and sent for sequencing.  
Initial sequence result showed peptide insertion, proline mutation and two unexpected 
errors at position 82 and 162.  These errors were corrected using site directed 
mutagenesis as shown in Appendix 1 (Figure A1.1). Repeated sequence data showed 
the desired sequence for B6.3 as shown in figure 5.5. 
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Figure 5.5 - Sequence of B6.3 - VP1 peptide sequence insertion is in red and proline mutation shown in 
green.   
 
After sequence data confirmed the desired DNA sequence, electroporation was used 
to insert the sequence into TG1 E. coli cells which were then grown in the presence of 
IPTG to stimulate protein expression.  Initially, expression was very weak however on 
concentration of the samples, the His tag on the protein could be detected on Western 
blot (figure 5.6).  
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Figure 5.6 - Western blot showing expression of MFE, MFEVP1, shMFE and MFEVP1 in E. coli with 
IPTG. There is weak expression of B6.3 (labelled shMFEVP1) in the concentrated sample. 
 
 
5.3.2 Insertion of free cystine into P.pastoris vector PPiczαB 
 
The aim of the work in this chapter is to produce αvβ6 specific single chain antibodies 
that can be attached to magnetic nanoparticles for the delivery of targeted magnetic 
fluid hyperthermia. Proteins can be attached to magnetic nanoparticles either non-
specifically via amine groups or using site-specific attachments via the –SH groups 
found on a free cystine molecule.  Large scale single chain production can be carried 
out in the yeast P.pastoris and to do this, the B6.3 construct should be transferred in a 
yeast vector such as PPICZαB.  To allow for site specific attachment of magnetic 
nanoparticles to the B6.3 scFv and to any future antibodies, using PCR, a cystine 
residue was inserted into the P.pastoris vector PPICZαB. To facilitate transfer from 
puc119 E. coli vector to the yeast vector, primers were designed to add a Not1 
restriction enzyme site and to remove the myc tag in a single step PCR reaction. 
Primers used were Ppic cys Sense (51GTACCTCGAGCCGCGGCGGCCGC 
CTGTCATCATCATCATCATCATTGATTTGTAGCCTTAGA31) and Ppic cys 
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Antisense (51 TGTGGGGGATCCGCACAAACGAAGGT31) Not 1 site shown in 
green, cystine in red and his tag in blue. Results from the PCR reaction are shown on 
the agarose gel in figure 5.7. 
 
 
Figure 5.7 - 1% agarose gel showing PCR products with varying template concentrations (1µl – 5µl) 
diluted 1:1000 and molecular weight markers II,IX. 
 
 
Having generated DNA sequence to be inserted into the PPICZαB vector by PCR, 
samples of the PCR reactions were run on agarose gel and then digested using 
enzymes BamHI and Not 1.  Figure 5.8 shows the digested products of original 
PPICZαB vector and the PCR products from the above gel. 
 
 
 
Figure 5.8 - 1% agarose gel showing digested PCR products, digested PPICZαB vector compared to 
control undigested vector and molecular weight markers II,IX 
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Digested PCR product and vector were run on agarose gel, the DNA was then excised 
and extracted from the gel. The products were ligated together then transformed into 
TOP 10F1 E. coli cells by electroporation.  Transformed cells were grown on LB 
plates in the presence of zeocin and colonies checked for insert acceptance by PCR 
screening using the primers Ppic cys sense and antisense as above.  Colonies which 
had accepted the insert on PCR screening were sent for sequencing, results shown 
below in figure 5.9. 
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Figure 5.9 - Sequence data showing removal of c-myc tag and insertion of cystine.  Sequencing primers 
used were 51AOX (51GACTGGTTCCAATTGACAAGC31) and Ppic cys reverse ( 
51AAATGAAGCCTGCATCTCTC31) 
 
 
 
Entire sequencing results for original PPICZαB vector, PPICZαBcys and are available 
in appendix 1 (Figures A1.2, A1.3). 
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5.3.3 Subcloning of B6.3 into PPICZαBcys vector 
 
Having now produced a new P.pastoris vector PPICZαBcys which would add a free 
cysteine residue to the single chain, I wanted to insert the DNA coding for B6.3 into 
the new vector ready for production of the scFv in yeast.  To begin with, B6.3 in 
puc119 vector and the newly produced PPICZαBcys vector were digested using the 
restriction enzymes Sfi and Not1.  Figure 5.10 shows the products of digestion 
reaction run on agarose gel. 
 
 
Figure 5.10  - % agarose gel showing products after digestion of B6.3 and PPICZαBcys compared to 
undigested controls. 
 
Following digestion, the bands containing the products of digestion were excised from 
gel and ligated together.  Ligated product was extracted using phenol and 
electroporated into TOP 10F1 E. coli cells for growth on LB/zeocin plates.  Colonies 
were selected to be sent for sequencing following PCR colony screening.  Sequencing 
results shown in figure 5.11 below used primers 51AOX 
(51GACTGGTTCCAATTGACAAGC31) and Ppic cys reverse 
(51AAATGAAGCCTGCATCTCTC31).  Full sequence data is shown in appendix 1 
(figure A1.4) 
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Figure 5.11 - Sequencing results for insertion of B6.3 into PPICZαBcys showing VP1 peptide and 
proline mutation (red), Not 1 restriction enzyme site (green) and cystine (blue)  
 
 
 
5.3.4 Production of shMFE in puc 119 vector then in PPICZαcys vector 
 
For control experiments, the original CEA binding scFv shMFE without VP1 insert or 
proline mutation needed to be inserted into the modified PPICZαBcys vector.  First, 
shMFE was amplified using PCR from PTCON vector and inserted into puc119 
vector using primers shMFE sense (51CATGCCATGGCCCAAGTTAA 
ACTGGAACAGTCC31) and shMFE antisense (51ATAGTTTAGCGGCCGCAG 
CCTTGATTTC31). 
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The PCR products and puc119 vector then cut using restriction enzymes Nco1 and 
Not1. The products of digestion were then ligated and the new construct 
shMFE/puc119 was transformed into TG1 cells. The cells were grown overnight then 
colonies picked for PCR screening and subsequently sent for sequencing (Appendix 1, 
Figure A1.5). 
 
 
Having inserted shMFE into puc119 vector, the DNA encoding for shMFE can now 
be cut from the vector and inserted into PPICZαBcys vector using restriction enzymes 
Sfi1 and Not1.  Figure 5.12 shows the products of digestion run on agarose gel. 
 
 
 
 
Figure 5.12 - 1% agarose gel showing products after digestion of shMFE and PPICZαBcys compared 
to undigested controls. 
 
Following digestion, the bands containing the products of digestion were excised from 
gel and ligated together.  Ligated product was extracted using phenol and 
electroporated into TOP 10F1 E. coli cells for growth on LB/zeocin plates.  Colonies 
were selected to be sent for sequencing following PCR colony screening using shMFE 
sense and shMFE antisense primers.  Figure 5.13 shows sequencing results with 
original tyrosine residue in red in position 115, no VP1 insert and cystine residue 
shown in blue. Entire sequence data can be seen in appendix 1 (Figure A1.6) 
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Figure 5.13 - Sequencing results for insertion of shMFE into PPICZαBcys showing original tyrosine 
(red), Not 1 restriction enzyme site (green) and cystine (blue). Compare to sequencing in section 5.3.3. 
 
 
5.3.5 Transformation of B6.3 and shMFE into X33 cells for production in Pichia 
pastoris 
 
Sequencing confirmed the correct sequence of B6.3 and shMFE in the PPICZαBcys 
vector so allow large scale production of the scFv in P.pastoris, the construct was first 
linearised using Pme1 enzyme and run on agarose gel (figure 5.14). 
 
 
Figure 5.14 - 1% agarose gel showing B6.3/PPICZαBcys after digestion with Pme1, compared to 
control uncut B6.3/PPICZαBcys and molecular weight markers II, IX. 
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Similarly, to produce shMFEcys in large scale and having confirmed the correct 
sequence above, Pme1 enzyme was used to linearise shMFE/PPICZαBcys construct, 
the results of which are shown below in figure 5.15. 
 
 
 
 
Figure 5.15 - 1% agarose gel showing shMFE/PPICZαBcys after digestion with Pme1, compared to 
control un cut shMFE/PPICZαBcys and molecular weight markers II, IX. 
 
 
 
For both the shMFE and B6.3, the linearised DNA was cut from agarose gel, purified 
and transformed into X33 cells which were grown on YPD/zeocin plates.  10 colonies 
were selected for PCR colony screening using primers 51AOX 
(51GACTGGTTCCAATTGACAAGC31) and 31AOX  
(51GCAAATGGCATTCTGACATCC31) and colonies grown in BMGY media to 
check for protein expression.  Figures 5.16 and 5.17 show expression of B6.3 and 
shMFE detected by western blot following incubation with methanol. 
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Figure 5.16 - Western blot showing expression of B6.3 in separate colonies labelled 2-10 after 33 hrs 
incubation. All colonies except for 2,4 show good expression levels  
 
 
 
 
Figure 5.17 - Western blot showing expression of shMFE in separate colonies labelled A-J after 33 hrs 
incubation. Colony D shows a particularly high level of expression. 
 
The colony which showed high levels of protein expression was then grown and large 
scale production continued.  Fermentation in P.pastoris produced yields of 0.98mg/ml 
after initial expanded bed-IMAC chromatography.  Size exclusion chromatography 
using Superdex 75 column revealed B6.3 eluted almost exclusively as a non-covalent 
dimer (Figure 5.18).  This was unexpected as previously, the non humanised 
MFEVP1(P) was produced in P.pastoris as a monomer (Kogelberg et al 2008).  The 
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purified dimer was a stable construct and could not be split into monomeric form even 
after freeze thawing, exposure to 3 M urea, in extremes of both acidic and basic pH. 
 
 
 
Figure 5.18 - B6.3 seen produced almost exclusively as a dimer following size exclusion 
chromatography using a Superdex 75 column. 
 
 
 
 
 
5.3.6 B6.3 specifically binds its ligand αvβ6  
 
To examine the specificity of B6.3 to it’s ligand αvβ6, ELISAs were set up which 
showed B6.3 bound to immobilized αvβ6.  Figure 5.19 shows binding of B6.3 in 
comparison to the murine MFEVP1(P) and MFE with TBS as a control. 
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Figure 5.19 - ELISA showing B6.3 bound to immobilized αvβ6. B6.3, MFEVP1(P) and MFE-23 were 
applied at 20µg/ml to immobilized αvβ6. Binding was detected with mouse anti-Tetra-His IgG 
followed by sheep anti-mouse horseradish peroxidase (HRP) linked secondary antibody. The data 
represent the mean of triplicate measurements and error bars represent the standard deviation at each 
data point. 
 
This ELISA confirms B6.3 binds immobilised αvβ6 in comparison to MFEVP1(P) 
and in comparison to MFE which shows minimal binding only.  Specificity of B6.3 
for the ligand αvβ6 was also confirmed on flow cytometry using the αvβ6 expressing 
cell line HT29 (Fig 5.20) 
 169 
 
 
 
 
Fig 5.20 - FACS - HT 29 cells were incubated with B6.3, MFEVP1(P), 10D5 and MFE-23 (all at 100 
µg/ml). Binding was detected with monoclonal mouse anti-polyhistidine followed by PE- labeled anti-
mouse IgG. In the omission control shown, cells were incubated with MFE-23 at 50 µg/ml followed by 
R-PE-labeled goat anti-rabbit IgG.  
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5.4 Magnetic Alternating Current Hyperthermia (MACH) 
 
The second aim of this chapter is to investigate the potential for the use of B6.3 to 
target αvβ6 expressing cells for the delivery of MACH.  MACH requires the use of 
superparamagnetic nanoparticles and two particles were investigated, Chemicell DX 
and FDA approved Resovist.  MACH was generated using the Magnetic Alternating 
Current Hyperthermia (MACH) system kindly supplied by Professor Quentin 
Pankhurst of the Royal Institution of Great Britain. 
 
 
5.4.1 Heating of nanoparticles using the MACH system 
 
Nanoparticles at concentrations between 0.1mg/ml and 10mg/ml were placed within 
the alternating magnetic field at 150V, 0.74A, 1 Mhz and temperature measurements 
were taken from a starting temperature of 37°C to simulate human body temperature. 
Chemicell DX particles achieved a maximum temperature of 61.5°C at 10mg/ml after 
6 mins and at 1mg/ml, the maximum temperature reached was 43°C (Figure 5.21 and 
Figure 5.23).   
 
 
 
Figure 5.21 - Graph showing heating of Chemicell DX particles at concentrations from 0.1mg/ml to 
10mg/ml.  Particles were suspended in 0.5mls of water in 1.5ml eppendorf tubes and temperature 
measurements taken using the Luxtron probe. 
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Resovist heating at 10mg/ml resulted in a maximum temperature of 70°C and of 41°C 
at 1mg/ml giving temperature increases of 33 °C and 4°C respectively (Figure 5.22 
and Figure 5.23) 
 
 
 
 
Figure 5.22 - Graph showing heating of Resovist particles at concentrations from 0.1mg/ml to 
10mg/ml. Temperature increases were measured using the Luxtron probe and particles were suspended 
in 0.5mls water in 1.5ml eppendorf tubes as before. 
 
The Figure 5.23 below shows the maximum temperatures reached for both Chemicell 
DX and Resovist when starting from 37°C.  The increasing maximum temperature 
reflects the increasing concentration of iron found at higher nanoparticles 
concentration levels.  For therapeutic hyperthermia the temperature increase would 
need to be at least 4°C as significant cell death is only seen at temperatures of 41°C 
and above (Jordan et al., 1999). 
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Figure 5.23 - Graph showing maximum temperature increases achieved for Resovist and Chemicell DX 
nanoparticles at concentrations from 01.mg/ml to 10mg/ml when placed within an alternating magnetic 
field at 1Mhz. 
 
 
 
5.4.2 Heating of B6.3-nanoparticle conjugates 
 
Resovist and Chemicell DX both display superparamagnetic properties enabling their 
use in the generation of MFH however each particle has a different coating.  Resovist 
has a dextran COO- coating and Chemicell a Dextran OH- coating. Chemicell 
particles were conjugated using the cyanogen bromide method and Resovist using 
carbodiimide activation (Figure 5.24).  
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Figure 5.24 – Alternative conjugation methods used for joining B6.3 and Cemicell and Resovist 
nanoparticles. 
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Results below indicate that the scFv-nanoparticle conjugates retain the ability to 
generate heat when placed within the alternating magnetic field of the MACH 
machine.  The particle concentration used were 0.25mg/ml to 1.25mg/ml to reflect 
potential in vivo situation, as it is unlikely that intravenously delivered scFv-
nanoparticle conjugates would accumulate at the tumour site at concentrations higher 
than this.  Figures 5.25 and 5.27 show increases in heating potential of B6.3-
Chemicell DX conjugates to a maximum of 44.8°C at 1.25 mg/ml after 4mins 20 sec. 
 
 
 
 
Figure 5.25 – Heating potential of conjugates of B6.3 and Chemicell DX particles at varying 
concentrations. Maximal heating achieved was 44.8°C at 1.25mg/ml of Chemicell nanoparticles. 
Temperature required for cell death (>41°C) was reached at concentration of 0.5mg/ml after less than 2 
minutes exposure to MFH.  ScFv-nanoparticle conjugates were suspended in 0.5mls water in 1.5ml 
eppendorf tubes. 
 
MACH heating of Resovist and B6.3 conjugates showed that concentrations of greater 
than 0.5mg/ml were required to reach temperatures of over 41°C.  There was little 
difference seen in the behaviour of conjugates at 0.25mg/ml and 0.5mg/ml although 
the rate of temperature increase at concentrations of 1 and 1.25mg/ml of B6.3 and 
Resovist was faster than that seen with the B6.3 and Chemicell-DX conjugates 
(Figure 5.26 and 5.27).  
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Figure 5.26 – Heating potential of conjugates of B6.3 and Resovist particles at varying concentrations.  
At concentrations of 0.5mg/ml the maximum temperature achieved was 40°C however at 1mg/ml, 
41°C was reached after only 68 seconds heating. Temperature measurements were taken using the 
Luxtron temperature probes placed in the 1.5ml eppendorf tubes used to contain the 0.5mls water in 
which the conjugates were suspended. 
 
 
Figure 5.27 – Graph showing the maximum temperature increases seen when Resovist and Chemicell – 
B6.3 conjugates were exposed to MACH at varying concentrations.  Maximal heating was seen with 
Resovist-B6.3 at 1mg/ml with a temperature increase to 45.3°C from a baseline of 37°C. 
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5.4.3 Iron uptake Assay 
 
To investigate whether the conjugation of B6.3 to the nanoparticles increased the 
cellular uptake of nanoparticles compared to nanoparticles alone, B6.3 -nanoparticle 
conjugates were incubated with αvβ6 expressing cell lines and the amount of iron in 
the cell was measured using a Ferrozine assay as described in chapter 2. Experiments 
were repeated in triplicate and at varying concentrations.   Figure 5.28 shows the 
colour change seen at the end of the assay with the darker colour indicating increasing 
iron uptake. 
 
 
 
 
Figure 5.28 – Example of the final stage of a Ferrozine iron uptake assay showing varying 
concentrations of ‘targeted’ B6.3-Resovist conjugates alongside varying concentrations of non targeted 
Resovist (‘non-T’). As the concentration of nanoparticles increases from 0.1mg/ml to 1mg/ml, there is 
a darker colour seen, indicating a greater concentration of iron is present. 
 
 
When B6.3-Chemicell-DX conjugates were incubated with the αvβ6 expressing A375 
cell line, there was a clear increase in relative iron uptake compared to when 
Chemicell-DX alone was incubated with A375 cells.  Figure 5.29 shows the relative 
iron uptake of targeted and non-targeted Chemicell-DX nanoparticles at 
concentrations from 0.1mg/ml through to 2.5mg/ml. 
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Figure 5.29 – Results of Ferrozine assay showing relative iron uptake by αvβ6 expressing cell line 
when cells were incubated with targeted B6.3 – Chemicell DX conjugates compared to Chemicell DX 
alone.  Experiments were done in triplicate and show that targeted nanoparticles are better taken up 
than non-targeted at each concentration tested. 
 
Looking at iron uptake by A375 cells after incubation with Resovist and with B6.3-
Resovist conjugates, there was again increased uptake with targeted compared to the 
non targeted nanoparticles and this observation was again seen at every concentration 
(Figure 5.30). 
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Figure 5.30 – Relative iron uptake seen with the Ferrozine assay comparing targeted and non targeted 
Resovist nanoparticles at varying concentrations.  Experiments again carried out in triplicate. Maximal 
iron uptake is seen at concentrations of 2.5mg/ml. 
 
 
 
5.4.4 MACH directed cell death 
 
This series of experiments was set up to investigate whether there was any difference 
in cell death when cells incubated with targeted or non targeted nanoparticles were 
exposed to MACH.  Three different αvβ6 expressing cell lines were selected; HT29, 
VB6, A375 and both Chemicell-DX and Resovist nanoparticles were tested with each 
cell line.  Cells were then incubated with either targeted B6.3 conjugated 
nanoparticles or non-targeted nanoparticles with cells alone used as a control.  Cells 
that were incubated with nanoparticles were then split into two groups – a ‘wash’ and 
‘non-wash’ group to remove any non specific binding of nanoparticles to the cells.  
Cells were then exposed to MACH and cell survival estimated using a standard MTT 
assay.  Full experimental details are set out in Chapter 2. 
 
Figure 5.31 shows the MACH machine and cells being placed with the coil which 
generates the alternating magnetic current and Figure 5.32 shows 96 well plates with 
cells plated out at varying concentrations from which strips of cells were removed to 
be placed within the MACH coil. In all cases, the ambient temperature was 
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maintained at 37°C using the Air Therm to simulate the in-vivo situation and results 
from these experiments are presented in Figures 5.33 to 5.35. 
 
 
Figure 5.31 – Experimental set up: A) MACH machine, B) Airtherm unit keeping baseline temperature 
at 37°C to simulate in-vivo situation, C) Single strip from 96 well plate containing cells within sterile 
tube, D) Cells placed within the coil where they are exposed to an alternating magnetic current.  
 
 
 
 
Figure 5.32 – 96 well plates showing VB6 cells incubated with varying concentrations of nanoparticles, 
both B6.3 conjugated (‘T’) alone (‘non T’).  The experiments were repeated in triplicate and horizontal 
rows of wells were removed in turn to be exposed to MACH before being returned to the incubator. 
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Figure 5.33 – VB6 cells with targeted and non targeted Chemicell and Resovist particles 
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Figure 5.34 – A375 cells with targeted and non targeted Chemicell and Resovist particles 
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Figure 5.35 – HT29 cells with targeted and non targeted Chemicell and Resovist particles 
Taking an overview of the data produced from these cell death experiments, there is a 
clear reduction in cell survival following exposure to MACH at particles concentrations 
of 2.5mg/ml and 5mg/ml when compared to cell survival in the ‘no MACH’ group.  This 
observation is consistently seen in all three cell types, with both Chemicell and Resovist 
nanoparticles and the effect appears to be irrespective of whether the nanoparticles are 
targeted or not. A second conclusion that can be drawn from the experiments is that 
MACH itself does not appear to be harmful to the cells as cell survival in the control 
groups (cells only) remains at around100% again for all three cell types and in each 
separate experiment. 
 
Looking at potentially more physiologically more feasible nanoparticle concentrations of 
1mg/ml and below, for all cell types at 1mg/ml there remains a reduction in cell survival 
when cells incubated with nanoparticles are exposed to MACH compared to the ‘no 
MACH’ group.  Table 5.1 shows the % cell survival of all three cell types and shows a 
significantly increased cell kill with targeted Resovist particles and A375 cells (p=0.01), 
this effect is also seen with HT29 cells and targeted Chemicell particles (p=0.04). 
 
 Chemicell Resovist 
 
 Cell Survival 
(%) 
P value Cell Survival 
(%) 
P value 
VB6 
 
Targeted 
Non targeted 
 
 
66.2 
75.0 
 
 
 
0.35 
 
 
66.2 
84.5 
 
 
 
0.08 
A375 
 
Targeted 
Non targeted 
 
 
74.5 
82.4 
 
 
 
0.33 
 
 
51.8 
79.8 
 
 
 
*0.01 
HT29 
 
Targeted 
Non targeted 
 
 
65.6 
93.7 
 
 
 
*0.04 
 
 
48.6 
70.6 
 
 
 
0.11 
 
Table 5.1: Comparison of % cell survival seen when cells are incubated with 1mg/ml either non targeted or 
targeted (B6.3 conjugated) nanoparticles and exposed to MACH. Significant findings asterisked. 
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At concentrations less than 1mg/ml there was no significant differences seen in cell 
survival rates for any cell type between cells exposed to MACH and those not exposed to 
MACH for either targeted or non targeted particles. 
 
 
5.5  Discussion 
 
Using a stepwise, rational structure based design approach, the novel scFv B6.3 has been 
manufactured using the CEA binding MFE-23 scFv as a scaffold.    MFE-23 was chosen 
as it is has been used in clinical trials and is well characterized (Boehm et al 2000, Lee at 
al 2002, Sainz-Pastor et al 2006).   
 
The first aim of this chapter was to insert the GH loop of the VP1 FMDV peptide into the 
CDR3 loop of shMFE-23 and to generate a novel scFv specific for αvβ6.  Previously, it 
has been shown that αvβ6 strongly binds the FMDV using β6 transfected cells whereas 
other integrins such as α5β1 and αvβ6 were not seen to be important for FMDV to bind 
epithelial cells (Jackson et al 2000). Thus, it was predicted that the αvβ6 binding capacity 
of VP1 peptide could be conferred to the scFv shMFE. 
 
To increase the specificity of the novel peptide, a proline to tyrosine mutation was 
introduced using the same PCR reaction to introduce the VP1 peptide sequence.  
Previously this single residue mutation at Y100bP was predicted to reduce CEA binding 
and has since been shown to eliminate binding of MFE-23 to CEA (Boehm and Perkins 
2000, Read et al 1995).  Throughout this chapter, the humanised version of MFE-23 has 
been used in an attempt to minimise anti-mouse antibody production if this construct is to 
be used in human trials in the future.   
 
The αvβ6 specific scFv was produced in yeast P.pastoris to GMP standards at 
concentrations of 0.98mg/ml and this antibody was subsequently shown to bind αvβ6 on 
ELISA. The ultimate aim of the work presented in this thesis is to produce a scFv which 
may ultimately be used for anti cancer therapies, in particular in OSCC.  To this end, 
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αvβ6 was chosen as a target as the integrin has previously been shown to modulate 
tumour cell invasion, inhibit apoptosis, regulate protease expression and activate TGF-β1 
and importantly, there is minimal expression on healthy epithelium (Ahmed et al 2002).   
 
Magnetic fluid hyperthermia is a novel approach to cancer therapy using an externally 
generated alternating magnetic field to excite and generate heat on nanometre sized iron 
particles which are in close proximity to tumour cells.  Previously this approach has been 
shown to be feasible and safe when delivered by direct intratumoural injection in clinical 
trials in patients with brain and prostate cancers (van Landeghem et al 2009, Johannsen et 
al 2006).  An alternative to direct intratumoural injection is to attach MNPs to scFvs with 
the aim of using the scFvs to target tumour cells and deliver the nanoparticles directly to 
the tumour.   
 
There are several methods to attach scFvs to MNPs, including non-specific amine 
attachments between the –NH2 groups on the scFv and –COOH groups found on the 
dextran coating on MNPs. An alternative method is to use site-specific attachments 
between the scFv and the MNPs, to this end P.pastoris vector PPICZαB was successfully 
manipulated so that a free terminal cystine residue would be introduced when the vector 
was used for scFv production in P.pastoris. The sequencing data presented above confirm 
that the cystine is present in the vector. This cystine residue could be used for future 
experiments where site specific attachment between free –SH groups present on the 
cystine and the –COOH groups  on dextran coated nanoparticles are required. 
 
The second aim of this chapter was to attach commercially available magnetic 
nanoparticles to B6.3 and to investigate potential hyperthermia mediated cell kill.  Using 
two alternate attachment methods, B6.3 was successfully conjugated to Resovist and 
Chemicell DX nanoparticles.  The new conjugates were then shown to generate heat 
when placed within an alternating magnetic field and also greater cellular uptake of iron 
was seen with the scFv-conjugated particles compared to particles alone.  Assessing cell 
death following exposure to MACH, there was a clear effect seen at concentrations of 
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greater than 2.5mg/ml and even at 1mg/ml a significant reduction in cell viability was 
seen in two out of six cell death experiments. 
These data suggest that conjugating nanoparticles to scFvs results in an increased cellular 
uptake of nanoparticles in vitro and at concentrations greater than 1mg/ml nanoparticles 
combined with MACH does effect cell death in vitro compared to MACH alone.  Given 
that intravenously delivered scFv-nanoparticle concentrations would be unlikely to reach 
concentrations of 1mg/ml and are more likely to be measured in nanograms/ml, perhaps a 
more feasible method of delivering nanoparticles to the tumour bed in vivo situation 
would be direct intratumoural injection as used by van Landeghem et al (2009).  A 
separate possibility is that the scFv/nanoparticle conjugates could be used to treat 
metastases in a similar way to the detection of sentinal node with radioactive tracers or 
blue dye.  These two methods could be considered as ways of accumulating sufficient 
nanoparticles to generate sufficient hyperthermia required to cause cell death. 
 
 
5.6 Summary 
 
The αvβ6 integrin is an exciting new target for SCC cancer therapy and results set out in 
earlier chapters have shown that the integrin is over expressed in non-melanoma skin 
cancers as well as in oral SCC.  In this chapter, the novel scFv B6.3 has been 
manufactured and shown to bind αvβ6 on ELISA and FACS analysis. Further, B6.3 has 
been successfully conjugated to two commercially available magnetic nanoparticles, 
demonstrating the potential application of these new conjugates for the delivery of 
targeted MACH against αvβ6 expressing cell lines. 
 
In conclusion, the results set out above have shown the successful design and 
manufacture of B6.3 and its potential for use in the development of MACH driven 
personalised medical therapies in patients with OSCC. 
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Chapter 6 
 
 
 
Conclusions and Future Challenges 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 188 
 
The aim of this thesis is to investigate the clinical usefulness of the αvβ6 integrin and it 
role as a potential target for antibody delivered MACH, a novel anticancer therapy.  This 
chapter aims to review the findings presented in this thesis and to suggest potential 
further avenues of research. 
 
The αvβ6 integrin is known to be over-expressed in many types of carcinoma with 
minimal expression in normal healthy tissues.  Whilst it has previously been reported that 
αvβ6 is over expressed in skin SCC (Thomas et al 2006), the expression in BCC and pre-
malignant actinic keratoses (AK) has not previously been studied.  The results presented 
in chapter 3 show 32% of AK express high αvβ6 levels compared to 79% of skin SCC 
and 32% of BCC.  Within the BCCs, the morphoeic subset were seen to show very high 
levels of αvβ6 expression and it was postulated that there may be a link between αvβ6 
and the production of a myofibroblast rich fibrotic stroma seen in morphoeic BCCs.  
 
Using a BCC model, data presented in Chapter 3 is suggestive that αvβ6 may activate 
TGF-β1 which in turn promotes invasion through the transdifferentiation of 
myofibroblasts. TGF-β1 is known to have a complex role in tumourigenesis and 
increased expression levels have been linked to cancer progression and metastatic spread 
in colorectal and prostate cancers (Tsushima et al 1996, Wikstrom et al 1998, Friedman et 
al 1995), further TGFβ has been shown to have complex interactions with the tumour 
microenvironment (reviewed in Bierie and Moses 2006) and to promote cell motility 
through the modulation of epithelial to mesenchymal transition (EMT).  The concept that 
the tumour stroma itself can have effects on the rate of tumour progression is gaining 
credence and there is strong evidence that TGFβ has a role in driving myofibroblast 
transdifferentiation, particularly in squamous cell carcinoma (Lewis et al 2004).   
 
The novel findings presented in Chapter 3 further support the idea that there is a 
synergistic relationship between tumour and tumour stroma which is in part regulated by 
TGFβ and highlights a possible role of αvβ6 as a pro-invasive factor in morphoeic BCC.  
This finding raises the possibility of targeted therapies against BCC which can be used to 
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modulate disease progression or recurrence, particularly in morphoeic type BCC which is 
often refractive to current therapies. 
 
Considering the clinical utility of αvβ6 not only as a potential target for anti cancer 
therapies but also as a potential prognostic marker for advanced disease, the hypothesis 
‘αvβ6 is an independent prognostic marker in OSCC’ was proposed and tested on a 
retrospective cohort of 282 patients with OSCC in Chapter 4. OSCC was selected as a 
cancer type to study as the 5-year survival rates remain at under 50% with very little 
improvement over the past 25 years.  Furthermore, the integrin has recently been shown 
to be an independent prognostic marker in colon, cervical and gastric carcinomas (Bates 
et al 2005, Hazelbag et al 2007 and Zhang et al 2008) and is known to be over expressed 
in OSCC. 
 
Following on from the identification of the importance of αvβ6 in the formation of a pro-
invasive myofibroblast rich tumour stroma in Chapter 3, the myofibroblast marker SMA 
was also examined as a potential prognostic marker in the same cohort of patients along 
with standard histopathological parameters.  The findings from Chapter 4 were that αvβ6 
was not an independent prognostic marker however, high SMA levels were strongly and 
significantly associated with adverse outcomes in the group of patients studied. 
 
Histological techniques are commonly used for analysing tumour samples due to the 
availability of formalin fixed paraffin embedded tissue and relative ease of application.  
Currently in OSCC there is no single prognostic marker in routine clinical use and the 
prognosis of OSCC patients is derived from the combination of several recognised 
pathological features (TNM staging).  Weaknesses with the TNM system for OSCC 
include the fact that it only includes the tumour diameter and not tumour depth which is 
the measurement found to consistently predict significantly poorer outcomes in OSCC 
however there is no clear consensus on the cut off point for tumour depth after which 
patients have a clearly adverse prognosis (Asakage et al 1998, Jung et al 2009).  Broders 
classification of well, moderate or poorly differentiated tumours has been used since 
1920 to provide prognostic information for various tumour types but has been shown to 
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be of limited value in predicting prognosis in OSCC (Okamoto et al 2002, Woolgar 
2006).  Many molecular markers in OSCC have been examined and to date no one 
marker has been confirmed as providing accurate prognostic information.  Clearly if there 
were a single marker that could be routinely examined for in laboratories and could 
provide an accurate prediction of prognosis this would greatly aid with the planning of 
future treatment strategies. 
 
Data presented in this thesis is in agreement with Vered et al (2010) who have recently 
shown that cancer associated fibroblasts as detected by SMA staining are an independent 
predictor of tumour recurrence in OSCC and they have also shown the persistence of 
these cells in OSCC metastases.  Similarly, data from this cohort of patients shows that 
high SMA expression is significantly associated with metastasis and extracapsular 
spread, raising the possibility that the myofibroblastic rich stroma may promote tumour 
dissemination. These findings tie in with the results from chapter 3, again highlighting 
the importance of the tumour stroma in modulating disease progression and identifying 
SMA as a possible target for future therapies. 
 
The final step in testing the clinical utility of αvβ6 integrin was to develop a technique to 
target the integrin and to use this to deliver anticancer therapy directly to tumour cells 
expressing αvβ6. Targeted hyperthermia was selected as the anticancer therapy of choice 
as it was felt that the heat might also affect the tumour stromal cells that had been 
identified as important for the promotion of tumourigenesis and to be indicators of 
adverse prognosis in the previous chapters. The work presented in Chapter 5 therefore 
details the design of a scFv antibody fragment specific for the αvβ6 integrin and the 
subsequent conjugation to nanoparticles for the generation of targeted hyperthermia.   
 
Clearly there are many challenges to overcome before we are able to effectively treat 
OSCC patients with targeted MACH driven therapies.  Data from Chapter 5 shows that 
the B6.3 scFv binds αvβ6 and that in-vitro B6.3-nanoparticle conjugates show increased 
cellular uptake.  Furthermore, significant cell death is seen when cells and nanoparticles 
are exposed to MACH at concentrations of greater than 1mg/ml.  These findings can be 
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compared to results from human experiments in patients with glioblastoma multiforma 
and prostate cancer in which nanoparticles were directly injected into the tumour giving 
very high particle/tumour concentrations of 10mg/ml (Maier-Hauff et al 2007, Johannsen 
et al 2010).  Other groups have achieved significant heating of tumours in murine 
experiments using nanoparticle concentrations were around 315ug per ml of tumour in 
which nanoparticle/antibody conjugates were delivered intravenously (DeNardo et al 
2005). 
 
The particles used in this thesis were chosen for their heating ability using the MACH 
system available and the ability to conjugate the particles to scFvs (Vigor 2010 PhD 
thesis). New particles are constantly becoming available and in the future it may be 
possible to increase the frequency and power delivered by MACH machine which may 
also effect greater heat generation.  Possible future directions for research in this area 
include in-vivo experiments using the current B6.3-nanoparticle conjugates looking at 
biodistribution and histological effects of MACH using SCC tumour xenographs.  One 
area where the use of MACH would be exciting is for the treatment of metastatic tumours 
in the draining lymph node basins.  One possible mechanism of delivery would be the 
injection of targeted nanoparticles into the tumour itself along the lines of sentinel node 
studies and then the nodal basin could be exposed to MACH.  This raises the possibility 
of treating subclinical micro-metastases that currently are undetectable. 
 
In conclusion, this thesis has produced some novel findings highlighting the clinical 
utility of the αvβ6 integrin as a potential target in cancers overexpressing αvβ6.  The 
identification of SMA as an independent prognostic marker merits further investigation, 
ideally in a prospectively designed multicentre study. Finally, the single chain antibody 
B6.3 has potential for use in its current form or as part of a whole antibody for the 
development of personalised medicine in αvβ6 expressing cancers. 
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Figure A1.1 VP1 peptide sequence shown in red, proline mutation in green. Errors in sequence shown in 
blue at position 82 and 162. Subsequently altered using site directed mutatgenesis: GGC (Glycine) corrected to 
GAC (Aspartate) using primers (51GCTACTTTTACTACCGACACTTCCGCTAATACC31) and 
(51GGTATTAGCGGAAGTGTCCGTAGTAAAAGTAGC31). Second, GGA (Glycine) corrected to AGA 
(Argenine) using primers (51GTTTCTGTTGGCGATAGAGTAACCATCGC31) and shMFE antisense G to A 
(51GCGATGGTTACTCTATCGCCAACAGAAAC31) 
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Figure A1.2 Original PpicZαB vector sequence showing c-myc and His tags in blue, Sfi, Not1 and 
BamH restriction enzyme sites in green and 31 and 51 AOX1 priming sites (from Invitrogen catalogue) 
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Figure A1.3 Sequencing data of PpicZαBcys vector showing removal of c-myc tag, insertion of 
cystine residue in red, His tag in blue, Sfi, Not1 and BamH restriction enzyme sites in green and 31 and 51 
AOX1 priming sites  
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Figure A1.4 : Sequencing results for insertion of shMFEVP1(P) into PpicZαBcys showing VP1 peptide and 
proline mutation (red), restriction enzyme sites (green) and cystine (blue)  
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Figure A1.5 : Sequencing results of shMFE in puc119 showing original tyrosine without proline mutation 
as in shMFEVP1(P) 
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Figure A1.6 : Sequencing results of shMFE PpicZα cys showing original tyrosine without proline mutation 
and cystine residue in blue. 
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